

Tuesday, November 18, 2025

Volume 56 No. 11



NOTICE – Items in this issue will be listed online weekly and printed monthly.

10X GENOMICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	476,793	445,764
Cost & expenses	518,237	590,484
Operating income	(41,444)	(144,720)
Other income (expense), net	3,574	982
Net before taxes	(24,714)	(129,320)
Income taxes	2,578	4,279
Net income	(27,292)	(133,599)
Earnings common share		
Primary	\$(0.22)	\$(1.11)
Fully Diluted	\$(0.22)	\$(1.11)
Common Shares:		
Full Diluted	123,965	120,067
Year-end	126,540	121,040

1STDIBS.COM INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	66,652	65,487
Cost & expenses	83,307	84,725
Operating income	(16,655)	(19,238)
Other income (expense), net	1,040	1,128
Net before taxes	(12,550)	(13,415)
Income taxes	75	8
Net income	(12,625)	(13,423)
Earnings common share		
Primary	\$(0.35)	\$(0.35)
Fully Diluted	\$(0.35)	\$(0.35)
Common Shares:		
Full Diluted	35,913	38,322
Year-end	36,614	36,828

4D MOLECULAR THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	119	36
Cost & expenses	174,381	131,760
Operating income	(174,262)	(131,724)
Other income (expense), net	(15)	(56)
Net income	(159,506)	(111,197)
Earnings common share		
Primary	\$(2.85)	\$(2.08)
Fully Diluted	\$(2.85)	\$(2.08)
Common Shares:		
Full Diluted	55,934	53,378
Year-end	46,771	51,997

A-MARK PRECIOUS METALS, INC

Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	3,680,766	2,715,096
Cost & expenses	3,673,494	2,700,214
Operating income	(311)	10,173
Net before taxes	(311)	10,173
Net income	(971)	8,418
Earnings common share		
Primary	\$(0.04)	\$0.39
Fully Diluted	\$(0.04)	\$0.37
Common Shares:		
Full Diluted	24,697	23,980
Year-end	24,644	23,184

Consolidated Balance Sheet Items, as of (\$000):

	2025	2024
Assets:		
Cash & equivalents	89,221	
Inventories	1,223,094	
Current assets	2,111,302	
Net property & equip.	45,519	

Total assets	2,579,371
Liabilities:	
Current liabilities	1,543,082
Long-term debt	293,339
Stockholders' equity	643,972
Net current assets	568,220

AAON, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	1,017,859	902,917
Cost & expenses	915,571	723,228
Operating income	102,288	179,689
Other income (expense), net	106	333
Net before taxes	90,430	178,325
Net income	75,561	143,869
Earnings common share		
Primary	\$0.93	\$1.77
Fully Diluted	\$0.91	\$1.72
Common Shares:		
Full Diluted	83,087	83,580
Year-end	81,593	81,247

ACACIA RESEARCH CORP

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	235,105,000	73,468,000
Cost & expenses	200,393,000	79,200,000
Operating income	19,494,000	(17,117,000)
Other income (expense), net	(1,319,000)	(14,857,000)
Gains or losses	1,828,000	(1,112,000)
Invest. income	3,512,000	
Net before taxes	25,357,000	(23,348,000)
Income taxes	5,660,000	(2,673,000)
Net income	19,697,000	(20,675,000)
Balance for common	(22,628,000)	
Earnings common share		
Primary	\$0.19	\$(0.23)
Fully Diluted	\$0.19	\$(0.23)
Common Shares:		
Full Diluted	97,038,414	99,893,336
Year-end	96,460,378	98,838,337

ACADIA HEALTHCARE COMPANY INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	2,491,310,000	2,379,725,000
Cost & expenses	2,142,151,000	1,879,503,000
Operating income	103,456,000	303,871,000
Other income (expense), net	(1,269,000)	
Net before taxes	103,456,000	303,871,000
Income taxes	18,139,000	72,916,000
Net income	85,317,000	230,955,000
Earnings common share		
Primary	\$0.82	\$2.44
Fully Diluted	\$0.82	\$2.42
Common Shares:		
Full Diluted	91,255,000	92,119,000
Year-end	90,431,462	91,757,352

ACADIA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	787,516,000	698,195,000
Cost & expenses	700,096,000	620,904,000
Operating income	87,420,000	77,291,000
Other income (expense), net	1,775,000	1,248,000
Net before taxes	112,585,000	96,990,000
Income taxes	(4,847,000)	14,281,000

Net income	117,432,000	82,709,000
Earnings common share		
Primary	\$0.70	\$0.50
Fully Diluted	\$0.69	\$0.50
Common Shares:		
Full Diluted	169,156,000	166,136,000
Year-end	169,146,043	166,351,715

ACCURAY INC (CA)

Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	93,942	101,545
Cost & expenses	105,255	103,694
Operating income	(11,313)	(2,149)
Other income (expense), net	291	(399)
Gains or losses	(2,210)	
Net before taxes	(21,207)	(3,329)
Income taxes	471	625
Net income	(21,678)	(3,954)
Earnings common share		
Primary	\$(0.18)	\$(0.04)
Fully Diluted	\$(0.18)	\$(0.04)
Common Shares:		
Full Diluted	118,946	100,225
Year-end	113,281	100,435

Consolidated Balance Sheet Items, as of (\$000):

	2025	2024
Assets:		
Cash & equivalents	63,344	
Inventories	155,503	
Current assets	303,603	
Net property & equip.	29,013	
Total assets	456,816	
Liabilities:		
Current liabilities	194,612	
Long-term debt	127,316	
Stockholders' equity	61,867	
Net current assets	108,991	

ACI WORLDWIDE INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	1,278,182	1,141,250
Cost & expenses	984,876	868,693
Operating income	221,080	185,847
Other income (expense), net	(1,093)	(1,692)
Invest. income	25,927	
Net before taxes	207,631	140,151
Income taxes	45,309	35,588
Net income	162,322	104,563
Earnings common share		
Primary	\$1.56	\$0.99
Fully Diluted	\$1.54	\$0.98
Common Shares:		
Full Diluted	105,264	106,552
Year-end	103,256	104,871

ACLARIS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	6,531	9,509
Cost & expenses	60,172	51,766
Operating income	(53,641)	(42,257)
Other income (expense), net	2,510	894
Net income	(45,128)	(35,513)
Earnings common share		
Primary	\$(0.37)	\$(0.50)
Fully Diluted	\$(0.37)	\$(0.50)
Common Shares:		
Full Diluted	122,531	71,250
Year-end	108,343	71,418

ACM RESEARCH INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	656,879	558,647
Cost & expenses	570,485	451,638
Operating income	86,394	107,009
Other income (expense), net	2,376	(626)
Invest. income	20,358	(707)
Net before taxes	114,414	109,875
Income taxes	6,733	17,712
Net income	107,681	92,163
Earnings common share		
Primary	\$1.35	\$1.17
Fully Diluted	\$1.26	\$1.07
Common Shares:		
Full Diluted	67,551	66,512
Year-end	64,876	62,546

ACV AUCTIONS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	575,961	477,642
Cost & expenses	588,897	509,598
Operating income	(45,343)	(58,307)
Net before taxes	(45,763)	(53,115)
Income taxes	817	448
Net income	(46,580)	(53,563)
Earnings common share		
Primary	\$(0.27)	\$(0.33)
Fully Diluted	\$(0.27)	\$(0.33)
Common Shares:		
Full Diluted	170,067	164,337
Year-end	172,171	167,046

ADAPTIVE BIOTECHNOLOGIES CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	205,295	131,498
Cost & expenses	248,375	258,935
Operating income	(44,350)	(128,712)
Net before taxes	(45,878)	(125,878)
Net income	(45,878)	(125,878)
Earnings common share		
Primary	\$(0.30)	\$(0.86)
Fully Diluted	\$(0.30)	\$(0.86)
Common Shares:		
Full Diluted	151,248	146,908
Year-end	152,581	147,562

ADDUS HOMECARE CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,049,452	857,455
Cost & expenses	940,850	771,360
Operating income	96,338	75,779
Net before taxes	87,297	73,139
Income taxes	21,169	19,067
Net income	66,128	54,072
Earnings common share		
Primary	\$3.67	\$3.24
Fully Diluted	\$3.60	\$3.17
Common Shares:		
Full Diluted	18,365	17,065
Year-end	18,483	18,133

ADEIA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	260,744	256,856
Cost & expenses	152,068	128,942
Operating income	66,249	71,127
Other income (expense), net	4,622	3,806
Net before taxes	39,952	34,704
Income taxes	2,588	6,109
Net income	37,364	28,595
Earnings common share		
Primary	\$0.34	\$0.26
Fully Diluted	\$0.33	\$0.25
Common Shares:		
Full Diluted	112,676	112,881
Year-end	109,469	109,193

ADICET BIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	90,228	96,872
Operating income	(90,228)	(96,872)
Other income (expense), net	(300)	(167)
Net income	(86,287)	(88,395)
Earnings common share		
Primary	\$(0.94)	\$(1.02)
Fully Diluted	\$(0.94)	\$(1.02)
Common Shares:		
Full Diluted	91,315	86,865
Year-end	83,254	82,401

ADMA BIOLOGICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	371,010,000	308,905,000
Cost & expenses	242,225,000	207,882,000
Operating income	128,692,000	100,660,000
Other income (expense), net	(3,531,000)	(107,000)
Net before taxes	121,061,000	91,001,000
Income taxes	23,510,000	5,224,000
Net income	97,551,000	85,777,000
Earnings common share		
Primary	\$0.41	\$0.37
Fully Diluted	\$0.40	\$0.35
Common Shares:		
Full Diluted	245,491,334	241,772,162
Year-end	238,332,393	236,378,607

ADVANTAGE SOLUTIONS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	2,610,511,000	2,674,039,000
Cost & expenses	2,423,159,000	2,645,494,000
Operating income	35,550,000	238,870,000
Gains or losses	83,000	359,000
Net before taxes	(69,495,000)	238,511,000
Income taxes	(3,490,000)	(38,042,000)
Income contin. oper.		(200,469,000)
Net income	(66,005,000)	146,726,000
Earnings common share		
Primary	\$(0.20)	\$(0.46)
Fully Diluted	\$(0.20)	\$(0.46)
Common Shares:		
Full Diluted	323,988,621	321,774,115
Year-end	313,070,048	308,018,008

AIRBNB INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	9,463,000	8,622,000
Cost & expenses	7,188,000	6,499,000
Operating income	2,275,000	2,123,000
Other income (expense), net	(74,000)	(49,000)
Net before taxes	2,744,000	2,709,000
Income taxes	574,000	522,000
Net income	2,170,000	2,187,000
Earnings common share		
Primary	\$3.53	\$3.45
Fully Diluted	\$3.47	\$3.38
Common Shares:		
Full Diluted	626,000	648,000
Year-end	608,000	627,000

AIRSCULPT TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	118,376	141,172
Cost & expenses	119,224	130,164
Operating income	(10,553)	2,315
Net before taxes	(15,147)	(2,323)
Income taxes	(2,197)	894
Net income	(12,950)	(3,217)
Earnings common share		
Primary	\$(0.22)	\$(0.06)
Fully Diluted	\$(0.22)	\$(0.06)
Common Shares:		
Full Diluted	60,202	57,544
Year-end	62,437	57,809

AKAMAI TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,113,263	2,971,229
Cost & expenses	2,558,054	2,519,411
Operating income	472,068	385,351
Other income (expense), net	(3,268)	(13,599)
Net before taxes	498,486	428,904
Income taxes	131,527	63,891
Net income	366,959	365,013
Earnings common share		
Primary	\$2.52	\$2.40
Fully Diluted	\$2.50	\$2.36
Common Shares:		
Full Diluted	147,041	154,765
Year-end	143,767	150,625

AKEBIA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	178,574,000	113,683,000
Cost & expenses	146,522,000	149,848,000
Operating income	32,052,000	(36,165,000)
Other income (expense), net	175,000	(478,000)
Gains or losses	(5,361,000)	1,345,000
Net before taxes	7,514,000	
Income taxes	615,000	
Net income	6,899,000	(46,606,000)
Earnings common share		
Primary	\$0.03	\$(0.22)
Fully Diluted	\$0.03	\$(0.22)
Common Shares:		
Full Diluted	262,680,943	208,343,679
Year-end	265,226,038	211,542,122

AKERO THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	251,991	207,398
Operating income	(251,991)	(207,398)
Other income (expense), net	(1,557)	
Net income	(222,796)	(182,036)
Earnings common share		
Primary	\$(2.76)	\$(2.76)
Fully Diluted	\$(2.76)	\$(2.76)
Common Shares:		
Full Diluted	80,808	65,983
Year-end	80,149	69,615

ALARM.COM HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	749,530	697,587
Cost & expenses	628,489	597,865
Operating income	98,690	77,693
Other income (expense), net	703	(1,665)
Equity earnings	(3,109)	
Net before taxes	121,885	102,729
Income taxes	27,965	10,349
Net income	97,029	92,380
Earnings common share		
Primary	\$1.97	\$1.89
Fully Diluted	\$1.80	\$1.73
Common Shares:		
Full Diluted	59,630	57,212
Year-end	49,761	49,332

ALECTOR INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	14,808	46,318
Cost & expenses	131,249	184,066
Operating income	(116,441)	(137,748)
Other income (expense), net	10,779	20,853
Net before taxes		(116,895)
Income taxes		80
Net income	(105,662)	(116,975)
Earnings common share		
Primary	\$(1.05)	\$(1.22)
Fully Diluted	\$(1.05)	\$(1.22)
Common Shares:		
Full Diluted	100,801	96,007
Year-end	107,446	97,930

ALIGN TECHNOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,987,403	3,003,793
Cost & expenses	2,596,972	2,540,314
Operating income	390,431	463,479
Other income (expense), net	6,837	(6,993)
Net before taxes	408,692	468,182
Income taxes	134,101	150,627
Net income	274,591	317,555
Earnings common share		
Primary	\$3.77	\$4.23
Fully Diluted	\$3.77	\$4.23
Common Shares:		
Full Diluted	72,880	75,149
Year-end	72,040	74,757

ALIGOS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Cost & expenses	68,188	71,907
Operating income	(66,171)	(68,591)
Other income (expense), net	1,556	18,478
Gains or losses	58,971	
Net before taxes	(4,028)	(48,757)
Income taxes	284	304
Net income	(4,312)	(49,061)
Earnings common share		
Primary	\$(0.44)	\$(7.84)
Fully Diluted	\$(0.44)	\$(7.84)
Common Shares:		
Full Diluted	9,717	6,259
Year-end	6,154	3,448

ALLBIRDS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	104,787	
Cost & expenses	164,029	205,687
Operating income	(59,242)	(71,782)
Other income (expense), net	1,752	2,457
Gains or losses		(430)
Net before taxes	(57,481)	(66,763)
Income taxes	219	877
Net income	(57,700)	(67,640)
Earnings common share		
Primary	\$(7.13)	\$(8.64)
Fully Diluted	\$(7.13)	\$(8.64)
Common Shares:		
Full Diluted	8,093	7,831
Year-end	8,213	7,930

ALLEGIAN TRAVEL COMPANY

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	1,950,390	1,884,884
Cost & expenses	1,789,284	1,667,759
Operating income	(29,676)	24,003
Other income (expense), net	(1,064)	(146)
Net before taxes	(98,778)	(26,753)
Income taxes	(22,140)	(2,745)
Net income	(76,638)	(24,008)
Balance for common		(24,626)
Earnings common share		
Primary	\$(4.26)	\$(1.38)
Fully Diluted	\$(4.26)	\$(1.38)
Common Shares:		
Full Diluted	18,010	17,802
Year-end	18,324	18,362

ALLIANCE RESOURCE PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	1,659,298	1,858,616
Cost & expenses	1,148,158	1,274,860
Operating income	287,960	378,782
Other income (expense), net	(23,562)	(5,277)
Gains or losses	11,021	8,437
Net before taxes	248,819	360,924
Net income	233,403	347,992
Balance for common	226,237	338,163
Earnings common share		
Primary	\$1.76	\$2.64
Fully Diluted	\$1.76	\$2.64
Common Shares:		
Full Diluted	128,374	127,932
Year-end	128,428	128,062

ALLIENT INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	411,124	407,958
Cost & expenses	369,138	374,982
Operating income	32,636	23,595
Other income (expense), net	(1,964)	(405)
Net before taxes	20,084	12,983
Income taxes	4,433	2,830
Net income	15,651	10,153
Earnings common share		
Primary	\$0.94	\$0.61
Fully Diluted	\$0.94	\$0.61
Common Shares:		
Full Diluted	16,708	16,581
Year-end	16,936	16,840

ALLOGENE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues		22
Cost & expenses	166,911	212,731
Operating income	(166,911)	(212,709)
Other income (expense), net	(32)	
Net income	(152,076)	(197,651)
Earnings common share		
Primary	\$(0.70)	\$(1.04)
Fully Diluted	\$(0.70)	\$(1.04)
Common Shares:		
Full Diluted	218,800	189,520
Year-end	223,164	209,500

ALPHA TEKNOVA INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	30,536	28,480
Cost & expenses	42,042	48,137
Operating income	(12,367)	(20,518)
Other income (expense), net	485	
Net before taxes	(12,381)	(21,076)
Income taxes	120	(50)
Net income	(12,501)	(21,026)
Earnings common share		
Primary	\$(0.23)	\$(0.47)
Fully Diluted	\$(0.23)	\$(0.47)
Common Shares:		
Full Diluted	53,463	44,520
Year-end	53,524	53,303

ALTIMMUNE INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	15,000	15,000
Cost & expenses	65,611,000	78,321,000
Operating income	(65,596,000)	(78,306,000)
Other income (expense), net	(163,000)	(70,000)
Net before taxes	(61,416,000)	
Income taxes	(681,000)	
Net income	(60,735,000)	(71,879,000)
Earnings common share		
Primary	\$(0.74)	\$(1.01)
Fully Diluted	\$(0.74)	\$(1.01)
Common Shares:		
Full Diluted	82,198,581	70,927,222
Year-end	95,598,665	71,124,407

ALX ONCOLOGY HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Cost & expenses	81,000	111,854
Operating income	(81,000)	(111,854)
Other income (expense), net	(19)	(19)
Net income	(78,847)	(105,687)
Earnings common share		
Primary	\$(1.48)	\$(2.05)
Fully Diluted	\$(1.48)	\$(2.05)
Common Shares:		
Full Diluted	53,452	51,545
Year-end	53,578	52,743

AMC NETWORKS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	411,124	407,958
Cost & expenses	369,138	374,982
Operating income	32,636	23,595
Other income (expense), net	(1,964)	(405)
Net before taxes	20,084	12,983
Income taxes	4,433	2,830
Net income	15,651	10,153
Earnings common share		
Primary	\$0.94	\$0.61
Fully Diluted	\$0.94	\$0.61
Common Shares:		
Full Diluted	16,708	16,581
Year-end	16,936	16,840

	2025	2024
Total Revenues	1,716,998	1,822,009
Cost & expenses	1,464,064	1,531,974
Operating income	184,184	214,619
Other income (expense), net	152,241	5,048
Net before taxes	228,732	125,967
Income taxes	73,792	54,433
Net income	154,940	71,534
Earnings common share		
Primary	\$3.25	\$1.31
Fully Diluted	\$2.63	\$1.21
Common Shares:		
Full Diluted	56,412	49,038
Year-end	43,455	44,097

AMERICAN PUBLIC EDUCATION INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	490,532	460,449
Cost & expenses	449,538	433,478
Operating income	28,968	11,531
Equity earnings		4,407
Net before taxes	25,904	9,989
Income taxes	6,955	2,433
Net income	18,949	3,149
Balance for common	12,697	(1,448)
Earnings common share		
Primary	\$0.71	\$(0.08)
Fully Diluted	\$0.68	\$(0.08)
Common Shares:		
Full Diluted	18,596	17,604
Year-end	18,080	17,711

AMERICAN SUPERCONDUCTOR CORP.

Earnings, 6 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	138,220,000	94,761,000
Cost & expenses	128,936,000	97,959,000
Operating income	8,610,000	(4,043,000)
Other income (expense), net	(21,000)	(489,000)
Net before taxes	11,790,000	(2,433,000)
Income taxes	316,000	(4,796,000)
Net income	11,474,000	2,363,000
Earnings common share		
Primary	\$0.28	\$0.07
Fully Diluted	\$0.27	\$0.06
Common Shares:		
Full Diluted	41,988,000	36,951,000
Year-end	45,186,789	39,429,369

AMGEN INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	26,885,000	24,338,000
Cost & expenses	20,525,000	19,391,000
Operating income	6,360,000	4,947,000
Other income (expense), net	3,204,000	1,288,000
Net before taxes	7,462,000	3,827,000
Income taxes	1,084,000	364,000
Net income	6,378,000	3,463,000
Earnings common share		
Primary	\$11.86	\$6.45
Fully Diluted	\$11.77	\$6.40
Common Shares:		
Full Diluted	542,000	541,000
Year-end	538,500	537,500

AMICUS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	448,998,000	378,589,000
Cost & expenses	426,592,000	363,178,000
Operating income	16,843,000	8,905,000
Other income (expense), net	12,452,000	(11,946,000)
Net before taxes	(2,952,000)	(36,690,000)
Income taxes	25,848,000	34,155,000
Net income	(28,800,000)	(70,845,000)
Earnings common share		
Primary	\$(0.09)	\$(0.23)
Fully Diluted	\$(0.09)	\$(0.23)
Common Shares:		
Full Diluted	308,139,134	303,792,479
Year-end	308,492,224	298,691,094

AMPHASTAR PHARMACEUTICALS INC (DE)

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	536,782	545,444
Cost & expenses	431,985	385,169
Operating income	104,797	160,275
Other income (expense), net	(492)	1,125
Equity earnings		573
Net before taxes	91,710	145,802
Income taxes	18,045	23,674
Net income	73,665	121,555
Earnings common share		
Primary	\$1.57	\$2.50
Fully Diluted	\$1.52	\$2.32
Common Shares:		
Full Diluted	48,565	52,307
Year-end	46,349	48,373

AMYLYX PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	88,036	
Cost & expenses	116,686	362,113
Operating income	(116,686)	(274,077)
Other income (expense), net	(1,062)	(1,371)
Net before taxes	(263,955)	
Income taxes	242	
Net income	(111,736)	(264,197)
Earnings common share		
Primary	\$(1.25)	\$(3.89)
Fully Diluted	\$(1.25)	\$(3.89)
Common Shares:		
Full Diluted	89,418	67,991
Year-end	109,766	68,546

ANDERSONS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	8,472,679	8,134,410
Cost & expenses	8,443,416	8,010,060
Operating income	53,891	133,507
Other income (expense), net	53,200	30,651
Net before taxes	53,891	133,507
Income taxes	5,682	16,911
Net income	48,209	116,596
Earnings common share		
Primary	\$0.83	\$2.03
Fully Diluted	\$0.82	\$2.01
Common Shares:		
Full Diluted	34,280	34,321
Year-end	33,839	34,071

ANGI INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	789,767	917,243
Cost & expenses	698,165	831,782
Operating income	59,458	19,720
Other income (expense), net	1,710	144
Net before taxes	58,031	19,629
Income taxes	21,423	(18,505)
Net income	36,608	38,134
Earnings common share		
Primary	\$0.78	\$0.70
Fully Diluted	\$0.77	\$0.70
Common Shares:		
Full Diluted	49,848	50,703
Year-end	43,687	49,773

ANI PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	636,306,000	423,802,000
Cost & expenses	491,176,000	373,709,000
Operating income	76,326,000	4,962,000
Other income (expense), net	1,084,000	(10,123,000)
Gains or losses	2,551,000	8,298,000
Net before taxes	64,312,000	(8,450,000)
Income taxes	13,465,000	(204,000)
Net income	50,847,000	(8,246,000)
Balance for common	44,830,000	(9,465,000)
Earnings common share		
Primary	\$2.26	\$(0.49)
Fully Diluted	\$2.15	\$(0.49)
Common Shares:		
Full Diluted	20,911,000	19,275,000
Year-end	22,472,899	21,080,727

ANIKI THERAPEUTICS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	82,204,000	121,197,000
Cost & expenses	93,901,000	154,116,000
Operating income	(11,697,000)	(32,919,000)
Net before taxes	(10,071,000)	(31,326,000)
Income taxes	1,709,000	3,194,000
Income contin. oper.	(11,780,000)	
Net income	(11,172,000)	(34,520,000)
Earnings common share		
Primary	\$(0.78)	\$(2.34)
Fully Diluted	\$(0.78)	\$(2.34)
Common Shares:		
Full Diluted	14,361,000	14,769,000
Year-end	14,421,000	14,694,000

ANNEXON INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	166,149	101,594
Operating income	(166,149)	(101,594)
Net income	(158,434)	(89,610)
Balance for common	(160,291)	
Earnings common share		
Primary	\$(1.08)	\$(0.68)
Fully Diluted	\$(1.08)	\$(0.68)
Common Shares:		
Full Diluted	148,521	130,946
Year-end	115,123	105,710

APA CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	7,242,000	7,235,000
Cost & expenses	3,231,000	4,475,000
Operating income	2,302,000	1,035,000
Other income (expense), net	29,000	(112,000)
Net before taxes	2,302,000	1,035,000
Net income	1,361,000	693,000
Earnings common share		
Primary	\$3.20	\$1.30
Fully Diluted	\$3.20	\$1.29
Common Shares:		
Full Diluted	361,000	348,000
Year-end	355,662	369,918

APPIAN CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	524,070	450,337
Cost & expenses	522,774	516,223
Operating income	1,296	(65,886)
Other income (expense), net	24,678	5,882
Net before taxes	10,026	(77,925)
Income taxes	3,690	690
Net income	6,336	(78,615)
Earnings common share		
Primary	\$0.09	\$(1.08)
Fully Diluted	\$0.08	\$(1.08)
Common Shares:		
Full Diluted	74,554	72,664
Year-end	73,818	72,430

APPLIED OPTOELECTRONICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	321,441	149,094
Cost & expenses	364,542	213,530
Operating income	(43,101)	(64,436)
Other income (expense), net	4,672	1,774
Gains or losses		(33)
Net income	(36,206)	(67,042)
Earnings common share		
Primary	\$(0.64)	\$(1.68)
Fully Diluted	\$(0.64)	\$(1.68)
Common Shares:		
Full Diluted	56,762	40,021
Year-end	68,065	44,852

APPROVIN CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	3,822,773,000	2,224,571,000
Cost & expenses	946,102,000	941,949,000
Operating income	2,876,671,000	1,282,622,000
Other income (expense), net	(21,389,000)	17,873,000
Net before taxes	2,699,556,000	1,077,215,000
Income taxes	368,617,000	83,803,000
Income contin. oper.	2,330,939,000	993,412,000
Net income	2,231,495,000	980,572,000
Balance for common	2,231,079,000	978,400,000
Earnings common share		
Primary	\$6.58	\$2.91
Fully Diluted	\$6.51	\$2.81
Common Shares:		
Full Diluted	342,668,000	348,273,000
Year-end	338,534,000	335,481,141

APYX MEDICAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	33,680	33,880
Cost & expenses	40,137	49,677
Operating income	(6,457)	(15,797)
Other income (expense), net	76	2
Net before taxes	(9,689)	(18,737)
Income taxes	176	163
Net income	(9,865)	(18,900)
Earnings common share		
Primary	\$(0.24)	\$(0.54)
Fully Diluted	\$(0.24)	\$(0.54)
Common Shares:		
Full Diluted	40,735	34,644
Year-end	37,819	34,644

AQUESTIVE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	31,530	45,694
Cost & expenses	73,742	62,886
Operating income	(42,212)	(17,192)
Other income (expense), net	(4,304)	(4,075)
Net income	(51,924)	(27,082)
Earnings common share		
Primary	\$(0.51)	\$(0.32)
Fully Diluted	\$(0.51)	\$(0.32)
Common Shares:		
Full Diluted	101,858	85,224
Year-end	121,658	91,178

ARCBEST CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,037,470	3,177,374
Cost & expenses	2,827,726	2,875,327
Operating income	98,566	206,273
Other income (expense), net	574	(28,118)
Net before taxes	93,650	181,254
Income taxes	25,436	36,928
Income contin. oper.		144,326
Income discount. oper.		600
Net income	68,214	144,926
Earnings common share		
Primary	\$2.97	\$6.14
Fully Diluted	\$2.96	\$6.06
Common Shares:		
Full Diluted	23,038	23,923
Year-end	22,592	23,462

ARHAUS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,014,377	924,096
Cost & expenses	945,757	865,683
Operating income	68,620	58,413
Other income (expense), net	354	447
Net before taxes	71,111	61,442
Income taxes	18,945	14,186
Net income	52,166	47,256
Earnings common share		
Primary	\$0.37	\$0.34
Fully Diluted	\$0.37	\$0.34
Common Shares:		
Full Diluted	141,311	140,732
Year-end	141,061	140,528

ARQ INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	90,905,000	81,919,000
Cost & expenses	84,213,000	78,201,000
Operating income	(1,732,000)	(2,372,000)
Other income (expense), net	1,054,000	1,058,000
Net before taxes		(3,740,000)
Income taxes		30,000
Net income	(2,583,000)	(3,770,000)
Balance for common		(3,770,000)
Earnings common share		
Primary	\$(0.06)	\$(0.11)
Fully Diluted	\$(0.06)	\$(0.11)
Common Shares:		
Full Diluted	41,478,000	34,085,000
Year-end	42,689,465	42,033,915

ARRAY TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,058,097	640,575
Cost & expenses	921,035	697,850
Operating income	119,111	(84,659)
Other income (expense), net	14,219	(1,662)
Net before taxes	123,603	(100,527)
Income taxes	30,092	12,964
Net income	93,511	(113,491)
Balance for common	49,136	(154,823)
Earnings common share		
Primary	\$0.32	\$(1.02)
Fully Diluted	\$0.32	\$(1.02)
Common Shares:		
Full Diluted	153,350	151,691
Year-end	152,748	151,934

ARVINAS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	253,100,000	204,200,000
Cost & expenses	297,000,000	396,200,000
Operating income	(43,900,000)	192,000,000
Other income (expense), net	(400,000)	(2,700,000)
Net before taxes	(13,300,000)	152,800,000
Income taxes	100,000	1,000,000
Net income	(13,400,000)	153,800,000
Earnings common share		
Primary	\$(0.18)	\$(2.14)
Fully Diluted	\$(0.18)	\$(2.14)
Common Shares:		
Full Diluted	72,900,000	71,900,000
Year-end	70,800,000	68,700,000

ASCENT INDUSTRIES CO**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	56,183,000	62,642,000
Cost & expenses	61,720,000	70,940,000
Operating income	(5,537,000)	(8,298,000)
Other income (expense), net	581,000	303,000
Net before taxes	(4,609,000)	(8,318,000)
Income taxes	(32,000)	4,413,000
Income contin. oper.	(4,577,000)	(12,731,000)
Net income	1,906,000	(12,571,000)
Earnings common share		
Primary	\$0.20	\$(1.24)
Fully Diluted	\$0.20	\$(1.24)
Common Shares:		
Full Diluted	9,733,000	10,111,000
Year-end	9,373,680	10,092,966

AST SPACEMOBILE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	16,613,000	2,500,000
Cost & expenses	196,655,000	131,658,000
Operating income	(296,774,000)	188,223,000
Other income (expense), net	(91,852,000)	1,661,000
Gains or losses	(65,300,000)	284,839,000
Net before taxes	(362,074,000)	473,062,000
Income taxes	1,284,000	1,172,000
Net income	(363,358,000)	474,234,000
Earnings common share		
Primary	\$(1.09)	\$(1.89)

Fully Diluted	\$(1.09)	\$(1.89)
Common Shares:		
Full Diluted	246,490,060	139,485,036
Year-end	271,981,894	170,039,305

ASTEC INDUSTRIES, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,009,800	
Cost & expenses	966,500	957,700
Operating income	43,000	(11,600)
Other income (expense), net	2,700	1,000
Net before taxes	37,200	(17,500)
Income taxes	10,300	(600)
Net income	26,900	(16,900)
Earnings common share		
Primary	\$1.17	\$(0.74)
Fully Diluted	\$1.16	\$(0.74)
Common Shares:		
Full Diluted	23,063	22,792
Year-end	22,876	22,802

ATHIRA PHARMA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	23,701	85,336
Operating income	(23,701)	(85,336)
Other income (expense), net	981	3,399
Net income	(22,720)	(81,937)
Earnings common share		
Primary	\$(5.80)	\$(21.30)
Fully Diluted	\$(5.80)	\$(21.30)
Common Shares:		
Full Diluted	3,919	3,841
Year-end	3,944	3,867

AVEANNA HEALTHCARE HOLDINGS INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	1,770,719	1,504,634
Cost & expenses	1,577,491	1,402,286
Operating income	185,418	94,016
Other income (expense), net	(5,805)	112
Gains or losses	(5,532)	2,217
Net before taxes	67,703	(21,863)
Income taxes	21,421	18,246
Net income	46,282	(40,109)
Earnings common share		
Primary	\$0.23	\$(0.21)
Fully Diluted	\$0.22	\$(0.21)
Common Shares:		
Full Diluted	211,920	192,734
Year-end	208,911	193,225

AVEPOINT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	304,810,000	241,299,000
Cost & expenses	286,300,000	238,986,000
Operating income	18,510,000	2,313,000
Other income (expense), net	6,024,000	(8,107,000)
Net before taxes	24,534,000	(5,794,000)
Income taxes	5,058,000	6,170,000
Net income	19,476,000	(11,964,000)
Earnings common share		
Primary	\$0.09	\$(0.07)
Fully Diluted	\$0.08	\$(0.07)
Common Shares:		
Full Diluted	228,985,000	182,753,000
Year-end	212,588,000	187,431,000

AVIAT NETWORKS, INC.**Earnings, 3 mos. to** (Consol. – \$000):

	09/26/25	09/27/24
Total Revenues	107,320	88,429
Cost & expenses	102,131	103,997
Operating income	5,189	(15,568)
Other income (expense), net	(973)	(710)
Net before taxes	2,504	(17,393)
Income taxes	2,342	(5,514)
Net income	162	(11,879)
Earnings common share		
Primary	\$0.01	\$(0.94)
Fully Diluted	\$0.01	\$(0.94)

Common Shares:

Full Diluted	12,976	12,646
Year-end	12,600	12,500

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	
Cash & equivalents	64,831	
Inventories	84,011	
Current assets	474,541	
Net property & equip.	18,766	
Total assets	643,316	
Liabilities:		
Current liabilities	258,202	
Long-term debt	102,042	
Stockholders' equity	263,636	
Net current assets	216,339	

AVIDITY BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	17,895	7,924
Cost & expenses	509,360	265,870
Operating income	(491,465)	(257,946)
Other income (expense), net	(1,466)	(449)
Net income	(447,530)	(220,045)
Earnings common share		
Primary	\$(3.38)	\$(2.08)
Fully Diluted	\$(3.38)	\$(2.08)
Common Shares:		
Full Diluted	132,281	105,902
Year-end	146,771	118,900

AXCELIS TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	600,718	765,448
Cost & expenses	517,575	609,185
Operating income	83,143	156,263
Other income (expense), net	2,569	1,257
Net before taxes	98,231	171,629
Income taxes	12,290	20,593
Net income	85,941	151,036
Earnings common share		
Primary	\$2.70	\$4.63
Fully Diluted	\$2.70	\$4.61
Common Shares:		
Full Diluted	31,863	32,780
Year-end	30,998	32,504

AXON ENTERPRISE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	1,994,770,000	1,433,086,000
Operating income	(11,958,000)	74,295,000
Interest expense		5,273,000
Other income (expense), net	(28,482,000)	(468,000)
Gains or losses	134,648,000	192,158,000
Net before taxes	85,211,000	296,939,000
Income taxes	(36,700,000)	55,089,000
Net income	121,911,000	241,850,000
Earnings common share		
Primary	\$1.57	\$3.20
Fully Diluted	\$1.48	\$3.12
Common Shares:		
Full Diluted	82,218,000	77,614,000
Year-end	78,891,165	76,084,179

BACKBLAZE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	108,073	93,842
Cost & expenses	127,031	126,359
Operating income	(18,958)	(32,517)
Net before taxes	(20,115)	(34,148)
Income taxes	84	6
Net income	(20,199)	(34,154)
Earnings common share		
Primary	\$(0.36)	\$(0.81)
Fully Diluted	\$(0.36)	\$(0.81)
Common Shares:		
Full Diluted	55,558	41,974
Year-end	57,678	44,265

BARRETT BUSINESS SERVICES, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	919,172	839,711
Cost & expenses	869,436	794,886
Operating income	43,643	39,162
Other income (expense), net	7,034	8,732
Net before taxes	50,544	47,761
Income taxes	12,492	11,568
Net income	38,052	36,193
Earnings common share		
Primary	\$1.48	\$1.38
Fully Diluted	\$1.45	\$1.35
Common Shares:		
Full Diluted	26,263	26,736
Year-end	25,624	25,937

BEL FUSE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	499,517,000	384,933,000
Cost & expenses	414,297,000	333,009,000
Operating income	85,220,000	51,924,000
Other income (expense), net	11,265,000	21,000
Net before taxes	85,487,000	54,423,000
Income taxes	17,817,000	11,663,000
Net income	67,670,000	42,760,000
Earnings common share		
Primary	\$5.30	\$3.38
Fully Diluted	\$5.30	\$3.38
Common Shares:		
Full Diluted	12,634,000	12,638,000
Year-end	12,662,063	12,547,811

BERRY CORP (BRY)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	543,871	588,714
Cost & expenses	506,824	403,819
Operating income	(124,057)	28,216
Other income (expense), net	211	(80)
Net before taxes	(124,057)	28,216
Income taxes	(34,964)	7,206
Net income	(89,093)	21,010
Earnings common share		
Primary	\$(1.15)	\$0.27
Fully Diluted	\$(1.15)	\$0.27
Common Shares:		
Full Diluted	77,466	76,903
Year-end	77,602	76,939

BIO-TECHNE CORP**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	286,555,000	289,458,000
Cost & expenses	238,897,000	249,471,000
Operating income	47,658,000	39,987,000
Other income (expense), net	2,296,000	1,434,000
Net before taxes	47,991,000	40,171,000
Income taxes	9,806,000	6,571,000
Net income	38,185,000	33,600,000
Balance for common	38,179,000	33,594,000
Earnings common share		
Primary	\$0.25	\$0.21
Fully Diluted	\$0.24	\$0.21
Common Shares:		
Full Diluted	156,362,000	161,115,000
Year-end	155,749,477	158,878,127

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025	2024
Cash & equivalents	144,962,000	
Inventories	203,188,000	
Current assets	609,507,000	
Net property & equip.	240,334,000	
Total assets	2,526,148,000	
Liabilities:		
Current liabilities	144,545,000	
Long-term debt	300,000,000	
Stockholders' equity	1,965,814,000	
Net current assets	464,962,000	

BIOCRYST PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	468,282,000	319,178,000
Cost & expenses	387,678,000	317,213,000

Operating income	80,604,000	1,965,000
Other income (expense), net	(4,244,000)	
Gains or losses		(37,000)
Net before taxes	19,374,000	(60,963,000)
Income taxes	1,358,000	1,123,000
Net income	18,016,000	(62,086,000)
Earnings common share		
Primary	\$0.09	\$(0.30)
Fully Diluted	\$0.08	\$(0.30)
Common Shares:		
Full Diluted	218,349,000	206,466,000
Year-end	210,522,000	207,119,000

BLACK DIAMOND THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	70,000	
Cost & expenses	39,868	60,506
Operating income	30,132	(60,506)
Other income (expense), net	4,474	5,198
Net income	37,483	(53,691)
Earnings common share		
Primary	\$0.66	\$(0.99)
Fully Diluted	\$0.65	\$(0.99)
Common Shares:		
Full Diluted	57,481	54,498
Year-end	56,943	56,522

BLACKLINE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	517,246	483,876
Cost & expenses	498,517	471,557
Operating income	18,729	12,319
Other income (expense), net	65,112	
Net before taxes	36,776	111,605
Income taxes	15,500	7,307
Net income	21,276	104,298
Earnings common share		
Primary	\$0.32	\$1.69
Fully Diluted	\$0.31	\$0.66
Common Shares:		
Full Diluted	64,008	73,131
Year-end	59,942	62,438

BLACKROCK TCP CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	70,791,072	100,223,575
Operating income	29,357,716	97,964,446
Other income (expense), net	146,531,210	(55,443,078)
Invest. income	(204,252,111)	(67,107,784)
Net income	29,357,716	(24,586,416)
Earnings common share		
Primary	\$0.35	\$(0.32)
Fully Diluted	\$0.35	\$(0.32)
Common Shares:		
Full Diluted	85,051,475	77,772,017
Year-end	85,011,001	85,591,134

BLINK CHARGING CO**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	49,421,000	70,830,000
Cost & expenses	102,710,000	108,962,000
Operating income	(53,289,000)	(38,132,000)
Other income (expense), net		1,580,000
Gains or losses	(7,000)	(15,000)
Net before taxes	(52,543,000)	(37,040,000)
Income taxes	123,000	192,000
Net income	(52,666,000)	(37,232,000)
Earnings common share		
Primary	\$(0.51)	\$(0.37)
Fully Diluted	\$(0.51)	\$(0.37)
Common Shares:		
Full Diluted	102,684,303	100,456,032
Year-end	103,100,485	101,067,207

BLOOMIN' BRANDS INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	2,980,773	2,978,455
Cost & expenses	2,796,820	2,724,410
Operating income	50,461	123,611

Other income (expense), net		(136,022)
Equity earnings	3,434	
Net before taxes	17,463	(57,866)
Income taxes	(10,249)	1,392
Income contin. oper.	24,278	(59,258)
Net income	24,992	(45,118)
Earnings common share		
Primary	\$0.26	\$(0.56)
Fully Diluted	\$0.25	\$(0.56)
Common Shares:		
Full Diluted	85,222	86,258
Year-end	85,167	84,830

BOWMAN CONSULTING GROUP LTD**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	361,054,000	313,341,000
Cost & expenses	325,630,000	296,181,000
Operating income	15,472,000	(3,412,000)
Other income (expense), net	(5,764,000)	(6,000,000)
Net before taxes	9,708,000	(9,412,000)
Income taxes	(1,175,000)	(6,543,000)
Net income	10,883,000	(2,869,000)
Balance for common	10,344,000	(2,869,000)
Earnings common share		
Primary	\$0.63	\$(0.18)
Fully Diluted	\$0.62	\$(0.18)
Common Shares:		
Full Diluted	16,756,227	15,559,279
Year-end	17,354,202	17,738,740

BRILLIANT EARTH GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	313,072	302,636
Cost & expenses	318,428	301,696
Operating income	(5,356)	940
Other income (expense), net	2,642	4,476
Net before taxes	(4,996)	1,589
Income taxes	56	222
Net income	(5,052)	1,367
Earnings common share		
Primary	\$(0.05)	\$0.01
Fully Diluted	\$(0.05)	\$0.01
Common Shares:		
Full Diluted	14,556	98,527
Year-end	15,170	13,670

BRUKER CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	2,459,300,000	2,386,800,000
Cost & expenses	2,467,400,000	2,205,800,000
Operating income	(8,100,000)	181,000,000
Other income (expense), net	(13,300,000)	(23,200,000)
Invest. income	5,900,000	
Equity earnings	(200,000)	200,000
Net before taxes	(46,200,000)	150,800,000
Income taxes	(8,500,000)	50,700,000
Net income	(37,500,000)	99,900,000
Earnings common share		
Primary	\$(0.25)	\$0.67
Fully Diluted	\$(0.25)	\$0.67
Common Shares:		
Full Diluted	151,700,000	148,700,000
Year-end	151,391,821	151,594,684

BUMBLE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	741,493	809,995
Cost & expenses	950,670	1,494,896
Operating income	(230,035)	(737,443)
Other income (expense), net	(10,546)	3,815
Net before taxes	(273,530)	(761,437)
Income taxes	21,977	16,263
Net income	(295,507)	(777,700)
Earnings common share		
Primary	\$(1.97)	\$(4.53)
Fully Diluted	\$(1.97)	\$(4.53)
Common Shares:		
Full Diluted	105,757	125,006
Year-end	112,694	112,558

C4 THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	24,931	30,407
Cost & expenses	117,008	112,312
Operating income	(92,077)	(81,905)
Net income	(84,508)	(70,743)
Earnings common share		
Primary	\$(1.18)	\$(1.03)
Fully Diluted	\$(1.18)	\$(1.03)
Common Shares:		
Full Diluted	71,474	68,959
Year-end	74,175	70,563

CABALETTA BIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	129,630	91,356
Operating income	(129,630)	(91,356)
Other income (expense), net	437	
Net income	(125,937)	(83,278)
Earnings common share		
Primary	\$(1.75)	\$(1.69)
Fully Diluted	\$(1.75)	\$(1.69)
Common Shares:		
Full Diluted	71,816	48,758
Year-end	96,265	48,850

CANTALOUPE INC**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	80,853,000	70,836,000
Cost & expenses	75,430,000	64,057,000
Operating income	1,628,000	4,107,000
Other income (expense), net	(51,000)	186,000
Net before taxes	1,013,000	3,749,000
Income taxes	1,932,000	177,000
Net income	(919,000)	3,572,000
Balance for common	(1,208,000)	3,283,000
Earnings common share		
Primary	\$0.02	\$0.04
Fully Diluted	\$0.02	\$0.04
Common Shares:		
Full Diluted	73,540,754	73,921,186
Year-end	73,693,758	72,986,172

Consolidated Balance Sheet Items, as of (\$):

	2025	2024
Assets:		
Cash & equivalents	54,985,000	
Inventories	47,655,000	
Current assets	163,466,000	
Net property & equip.	39,761,000	
Total assets	389,514,000	
Liabilities:		
Current liabilities	90,132,000	
Long-term debt	36,353,000	
Stockholders' equity	254,558,000	
Net current assets	73,334,000	

CARDLYTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	177,178	204,301
Cost & expenses	253,860	371,737
Operating income	(95,721)	(187,185)
Other income (expense), net	(104,000)	13,017
Net income	(95,238)	(173,715)
Earnings common share		
Primary	\$(1.81)	\$(3.66)
Fully Diluted	\$(1.81)	\$(3.66)
Common Shares:		
Full Diluted	52,708	47,469
Year-end	51,257	50,342

CARECLOUD INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	86,076,000	82,598,000
Cost & expenses	67,110,000	66,048,000
Operating income	8,225,000	5,665,000
Other income (expense), net	(104,000)	(227,000)
Net before taxes	8,036,000	4,674,000
Income taxes	126,000	119,000
Net income	7,910,000	4,555,000
Balance for common	2,369,000	(4,469,000)
Earnings common share		
Primary	\$0.07	\$(0.28)

Fully Diluted	\$0.07	\$(0.28)
Common Shares:		
Full Diluted	36,236,128	16,114,330
Year-end	42,397,039	16,221,820

CARGURUS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	697,887	665,846
Cost & expenses	559,561	698,358
Operating income	125,273	(39,866)
Other income (expense), net	(271)	122
Net before taxes	132,526	(30,681)
Income taxes	26,421	(5,772)
Net income	106,105	(24,909)
Earnings common share		
Primary	\$1.06	\$(0.24)
Fully Diluted	\$1.04	\$(0.24)
Common Shares:		
Full Diluted	101,640	104,770
Year-end	96,125	103,339

CARLYLE GROUP INC (THE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	2,357,400	3,255,600
Operating income	697,400	1,128,300
Other income (expense), net		200
Invest. income	176,100	(9,600)
Net before taxes	697,400	1,128,300
Income taxes	98,200	264,500
Net income	599,200	863,800
Earnings common share		
Primary	\$1.25	\$2.26
Fully Diluted	\$1.22	\$2.21
Common Shares:		
Full Diluted	369,933	367,074
Year-end	360,137	357,681

CARLYLE SECURED LENDING INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	111,936	96,030
Operating income	76,718	80,206
Other income (expense), net	14,214	13,790
Gains or losses	(32)	90
Invest. income	(38,313)	(26,465)
Net income	52,587	67,621
Balance for common	51,761	64,996
Earnings common share		
Primary	\$0.78	\$1.28
Fully Diluted	\$0.78	\$1.20
Common Shares:		
Full Diluted	67,775	56,418
Year-end	72,903	50,848

CARTESIAN THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,850	39,672
Cost & expenses	66,616	56,838
Operating income	(64,766)	(17,166)
Other income (expense), net	5,306	5,982
Gains or losses	21,734	(55,987)
Net income	(37,726)	(67,171)
Earnings common share		
Primary	\$(1.45)	\$(4.61)
Fully Diluted	\$(1.45)	\$(4.61)
Common Shares:		
Full Diluted	25,962	14,562
Year-end	26,004	23,897

CASS INFORMATION SYSTEMS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	111,948	117,210
Operating income	28,770	18,229
Net before taxes	28,770	18,229
Income taxes	5,848	3,829
Income contin. oper.	22,922	14,400
Net income	26,927	14,574
Earnings common share		
Primary	\$2.03	\$1.08
Fully Diluted	\$1.99	\$1.06

Common Shares:		
Full Diluted	13,537	13,798
Year-end	13,120	13,582

CELSIUS HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,793,641,000	1,023,433,000
Cost & expenses	1,678,644,000	849,209,000
Operating income	114,997,000	174,224,000
Other income (expense), net	7,022,000	
Net before taxes	102,427,000	205,267,000
Income taxes	19,167,000	41,317,000
Net income	83,260,000	163,950,000
Balance for common	54,699,000	131,005,000
Earnings common share		
Primary	\$0.22	\$0.56
Fully Diluted	\$0.22	\$0.55
Common Shares:		
Full Diluted	252,801,000	237,480,000
Year-end	257,784,000	234,982,044

CENTURY ALUMINUM CO.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,894,200	1,589,400
Cost & expenses	1,769,100	1,517,300
Operating income	125,100	72,100
Other income (expense), net	(17,500)	241,500
Gains or losses	(51,200)	(600)
Net before taxes	26,400	283,300
Income taxes	(800)	3,000
Net income	27,200	280,300
Balance for common	38,000	276,100
Earnings common share		
Primary	\$0.41	\$2.98
Fully Diluted	\$0.40	\$2.83
Common Shares:		
Full Diluted	94,600	98,800
Year-end	93,342	92,799

CERTARA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	315,190	284,787
Cost & expenses	252,906	252,913
Operating income	20,180	(7,734)
Net before taxes	10,526	(19,364)
Income taxes	6,226	(736)
Net income	4,300	(18,628)
Earnings common share		
Primary	\$0.03	\$(0.12)
Fully Diluted	\$0.03	\$(0.12)
Common Shares:		
Full Diluted	161,264	160,225
Year-end	159,397	160,900

CERUS CORP.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	177,259	157,346
Operating income	(8,040)	(12,776)
Other income (expense), net	2,427	1,468
Net before taxes	(13,218)	(18,305)
Income taxes	235	94
Net income	(13,453)	(18,399)
Earnings common share		
Primary	\$(0.07)	\$(0.10)
Fully Diluted	\$(0.07)	\$(0.10)
Common Shares:		
Full Diluted	190,083	184,170
Year-end	192,037	185,626

CEVA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	78,307	77,716
Cost & expenses	88,807	84,886
Operating income	(10,948)	(7,619)
Other income (expense), net	(261)	(97)
Net before taxes	(5,743)	(2,754)
Income taxes	3,797	4,296
Net income	(9,540)	(7,050)
Earnings common share		

Primary	\$(0.40)	\$(0.30)
Fully Diluted	\$(0.40)	\$(0.30)
Common Shares:		
Full Diluted	23,869	23,605
Year-end	24,017	23,627

CHORD ENERGY CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,707,687	3,796,408
Cost & expenses	2,500,394	2,204,522
Operating income	105,568	834,850
Other income (expense), net	(7,309)	27,499
Gains or losses	82,674	29,753
Net before taxes	127,609	853,156
Income taxes	167,566	215,126
Net income	(39,957)	638,030
Balance for common	(41,270)	635,432
Earnings common share		
Primary	\$(0.72)	\$12.61
Fully Diluted	\$(0.72)	\$12.34
Common Shares:		
Full Diluted	57,141	51,507
Year-end	56,865	61,480

CIDARA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,275	1,275
Cost & expenses	141,281	123,195
Operating income	(141,281)	(121,920)
Other income (expense), net	(110)	
Income contin. oper.		(117,922)
Net income	(132,431)	(117,520)
Earnings common share		
Primary	\$(7.00)	\$(22.53)
Fully Diluted	\$(7.00)	\$(22.53)
Common Shares:		
Full Diluted	18,916	5,215
Year-end	29,335	7,047

CLARUS CORP (NEW)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	185,027	192,910
Cost & expenses	205,716	213,179
Operating income	(20,689)	(20,269)
Other income (expense), net	999	669
Net before taxes	(19,172)	(18,402)
Income taxes	(3,877)	(3,290)
Income contin. oper.		(15,112)
Net income	(15,295)	13,234
Earnings common share		
Primary	\$(0.40)	\$0.35
Fully Diluted	\$(0.40)	\$0.35
Common Shares:		
Full Diluted	38,390	38,286
Year-end	38,402	38,362

CLIMB BIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	48,587	71,109
Operating income	(48,587)	(71,109)
Net income	(42,335)	(65,481)
Earnings common share		
Primary	\$(0.63)	\$(1.57)
Fully Diluted	\$(0.63)	\$(1.57)
Common Shares:		
Full Diluted	67,686	41,760
Year-end	68,184	67,224

CLOVER HEALTH INVESTMENTS CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,436,601,000	1,034,168,000
Cost & expenses	1,471,545,000	1,057,482,000
Operating income	(36,210,000)	(24,301,000)
Gains or losses	(19,000)	(484,000)
Income contin. oper.		(24,785,000)
Net income	(36,229,000)	(20,917,000)
Earnings common share		
Primary	\$(0.07)	\$(0.06)
Fully Diluted	\$(0.07)	\$(0.06)

Common Shares:	
Full Diluted	510,191,111 488,501,812
Year-end	506,866,208 500,289,270

CODEXIS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	31,472	37,885
Cost & expenses	83,770	89,063
Operating income	(52,298)	(51,178)
Other income (expense), net	(3,217)	(6,421)
Net before taxes	(53,546)	(54,869)
Income taxes	29	31
Net income	(53,575)	(54,900)
Earnings common share		
Primary	\$(0.62)	\$(0.78)
Fully Diluted	\$(0.62)	\$(0.78)
Common Shares:		
Full Diluted	86,045	70,759
Year-end	90,281	81,376

COGENT BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	233,870	202,205
Operating income	(233,870)	(202,205)
Other income (expense), net	(14)	44
Net income	(226,445)	(187,932)
Balance for common	(189,468)	
Earnings common share		
Primary	\$(1.55)	\$(1.85)
Fully Diluted	\$(1.55)	\$(1.85)
Common Shares:		
Full Diluted	121,864	101,435
Year-end	139,828	110,458

COGENT COMMUNICATIONS HOLDINGS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	735,242	783,813
Cost & expenses	613,365	717,438
Operating income	(89,879)	(164,372)
Other income (expense), net	(5,606)	
Gains or losses		22,202
Net before taxes	(197,382)	(204,638)
Income taxes	(45,989)	(43,881)
Net income	(151,393)	(160,757)
Earnings common share		
Primary	\$(3.17)	\$(3.39)
Fully Diluted	\$(3.17)	\$(3.39)
Common Shares:		
Full Diluted	47,827	47,454
Year-end	49,121	49,013

COGNITION THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	34,128	43,243
Operating income	(34,128)	(43,243)
Other income (expense), net	13,992	17,329
Net income	(20,144)	(26,129)

COHERENT CORP**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,581,378	
Cost & expenses	1,305,771	1,262,188
Operating income	216,886	19,303
Net before taxes	216,886	19,303
Income taxes	(8,310)	(5,558)
Net income	225,196	24,861
Balance for common	192,870	(5,946)
Earnings common share		
Primary	\$1.24	\$(0.04)
Fully Diluted	\$1.19	\$(0.04)
Common Shares:		
Full Diluted	190,684	153,626
Year-end	156,953	154,516

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025
Cash & equivalents	852,778
Inventories	1,632,605
Current assets	4,041,955
Net property & equip.	1,944,353
Total assets	14,698,845
Liabilities:	
Current liabilities	1,735,975
Long-term debt	3,259,406
Stockholders' equity	8,687,415
Net current assets	2,305,980

COHERUS ONCOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	29,424	18,656
Cost & expenses	164,678	172,925
Operating income	(135,254)	(154,269)
Other income (expense), net	5,229	(6,210)
Income contin. oper.	(136,777)	(169,301)
Net income	205,667	79,203
Earnings common share		
Primary	\$1.77	\$0.69
Fully Diluted	\$1.77	\$0.69
Common Shares:		
Full Diluted	116,056	114,263
Year-end	116,236	115,213

COLLEGIUM PHARMACEUTICAL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	575,118	449,500
Cost & expenses	456,239	317,716
Operating income	118,879	131,784
Other income (expense), net		(11,329)
Net before taxes	63,583	81,299
Income taxes	17,676	24,645
Net income	45,907	56,654
Earnings common share		
Primary	\$1.45	\$1.75
Fully Diluted	\$1.28	\$1.51
Common Shares:		
Full Diluted	39,386	40,400
Year-end	31,601	32,230

COLUMBIA SPORTSWEAR CO.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,327,123	2,271,994
Cost & expenses	2,236,820	2,138,574
Operating income	90,303	133,420
Other income (expense), net	4,447	2,030
Net before taxes	109,275	158,355
Income taxes	25,218	37,639
Net income	84,057	120,716
Earnings common share		
Primary	\$1.53	\$2.05
Fully Diluted	\$1.53	\$2.04
Common Shares:		
Full Diluted	55,114	59,043
Year-end	54,060	57,261

COMMERCE.COM INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	252,832	245,899
Cost & expenses	255,709	279,479
Operating income	(9,632)	(40,933)
Other income (expense), net	3,499	11,525
Net before taxes	(10,021)	(23,949)
Income taxes	957	691
Net income	(10,978)	(24,640)
Earnings common share		
Primary	\$(0.14)	\$(0.32)
Fully Diluted	\$(0.14)	\$(0.32)
Common Shares:		
Full Diluted	79,911	77,319
Year-end	81,254	78,349

COMTECH TELECOMMUNICATIONS CORP.**Annual Report****Consolidated Income Statement, Years Ended Jul. 31 (\$000):**

	2025	2024	2023	Weighted average shares outstanding				long-term debt	4,050	4,050		
Proxy solicitation costs	2,682	...	...	- diluted	29,405	28,799	28,002	Interest payable	15	1,072		
Total revenues	499,528	540,403	549,994	Year end shares outstanding	29,410	28,733	28,063	Other accrued liabilities	13,628	7,310		
Net Sales	499,528	540,403	...	Income (loss) per share - continuing operations - basic	\$(6.95)	\$(4.70)	...	Contract liabilities	62,546	65,834		
Net sales	...	...	549,994	Net income (loss) per share - basic	\$(6.95)	\$(4.70)	\$(1.21)	Accrued expenses and other current liabilities	58,423	62,245		
Cost of sales	...	...	365,534	Income (loss) per share - continuing operations - diluted	\$(6.95)	\$(4.70)	...	Accrued contributions for constructing long-lived assets	2,789	...		
Gross profit	127,874	157,179	184,460	Net income (loss) per share - diluted	\$(6.95)	\$(4.70)	\$(1.21)	Total current liabilities	158,249	183,547		
Selling, general and administrative	143,487	123,198	...	Dividends per common share	...	...	\$0.20	Non-current portion of long-term debt, net	114,414	170,486		
Selling, general & administrative expenses	...	...	120,003	Full-Time Employees	1,385	1,676	1,718	Operating lease liabilities, non-current	29,376	30,258		
Research & development expenses	17,408	24,077	48,631	Total number of employees	1,385	1,676	...	Income taxes payable	1,818	2,231		
Amortization of acquired in-process research & development	...	...	21,396	Number of common stockholders	760	764	770	Deferred tax liability, net	4,619	6,193		
Amortization of intangibles	21,723	21,154	...	Cost of Sales	371,654	383,224	...	Long-term contract liabilities	21,005	21,035		
CEO transition costs	...	...	9,090	Interest (income) and other	(155)	(678)	...	Other liabilities	3,950	12,355		
CEO transition costs	2,117	2,916	...	Write-off of deferred financing costs	8,977	1,832	...	Warrant and derivative liabilities	17,849	...		
Loss on business divestiture	...	(1,199)	...	Change in fair value of warrants and derivatives	38,498	4,273	...	Non-current portion of subordinated credit facility, net	95,588	...		
Impairment of long-lived assets, including goodwill	79,555	64,525	...	Consolidated Balance Sheet, Years Ended Jul. 31 (\$'000):				Total liabilities	446,868	426,105		
Total expenses	266,972	237,069	199,120		2025	2024		Common stock	4,444	4,377		
Operating income (loss)	(139,098)	(79,890)	(14,660)	Cash & cash equivalents	40,019	32,433		Additional paid-in capital	548,722	640,145		
Interest expense	45,650	22,153	14,961	Accounts receivable, net - Balancing value	144,837	195,595		Retained earnings	(6,895)	103,580		
Other income (expense), net	...	...	(1,226)	Accounts receivable, gross	163,993	197,527		Treasury stock	441,849	441,849		
Income (loss) before provision for (benefit from) income taxes - U.S.	...	...	(21,327)	Less allowance for doubtful accounts	19,156	1,932		Preferred Stock - Redeemable - Convertible	189,545	180,076		
Income (loss) before provision for (benefit from) income taxes - foreign	...	...	(9,520)	Raw materials & components	64,022	72,820		Total stockholders' equity (deficit)	293,967	486,329		
Income (loss) before provision for (benefit from) income taxes	(155,382)	(100,280)	(30,847)	Work in process	31,356	38,587		Total Equity	293,967	486,329		
Federal	673	377	(258)	Less reserve for excess & obsolete inventories	26,423	18,271		Recent Dividends:				
State	514	1,181	1,412	Inventories net	68,955	93,136		1. Comtech Telecommunications Corp. series A convertible preferred.				
Foreign	433	1,137	958	Prepaid expenses and other current assets	16,375	15,387		ExDate	Amt	Declared	Record	Payable
Federal	...	(2,345)	(4,623)	Total current assets	270,186	336,551		01/18/2022	0.10	12/09/2021	01/19/2022	02/18/2022
State	...	(834)	(815)	Machinery & equipment	138,678	142,405		04/19/2022	0.10	03/10/2022	04/20/2022	05/20/2022
Foreign	(1,700)	189	(622)	Leasehold improvements	17,698	17,175		07/19/2022	0.10	06/09/2022	07/20/2022	08/19/2022
Net Income After Taxes	(155,302)	(99,985)	...	Property, plant and equipment, gross	33,595	28,869		10/18/2022	0.10	09/29/2022	10/19/2022	11/18/2022
Provision for (benefit from) income taxes	(80)	(295)	(3,948)	Software Development	189,971	188,449		01/17/2023	0.10	12/08/2022	01/18/2023	02/17/2023
(Loss) gain on extinguishment of convertible preferred stock	(51,179)	...	...	Property, plant & equipment, gross	146,561	141,121		2. Comtech Telecommunications Corp. common.				
Net income (loss)	(155,302)	(99,985)	(26,899)	Less accumulated depreciation & amortization	43,410	47,328		No dividends paid.				
Convertible preferred stock issuance costs	...	4,349	...	Property, plant and equipment, net	104,151	93,813		Annual Dividends:				
Establishment of initial convertible preferred stock purchase option liability	...	19,555	...	Operating lease right-of-use assets, net	30,812	31,590		1. Comtech Telecommunications Corp. series A convertible preferred.				
Dividend on convertible preferred stock	100,128	11,551	7,007	Goodwill	204,625	284,180		2022	0.40	2023	0.10	
Net income (loss) attributable to common stockholders	(204,251)	(135,440)	(33,906)	Intangibles with finite lives, net	173,105	194,828		2. Comtech Telecommunications Corp. common.				
Weighted average shares outstanding - basic	29,405	28,799	28,002	Deferred financing costs, net	1,907	3,251		No dividends paid.				
				Other assets, net	16,790	14,706		CONDUENT INC				
				Total assets	740,835	912,434		Earnings, 9 mos. to Sep 30(Consol. – \$Millions):				
				Accounts payable	25,965	42,477			2025	2024		
				Accrued wages & benefits	21,158	22,131		Total Revenues	2,272	2,556		
				Accrued contract costs	6,676	17,267		Cost & expenses	2,224	1,751		
				Accrued acquisition-related costs	8,475	7,049		Operating income	(132)	586		
				Accrued commissions & royalties	4,867	5,396		Net before taxes	(132)	586		
				Accrued legal costs	830	3,092		Income taxes	5	148		
				Operating lease liabilities, current	7,250	7,869		Net income	(137)	438		
				Current portion of				Balance for common	(144)	431		
								Earnings common share				
								Primary	\$(0.90)	\$2.28		
								Fully Diluted	\$(0.90)	\$2.22		
								Common Shares:				
								Full Diluted	160	197		
								Year-end	155	160		
								CONNECTONE BANCORP INC (NEW)				
								Earnings, 9 mos. to Sep 30(Consol. – \$000):				
									2025	2024		
								Cost & expenses	410,814	329,582		
								Operating income	59,374	72,010		
								Net before taxes	59,374	72,010		
								Income taxes	18,449	18,588		
								Net income	40,925	53,422		
								Balance for common	36,311	48,762		

Earnings common share		
Primary	\$0.83	\$1.27
Fully Diluted	\$0.83	\$1.27
Common Shares:		
Full Diluted	43,746	38,458
Year-end	50,273	38,368

CONSENSUS CLOUD SOLUTIONS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	262,626	263,399
Cost & expenses	148,150	147,426
Operating income	114,476	115,973
Other income (expense), net	(3,285)	2,496
Net before taxes	86,400	96,028
Income taxes	22,376	24,664
Net income	64,024	71,364
Earnings common share		
Primary	\$3.31	\$3.71
Fully Diluted	\$3.29	\$3.69
Common Shares:		
Full Diluted	19,479	19,321
Year-end	18,986	19,304

CONSTELLATION ENERGY CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$Millions):

	2025	2024
Total Revenues	18,186	18,186
Cost & expenses	16,228	13,938
Operating income	2,488	3,380
Other income (expense), net	729	693
Equity earnings	1	1
Net before taxes	2,819	3,657
Income taxes	928	768
Net income	1,891	2,888
Earnings common share		
Primary	\$6.02	\$9.20
Fully Diluted	\$6.02	\$9.17
Common Shares:		
Full Diluted	314	316
Year-end	312	313

CORVEL CORP**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	474,354,000	436,102,000
Cost & expenses	403,171,000	379,398,000
Operating income	71,183,000	56,704,000
Net before taxes	71,183,000	56,704,000
Income taxes	16,042,000	11,729,000
Net income	55,141,000	44,975,000
Earnings common share		
Primary	\$1.07	\$0.88
Fully Diluted	\$1.06	\$0.87
Common Shares:		
Full Diluted	51,817,000	51,981,000
Year-end	51,293,374	51,405,480

COVENANT LOGISTICS GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	869,098,000	854,145,000
Cost & expenses	774,113,000	753,538,000
Operating income	27,116,000	36,147,000
Other income (expense), net	11,622,000	11,763,000
Net before taxes	29,943,000	37,569,000
Income taxes	7,276,000	8,817,000
Income contin. oper.	22,667,000	28,752,000
Net income	25,496,000	29,202,000
Earnings common share		
Primary	\$0.99	\$1.11
Fully Diluted	\$0.94	\$1.05
Common Shares:		
Full Diluted	27,156,000	27,654,000
Year-end	25,047,178	26,359,334

CRICUT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	505,183	503,229
Cost & expenses	423,086	440,996
Operating income	82,097	62,233
Other income (expense), net	1,064	2,067
Net before taxes	92,095	72,244

Income taxes	23,181	21,340
Net income	68,914	50,904
Earnings common share		
Primary	\$0.32	\$0.24
Fully Diluted	\$0.32	\$0.24
Common Shares:		
Full Diluted	214,016	215,281
Year-end	212,195	214,422

CRINETICS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,535	1,535
Cost & expenses	384,638	245,148
Operating income	(383,103)	(244,109)
Other income (expense), net	(232)	(301)
Equity earnings	470	470
Net income	(342,502)	(217,813)
Earnings common share		
Primary	\$(3.66)	\$(2.82)
Fully Diluted	\$(3.66)	\$(2.82)
Common Shares:		
Full Diluted	93,707	77,173
Year-end	94,548	80,841

CSG SYSTEMS INTERNATIONAL INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	900,196	880,596
Cost & expenses	796,598	775,271
Operating income	89,699	89,039
Other income (expense), net	(4,240)	(1,455)
Net before taxes	67,761	71,243
Income taxes	18,881	18,859
Net income	48,880	52,384
Earnings common share		
Primary	\$1.76	\$1.84
Fully Diluted	\$1.74	\$1.83
Common Shares:		
Full Diluted	28,123	28,621
Year-end	28,608	29,292

CULLINAN THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	186,389	141,871
Operating income	(186,389)	(141,871)
Other income (expense), net	(374)	(205)
Net income	(169,166)	(119,928)
Earnings common share		
Primary	\$(2.58)	\$(2.30)
Fully Diluted	\$(2.58)	\$(2.30)
Common Shares:		
Full Diluted	58,999	52,157
Year-end	59,076	58,141

CURIS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	8,305	7,563
Cost & expenses	33,637	43,111
Operating income	(25,332)	(35,548)
Other income (expense), net	(1,871)	236
Net income	(26,938)	(33,771)
Earnings common share		
Primary	\$(2.19)	\$(5.77)
Fully Diluted	\$(2.19)	\$(5.77)
Common Shares:		
Full Diluted	12,294	5,848
Year-end	12,734	6,020

CVRX INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	40,627	35,950
Cost & expenses	80,708	85,166
Operating income	(40,081)	(49,216)
Other income (expense), net	3,108	2,905
Net before taxes	(41,383)	(49,188)
Income taxes	(11)	126
Net income	(41,372)	(49,314)
Earnings common share		
Primary	\$(1.59)	\$(2.25)
Fully Diluted	\$(1.59)	\$(2.25)

Common Shares:		
Full Diluted	26,040	21,885
Year-end	26,194	24,204

CYTEK BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	139,352	142,977
Cost & expenses	174,142	166,486
Operating income	(34,790)	(23,509)
Other income (expense), net	8,543	3,972
Net before taxes	(25,810)	(16,023)
Income taxes	(3,347)	(360)
Net income	(22,463)	(15,663)
Earnings common share		
Primary	\$(0.18)	\$(0.12)
Fully Diluted	\$(0.18)	\$(0.12)
Common Shares:		
Full Diluted	127,604	131,121
Year-end	127,865	129,766

CYTOMX THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	75,538	100,010
Cost & expenses	69,970	92,694
Operating income	5,568	7,316
Other income (expense), net	33	(19)
Net before taxes	9,326	13,155
Income taxes	184	162
Net income	9,142	12,993
Earnings common share		
Primary	\$0.07	\$0.15
Fully Diluted	\$0.07	\$0.15
Common Shares:		
Full Diluted	128,860	84,429
Year-end	165,070	78,233

DATADOG INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,473,964	2,473,964
Cost & expenses	2,527,693	1,901,656
Operating income	(53,729)	44,892
Other income (expense), net	(11,356)	109,647
Net before taxes	73,551	150,114
Income taxes	12,377	11,962
Net income	61,174	138,152
Earnings common share		
Primary	\$0.18	\$0.41
Fully Diluted	\$0.18	\$0.36
Common Shares:		
Full Diluted	361,905	383,383
Year-end	350,555	339,270

DEFINITIVE HEALTHCARE CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	179,987	189,914
Cost & expenses	351,027	772,966
Operating income	(197,644)	(611,257)
Other income (expense), net	8,541	68,066
Net before taxes	(192,056)	(543,133)
Income taxes	(9,906)	(36,404)
Net income	(182,150)	(506,729)
Earnings common share		
Primary	\$(1.20)	\$(3.02)
Fully Diluted	\$(1.20)	\$(3.02)
Common Shares:		
Full Diluted	107,761	117,186
Year-end	103,012	115,444

DENALI THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	417,977	372,032
Operating income	(417,977)	(308,020)
Gains or losses		14,537
Net income	(383,991)	(308,020)
Earnings common share		
Primary	\$(2.24)	\$(1.89)
Fully Diluted	\$(2.24)	\$(1.89)
Common Shares:		
Full Diluted	171,702	162,589
Year-end	146,626	143,840

DENTSPLY SIRONA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,719,000	2,888,000
Cost & expenses	3,002,000	3,258,000
Operating income	(283,000)	(370,000)
Other income (expense), net	10,000	10,000
Net before taxes	(339,000)	(413,000)
Income taxes	114,000	69,000
Net income	(453,000)	(482,000)
Earnings common share		
Primary	\$(2.27)	\$(2.35)
Fully Diluted	\$(2.27)	\$(2.35)
Common Shares:		
Full Diluted	199,300	204,700
Year-end	199,500	198,800

DESIGN THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	61,298,000	45,689,000
Operating income	(61,298,000)	(45,689,000)
Other income (expense), net	7,503,000	9,752,000
Net income	(53,795,000)	(35,937,000)
Earnings common share		
Primary	\$(0.95)	\$(0.64)
Fully Diluted	\$(0.95)	\$(0.64)
Common Shares:		
Full Diluted	56,856,779	56,555,312
Year-end	56,963,757	56,621,037

DIAMONDBACK ENERGY, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	11,650,000,000	7,355,000,000
Cost & expenses	3,953,000,000	2,677,000,000
Operating income	4,048,000,000	2,984,000,000
Other income (expense), net	176,000,000	112,000,000
Gains or losses	149,000,000	101,000,000
Net before taxes	4,207,000,000	3,096,000,000
Income taxes	894,000,000	685,000,000
Net income	3,313,000,000	2,411,000,000
Balance for common	3,108,000,000	2,247,000,000
Earnings common share		
Primary	\$10.71	\$12.00
Fully Diluted	\$10.71	\$12.00
Common Shares:		
Full Diluted	290,188,000	187,253,000
Year-end	286,876,206	292,742,664

DIODES, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,090,495,000	971,822,000
Cost & expenses	1,050,725,000	921,792,000
Operating income	22,577,000	38,533,000
Other income (expense), net	(4,408,000)	1,678,000
Gains or losses	41,734,000	1,310,000
Net before taxes	69,488,000	50,412,000
Income taxes	12,638,000	9,799,000
Net income	56,850,000	40,613,000
Earnings common share		
Primary	\$1.21	\$0.78
Fully Diluted	\$1.20	\$0.77
Common Shares:		
Full Diluted	46,454,000	46,378,000
Year-end	46,383,277	46,146,009

DORCHESTER MINERALS LP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	110,975	121,811
Cost & expenses	21,356	18,976
Operating income	41,162	78,208
Net income	41,162	78,208
Earnings common share		
Primary	\$0.84	\$1.89
Fully Diluted	\$0.84	\$1.89
Common Shares:		
Full Diluted	47,451	39,954
Year-end	48,256	47,340

DRAFTKINGS INC (NEW)**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	4,065,332,000	
Cost & expenses	4,232,909,000	3,844,747,000
Operating income	(167,577,000)	469,820,000
Other income (expense), net	41,201,000	(5,801,000)
Gains or losses	877,000	(8,282,000)
Equity earnings	(1,421,000)	19,000
Net before taxes	(140,012,000)	447,623,000
Income taxes	(5,875,000)	(75,208,000)
Net income	(132,716,000)	372,434,000
Earnings common share		
Primary	\$(0.27)	\$(0.78)
Fully Diluted	\$(0.27)	\$(0.78)
Common Shares:		
Full Diluted	495,522,000	479,981,000
Year-end	496,503,000	487,169,000

DRILLING TOOLS INTERNATIONAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	121,118,000	114,600,000
Cost & expenses	94,300,000	85,752,000
Operating income	(3,954,000)	11,616,000
Other income (expense), net	(6,335,000)	(5,241,000)
Gains or losses	(70,000)	429,000
Net before taxes	(3,954,000)	4,774,000
Income taxes	1,024,000	415,000
Net income	(4,978,000)	4,359,000
Earnings common share		
Primary	\$(0.14)	\$0.14
Fully Diluted	\$(0.14)	\$0.14
Common Shares:		
Full Diluted	35,516,692	31,404,333
Year-end	35,661,297	34,704,696

DRIVEN BRANDS HOLDINGS INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	1,602,835	1,775,471
Cost & expenses	1,338,639	1,465,720
Operating income	161,313	178,532
Other income (expense), net	(4,549)	(205)
Net before taxes	82,674	53,315
Income taxes	(7,487)	33,842
Income contin. oper.	90,161	
Net income	113,932	19,473
Earnings common share		
Primary	\$0.69	\$0.12
Fully Diluted	\$0.69	\$0.12
Common Shares:		
Full Diluted	163,686	160,713
Year-end	164,454	164,114

DUOLINGO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	754,721	538,474
Cost & expenses	662,605	487,991
Operating income	92,116	48,713
Other income (expense), net	2,158	(759)
Net before taxes	127,909	79,954
Income taxes	(244,202)	5,287
Net income	372,111	74,667
Earnings common share		
Primary	\$8.17	\$1.73
Fully Diluted	\$7.63	\$1.57
Common Shares:		
Full Diluted	48,766	47,515
Year-end	46,109	43,944

DXP ENTERPRISES, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,488,975	1,331,126
Cost & expenses	1,358,776	1,225,035
Operating income	130,199	106,091
Other income (expense), net	687	(263)
Gains or losses	(932)	(380)
Net before taxes	88,221	62,291
Income taxes	22,389	13,165
Net income	65,832	49,126
Balance for common	65,764	49,058
Earnings common share		
Primary	\$4.19	\$3.08

Fully Diluted	\$3.98	\$2.93
Common Shares:		
Full Diluted	16,533	16,755
Year-end	15,677	15,695

DYNE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	352,055	246,778
Operating income	(352,055)	(246,778)
Other income (expense), net	(1,408)	(428)
Net income	(334,259)	(227,876)
Earnings common share		
Primary	\$(2.74)	\$(2.49)
Fully Diluted	\$(2.74)	\$(2.49)
Common Shares:		
Full Diluted	121,980	91,512
Year-end	142,613	101,753

ECHOSTAR CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	11,208,975	11,858,578
Cost & expenses	26,779,711	10,629,599
Operating income	(16,943,415)	(241,380)
Other income (expense), net	105,480	(65,501)
Net before taxes	(17,596,209)	(513,367)
Income taxes	(4,304,736)	(53,733)
Net income	(13,291,473)	(459,634)
Earnings common share		
Primary	\$(46.25)	\$(1.67)
Fully Diluted	\$(46.25)	\$(1.67)
Common Shares:		
Full Diluted	287,362	271,616
Year-end	287,808	271,829

EDGEWISE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	135,427	113,292
Operating income	(135,427)	(113,292)
Net income	(117,579)	(94,151)
Earnings common share		
Primary	\$(1.15)	\$(1.03)
Fully Diluted	\$(1.15)	\$(1.03)
Common Shares:		
Full Diluted	101,892	91,640
Year-end	105,762	94,409

EDITAS MEDICINE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	15,779	1,710
Cost & expenses	168,034	206,269
Operating income	(152,255)	(204,559)
Other income (expense), net	(2,184)	
Net income	(154,440)	(191,698)
Earnings common share		
Primary	\$(1.80)	\$(2.33)
Fully Diluted	\$(1.80)	\$(2.33)
Common Shares:		
Full Diluted	85,878	82,246
Year-end	93,264	82,539

EHEALTH INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	227,770	217,229
Cost & expenses	287,541	306,298
Operating income	(59,771)	(89,069)
Other income (expense), net	3,894	6,425
Net before taxes	(63,257)	(91,161)
Income taxes	(16,118)	(3,736)
Net income	(47,139)	(87,425)
Balance for common	(84,336)	(120,647)
Earnings common share		
Primary	\$(2.78)	\$(4.13)
Fully Diluted	\$(2.78)	\$(4.13)
Common Shares:		
Full Diluted	30,347	29,211
Year-end	30,700	29,540

ENACT HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	242,907	172,829
Operating income	635,752	670,207
Other income (expense), net		(10,930)
Net before taxes	635,752	670,207
Income taxes	138,669	144,877
Net income	497,083	525,330
Earnings common share		
Primary	\$3.32	\$3.34
Fully Diluted	\$3.30	\$3.31
Common Shares:		
Full Diluted	150,659	158,558
Year-end	145,566	154,450

ENERGY RECOVERY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	68,116	77,873
Cost & expenses	75,542	83,764
Operating income	(7,426)	(5,891)
Other income (expense), net	25	(45)
Net before taxes	(4,541)	(1,120)
Income taxes	(589)	(699)
Net income	(3,952)	(421)
Earnings common share		
Primary	\$(0.07)	\$(0.01)
Fully Diluted	\$(0.07)	\$(0.01)
Common Shares:		
Full Diluted	54,101	57,409
Year-end	52,980	56,505

ENOVIX CORP**Earnings, 9 mos. to** (Consol. – \$):

	09/28/25	09/29/24
Total Revenues	20,556,000	13,357,000
Cost & expenses	153,822,000	221,510,000
Operating income	(133,266,000)	208,153,000
Other income (expense), net	6,262,000	(1,509,000)
Gains or losses	11,778,000	17,359,000
Net before taxes	(123,011,000)	187,626,000
Income taxes	(1,445,000)	(2,544,000)
Net income	(121,566,000)	185,082,000
Earnings common share		
Primary	\$(0.59)	\$(1.07)
Fully Diluted	\$(0.59)	\$(1.07)
Common Shares:		
Full Diluted	204,758,291	172,393,869
Year-end	215,367,757	177,591,877

ENTRADA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	24,122	173,384
Cost & expenses	139,812	120,506
Operating income	(115,690)	52,878
Net before taxes	(103,754)	67,224
Income taxes	832	2,729
Net income	(104,586)	64,495
Earnings common share		
Primary	\$(2.53)	\$1.79
Fully Diluted	\$(2.53)	\$1.72
Common Shares:		
Full Diluted	41,293	37,583
Year-end	38,219	37,400

EPLUS INC**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,246,141,000	1,029,024,000
Cost & expenses	1,147,227,000	959,985,000
Operating income	85,035,000	58,455,000
Other income (expense), net	5,775,000	2,027,000
Net before taxes	90,810,000	60,482,000
Income taxes	25,522,000	16,490,000
Income contin. oper.	65,288,000	43,992,000
Net income	72,552,000	58,649,000
Earnings common share		
Primary	\$2.76	\$2.20
Fully Diluted	\$2.75	\$2.19
Common Shares:		
Full Diluted	26,407,000	26,750,000
Year-end	26,565,000	26,798,000

ESPERION THERAPEUTICS INC (NEW)**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	234,689,000	263,201,000
Cost & expenses	259,649,000	204,379,000
Operating income	(24,960,000)	58,822,000
Other income (expense), net	2,415,000	(46,420,000)
Net income	(84,513,000)	(30,427,000)
Earnings common share		
Primary	\$(0.43)	\$(0.17)
Fully Diluted	\$(0.43)	\$(0.17)
Common Shares:		
Full Diluted	198,153,654	184,366,434
Year-end	205,430,219	195,440,498

EVERCOMMERCE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	437,754	418,481
Cost & expenses	341,674	344,163
Operating income	45,960	13,562
Net before taxes	15,501	(20,113)
Income taxes	3,002	7,564
Income contin. oper.	12,499	(27,677)
Net income	11,556	(28,856)
Earnings common share		
Primary	\$0.06	\$(0.16)
Fully Diluted	\$0.06	\$(0.16)
Common Shares:		
Full Diluted	184,710	185,317
Year-end	180,040	183,821

EVERSPIN TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	40,399	37,159
Cost & expenses	45,837	42,693
Operating income	(5,438)	(5,534)
Other income (expense), net	2,394	5,187
Net before taxes	(1,781)	(347)
Income taxes	1	86
Net income	(1,782)	(433)
Earnings common share		
Primary	\$(0.08)	\$(0.02)
Fully Diluted	\$(0.08)	\$(0.02)
Common Shares:		
Full Diluted	22,456	21,530
Year-end	22,757	21,833

EVOLUS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	206,876	187,327
Cost & expenses	240,859	215,501
Operating income	(36,882)	(32,097)
Other income (expense), net	(549)	380
Net before taxes	(51,479)	(43,405)
Income taxes	292	224
Net income	(51,771)	(43,629)
Earnings common share		
Primary	\$(0.80)	\$(0.71)
Fully Diluted	\$(0.80)	\$(0.71)
Common Shares:		
Full Diluted	64,324	61,563
Year-end	64,766	63,251

EXELON CORP

Ctfs. Offered On Feb. 19, 2025, Co. closed its public offering and sale of \$1,000,000,000 aggregate principal amount of its 6.500% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 (the "notes"). Proceeds to the Company (after deducting underwriting discounts but before deducting offering expenses payable by Co. estimated at approximately \$2.2 million) from the sale of the notes were approximately \$990 million. The purchase and sale of the notes was made pursuant to an underwriting agreement dated Feb.13, 2025, with Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as the representatives of the several underwriters named on Schedule I thereto, pursuant to which the notes were issued and sold to such underwriters, severally and not jointly, for resale at a public offering price of 100.000% of the aggregate principal amount of the notes. Interest on the notes accrues from and including Feb. 19, 2025 and is payable semi-annually in arrears on Mar.15 and Sept 15 of each year, beginning on Sept15, 2025, and at maturity on Mar. 15, 2055. The notes bear interest (i) from and including Feb.19, 2025

to, but excluding, Mar. 15, 2035 at the rate of 6.500% per annum and (ii) from and including Mar. 15, 2035, during each Reset Period at a rate per annum equal to the Five-year U.S. Treasury Rate as of the most recent Reset Interest Determination Date plus a spread of 1.975%, to be reset on each Reset Date. So long as no event of default (as defined in the Indenture) with respect to the notes has occurred and is continuing, the Company may, at its option, defer interest payments on the notes, from time to time, for one or more deferral periods of up to 20 consecutive semi-annual interest payment periods each, except that no such optional deferral period may extend beyond the final maturity date of the notes or end on a day other than the day immediately preceding an interest payment date. Co. may redeem some or all of the notes, at its option, in whole or in part (i) on any day in the period commencing on December 15, 2034 and ending on and including Mar. 15, 2035 and (ii) after March 15, 2035, on any interest payment date, at a redemption price in cash equal to 100% of the principal amount of the notes being redeemed, plus, subject to the terms and conditions of the notes, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date. At Co.'s option, Co. may also redeem all of the notes upon the occurrence of certain specified events at the redemption prices provided therein, plus accrued and unpaid interest on the notes to, but excluding, the redemption date.

EXELON CORP

Dividend Announcement On July 29, 2025, Co.'s Board of Directors declared a regular quarterly dividend of \$0.40 per share on its common stock, payable on Sept. 15, 2025, to shareholders of record as of the close of business on Aug. 11, 2025.

EXELON CORP

Dividend Announcement On Oct. 29, 2025, Co.'s Board of Directors declared a regular quarterly dividend of \$0.40 per share on its common stock, payable on Dec. 15, 2025, to shareholders of record as of the close of business on Nov. 10, 2025.

EXELON CORP

Notes Sold On Feb. 21, Co. issued and sold \$1.0 billion in aggregate principal amount of Notes. The Notes were issued under an indenture, dated as of June 11, 2015 (the "Base Indenture"), between Co. and The Bank of New York Mellon Trust Company, N.A., as trustee, as amended and supplemented by the Eighth Supplemental Indenture, dated as of Feb. 1, 2025 (the "Eighth Supplemental Indenture"). A portion of the net proceeds from the sale of the Notes, together with available cash balances, will be used to repay \$464 million of Co.'s currently outstanding commercial paper borrowings having an approximate weighted average interest rate of 4.537% per annum as of February 11, 2025. The remainder of the net proceeds will be used for general corporate purposes. The 2031 Notes will pay interest at the fixed rate of 5.125% per annum, and the 2055 Notes will pay interest at the fixed rate of 5.875% per annum. Interest on the Notes will be payable semi-annually on Mar. 15 and Sept. 15 of each year, beginning on Sept. 15, 2025. The 2031 Notes will mature on Mar. 5, 2031, and the 2055 Notes will mature on Mar. 15, 2055.

EXELON CORP

Offering On May 2, 2025, Co. entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc., Credit Agricole Securities (USA) Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., RBC Capital Markets, LLC, Scotia Capital (USA) Inc. and Wells Fargo Securities, LLC, each as sales agent and as forward seller (collectively, the "Sales Agents"), and Bank of America, N.A., Barclays Bank PLC, BNP Paribas, Citibank, N.A., Crédit Agricole Corporate and Investment Bank, Goldman Sachs & Co. LLC, JPMorgan Chase Bank, National Association, Mizuho Markets Americas LLC, Morgan Stanley & Co. LLC, MUFG Securities EMEA plc, Royal Bank of Canada, The Bank of Nova Scotia and Wells Fargo Bank, National Association, each as forward purchaser (the "Forward Purchasers"), establishing an at-the-market equity distribution program, pursuant to which Co., through the Sales Agents, may offer and sell from time to time shares of Co.'s common stock, no par value (the "Common Stock"), having an aggregate gross sales price of up to \$2,500,000,000. In no event will the aggregate number of shares of Common Stock sold through the Sales Agents or the Forward Sellers under the Equity Distribution Agreement and under any Forward Sale Agreement have an aggregate gross sales price in excess of \$2,500,000,000. Co. has no obligation to offer or sell any shares of Common Stock under the Equity Distribution Agreement and may at any time suspend or terminate offers and sales under the Equity Distribution Agreement. The Equity Distribution Agreement provides that, in addition to the issuance and sale of shares of Common Stock by Co.

to or through the Sales Agents, Co. may enter into one or more forward sale transactions under master forward confirmations to be entered into by Co. and the relevant Forward Purchasers, and related supplemental confirmations to be entered into by Co. and such Forward Purchaser (each, a "Forward Sale Agreement"). In connection with any Forward Sale Agreement, the relevant Forward Purchaser will borrow from third parties and, through the relevant Sales Agent, offer a number of shares of Common Stock equal to the number of shares of Common Stock underlying the particular Forward Sale Agreement. Co. will not initially receive any proceeds from the sale of borrowed shares of Common Stock by a Forward Seller. Co. expects to receive proceeds from the sale of shares of Common Stock upon future physical settlement(s) of the relevant Forward Sale Agreement with the relevant Forward Purchaser on dates specified by Co. on or prior to the maturity date of such Forward Sale Agreement, in which case, Co. will expect to receive, subject to certain adjustments, aggregate net cash proceeds at settlement equal to the number of shares underlying the relevant Forward Sale Agreement, multiplied by the relevant forward sale price. Although Co. expects to physically settle any Forward Sale Agreements, it may elect to cash settle or net share settle a Forward Sale Agreement, in which case Co. may not receive any proceeds (in the case of cash settlement) or will not receive any proceeds (in the case of net share settlement), and Co. may owe cash (in the case of cash settlement) or shares of Common Stock (in the case of net share settlement) to the relevant Forward Purchaser. Co. expects to use any net proceeds from sales of shares of Common Stock under the Equity Distribution Agreement and, if applicable, upon settlement of any Forward Sale Agreements for general corporate purposes, including the repayment of indebtedness. Sales of shares of Common Stock under the Equity Distribution Agreement, if any, may be made (i) by any method or payment permitted by law to be an "at the market offering" as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on or through The Nasdaq Stock Market, or on another market for the Common Stock, or sales made to or through a market maker other than on an exchange or through an electronic communications network or (ii) in privately negotiated transactions (if, and only if, Co., the Sales Agents and any related Forward Seller and Forward Purchaser have so agreed in writing). Any shares of Common Stock offered under the Equity Distribution Agreement will be offered pursuant to Co.'s Registration Statement on Form S-3 (No. 333-333-284911) (the "Registration Statement").

EXELON CORP

Official Changes On Mar. 10, 2025, Co.'s Board of Directors appointed David DeWalt as an independent director of Exelon, effective immediately.

EXP WORLD HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2025	2024
Cost & expenses	3,589,202,000	3,477,456,000
Operating income	(8,736,000)	(7,971,000)
Other income (expense), net	1,989,000	2,934,000
Net before taxes	(6,747,000)	(5,037,000)
Income taxes	3,071,000	3,508,000
Income contin. oper.	(8,545,000)	
Net income	(9,818,000)	(11,762,000)
Earnings common share		
Primary	\$(0.06)	\$(0.08)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	155,985,872	153,858,160
Year-end	158,836,724	153,551,386

EXPEDIA GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	11,186,000	10,507,000
Cost & expenses	9,068,000	8,778,000
Operating income	1,451,000	1,103,000
Other income (expense), net	(8,000)	6,000
Gains or losses	(125,000)	126,000
Net before taxes	1,337,000	1,207,000
Income taxes	248,000	284,000
Net income	1,089,000	923,000
Earnings common share		
Primary	\$8.63	\$7.07
Fully Diluted	\$8.18	\$6.75
Common Shares:		
Full Diluted	133,188	138,655
Year-end	123,037	128,839

EXPENSIFY INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	106,903	102,232
Cost & expenses	120,985	103,517
Operating income	(14,082)	(1,285)
Net before taxes	(12,773)	(2,318)
Income taxes	1,499	6,425
Net income	(14,272)	(8,743)
Earnings common share		
Primary	\$(0.15)	\$(0.10)
Fully Diluted	\$(0.15)	\$(0.10)
Common Shares:		
Full Diluted	92,115	86,643
Year-end	93,032	88,927

EXPONENT INC.

Earnings, 9 mos. to (Consol. - \$000):

	10/03/25	09/27/24
Total Revenues	434,589	421,748
Cost & expenses	343,942	329,444
Operating income	90,647	92,304
Other income (expense), net	15,175	16,322
Net before taxes	113,192	116,042
Income taxes	31,945	30,629
Net income	81,247	85,413
Earnings common share		
Primary	\$1.59	\$1.67
Fully Diluted	\$1.58	\$1.66
Common Shares:		
Full Diluted	51,454	51,527
Year-end	49,950	50,765

EYEPOINT PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	30,751	31,685
Cost & expenses	203,840	132,300
Operating income	(173,089)	(100,615)
Net before taxes	(164,260)	
Income taxes	93	
Net income	(164,353)	(89,471)
Earnings common share		
Primary	\$(2.35)	\$(1.67)
Fully Diluted	\$(2.35)	\$(1.67)
Common Shares:		
Full Diluted	69,955	53,526
Year-end	69,570	53,524

FIDUS INVESTMENT CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2025	2024
Cost & expenses	59,032,000	52,027,000
Operating income	66,898,000	62,904,000
Other income (expense), net	7,379,000	(5,927,000)
Invest. income	4,832,000	12,161,000
Net before taxes	66,898,000	62,904,000
Income taxes	2,818,000	2,205,000
Net income	64,080,000	60,699,000
Earnings common share		
Primary	\$1.55	\$1.74
Fully Diluted	\$1.55	\$1.74
Common Shares:		
Full Diluted	34,991,361	32,138,865
Year-end	36,347,868	33,914,652

FIRST ADVANTAGE CORP (NEW)

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	1,154,372	553,081
Cost & expenses	880,929	444,823
Operating income	87,597	18,290
Other income (expense), net	(661)	
Net before taxes	(44,470)	(9,824)
Income taxes	(6,177)	83
Net income	(38,293)	(9,907)
Earnings common share		
Primary	\$(0.22)	\$(0.07)
Fully Diluted	\$(0.22)	\$(0.07)
Common Shares:		
Full Diluted	173,071	143,851
Year-end	174,036	145,559

FIVE STAR BANCORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Cost & expenses	126,923	108,639
Operating income	60,724	45,354
Other income (expense), net	985	988
Net before taxes	60,724	45,354
Income taxes	16,761	13,000
Net income	43,963	32,354
Earnings common share		
Primary	\$2.07	\$1.63
Fully Diluted	\$2.07	\$1.63
Common Shares:		
Full Diluted	21,268	19,860
Year-end	21,367	21,320

FIVE9, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	848,806	763,278
Cost & expenses	839,752	818,761
Operating income	9,054	(55,483)
Other income (expense), net		6,615
Net before taxes	21,912	(23,906)
Income taxes	2,209	466
Net income	19,703	(24,372)
Earnings common share		
Primary	\$0.26	\$(0.33)
Fully Diluted	\$0.22	\$(0.33)
Common Shares:		
Full Diluted	88,413	74,192
Year-end	78,214	75,208

FLYWIRE CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	465,481	374,594
Cost & expenses	453,221	376,074
Operating income	12,260	(1,480)
Invest. income	166	
Net before taxes	21,129	16,764
Income taxes	7,665	(2,035)
Net income	13,464	18,799
Earnings common share		
Primary	\$0.11	\$0.15
Fully Diluted	\$0.11	\$0.15
Common Shares:		
Full Diluted	127,495	129,322
Year-end	122,112	124,449

FOGHORN THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	21,662	
Cost & expenses	84,173	98,424
Operating income	(62,511)	(78,678)
Other income (expense), net	2,859	2,757
Net income	(52,619)	(67,117)
Earnings common share		
Primary	\$(0.84)	\$(1.28)
Fully Diluted	\$(0.84)	\$(1.28)
Common Shares:		
Full Diluted	62,953	52,242
Year-end	56,543	55,593

FORRESTER RESEARCH INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	295,830	324,429
Cost & expenses	360,686	309,628
Operating income	(76,178)	1,291
Other income (expense), net	(4,557)	2,716
Gains or losses	(114)	
Net before taxes	(82,875)	1,712
Income taxes	2,610	7,891
Net income	(85,485)	(6,179)
Earnings common share		
Primary	\$(4.49)	\$(0.32)
Fully Diluted	\$(4.49)	\$(0.32)
Common Shares:		
Full Diluted	19,022	19,147
Year-end	18,989	18,983

FORTINET INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2025	2024
Total Revenues	4,894,600	4,295,700
Cost & expenses	3,435,500	3,066,400
Operating income	1,459,100	1,229,300
Other income (expense), net	58,000	113,000
Equity earnings	(10,300)	23,900
Net before taxes	1,631,400	1,440,100
Income taxes	294,300	197,200
Net income	1,347,400	1,219,000
Earnings common share		
Primary	\$1.77	\$1.60
Fully Diluted	\$1.75	\$1.58
Common Shares:		
Full Diluted	770,200	770,800
Year-end	742,900	765,700

FOX FACTORY HOLDING CORP**Earnings, 9 mos. to (Consol. – \$000):**

	10/03/25	09/27/24
Total Revenues	1,106,249	1,041,084
Cost & expenses	1,291,548	961,462
Operating income	(216,958)	46,267
Other income (expense), net	1,950	458
Net before taxes	(256,242)	5,303
Income taxes	1,449	(1,388)
Net income	(257,691)	6,691
Earnings common share		
Primary	\$(6.17)	\$0.16
Fully Diluted	\$(6.17)	\$0.16
Common Shares:		
Full Diluted	41,771	41,719
Year-end	41,801	41,683

FRESHWORKS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	616,069	525,849
Cost & expenses	642,598	640,667
Operating income	(26,529)	(114,818)
Other income (expense), net	2,696	(100)
Net before taxes	6,392	(74,847)
Income taxes	14,115	(1,379)
Net income	(7,723)	(73,468)
Earnings common share		
Primary	\$(0.03)	\$(0.24)
Fully Diluted	\$(0.03)	\$(0.24)
Common Shares:		
Full Diluted	293,882	299,931
Year-end	281,744	302,578

FRONTDOOR INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,660,000	1,461,000
Cost & expenses	1,274,000	1,145,000
Operating income	336,000	303,000
Other income (expense), net	16,000	15,000
Net before taxes	336,000	303,000
Income taxes	83,000	77,000
Net income	253,000	226,000
Earnings common share		
Primary	\$3.44	\$2.92
Fully Diluted	\$3.38	\$2.90
Common Shares:		
Full Diluted	75,000	78,000
Year-end	72,433	75,783

FRONTIER GROUP HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,727,000	2,773,000
Cost & expenses	2,860,000	2,707,000
Operating income	(198,000)	13,000
Net before taxes	(186,000)	35,000
Income taxes	4,000	4,000
Net income	(190,000)	31,000
Earnings common share		
Primary	\$(0.84)	\$0.14
Fully Diluted	\$(0.84)	\$0.14
Common Shares:		
Full Diluted	227,516	226,116
Year-end	228,230	224,518

FULGENT GENETICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	239,335	207,256
Cost & expenses	288,188	259,066
Operating income	(54,858)	(57,783)
Other income (expense), net	(9,817)	(9,519)
Net before taxes	(40,751)	(43,911)
Income taxes	(2,770)	(6,281)
Net income	(37,981)	(37,630)
Earnings common share		
Primary	\$(1.21)	\$(1.22)
Fully Diluted	\$(1.21)	\$(1.22)
Common Shares:		
Full Diluted	30,708	30,095
Year-end	30,854	30,537

FUNKO INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	635,113	756,121
Cost & expenses	642,311	702,146
Operating income	(51,517)	7,566
Other income (expense), net	304	(1,994)
Net before taxes	(65,195)	(10,791)
Income taxes	2,920	2,859
Net income	(68,115)	(13,650)
Earnings common share		
Primary	\$(1.24)	\$(0.26)
Fully Diluted	\$(1.24)	\$(0.26)
Common Shares:		
Full Diluted	54,184	51,781
Year-end	54,740	52,692

GAIA INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	73,456,000	65,930,000
Cost & expenses	77,905,000	70,168,000
Operating income	(4,449,000)	(4,238,000)
Net before taxes	(4,440,000)	
Income taxes	61,000	
Income contin. oper.	(4,501,000)	
Net income	(4,560,000)	(4,634,000)
Earnings common share		
Primary	\$(0.16)	\$(0.19)
Fully Diluted	\$(0.16)	\$(0.19)
Common Shares:		
Full Diluted	24,805,000	23,312,000
Year-end	25,044,338	23,401,955

GCM GROSVENOR INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	380,470,000	348,751,000
Cost & expenses	301,721,000	318,879,000
Operating income	78,749,000	29,872,000
Other income (expense), net	2,976,000	1,478,000
Gains or losses	12,476,000	(9,290,000)
Invest. income	13,836,000	9,644,000
Net before taxes	90,896,000	13,729,000
Income taxes	7,013,000	7,544,000
Net income	83,883,000	6,185,000
Earnings common share		
Primary	\$0.53	\$0.25
Fully Diluted	\$0.23	\$(0.06)
Common Shares:		
Full Diluted	196,265,764	188,826,896
Year-end	53,351,513	44,885,521

GENERATION BIO CO**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	11,082	15,704
Cost & expenses	57,312	134,531
Operating income	(46,230)	(118,827)
Net income	(41,245)	(110,286)
Earnings common share		
Primary	\$(6.14)	\$(16.60)
Fully Diluted	\$(6.14)	\$(16.60)
Common Shares:		
Full Diluted	6,713	6,657
Year-end	6,736	6,675

GENTEX CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	1,889,867,355	1,771,676,766
Cost & expenses	1,536,033,176	1,401,718,280
Operating income	353,834,179	369,958,486
Other income (expense), net	(4,165,750)	4,475,771
Net before taxes	349,668,429	374,434,257
Income taxes	58,257,230	57,614,063
Net income	291,411,199	316,820,194
Balance for common	287,604,070	312,402,061
Earnings common share		
Primary	\$1.31	\$1.38
Fully Diluted	\$1.31	\$1.38
Common Shares:		
Full Diluted	219,348,681	227,009,932
Year-end	218,951,804	227,443,290

GERON CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	135,866	29,457
Cost & expenses	178,911	183,139
Operating income	(43,045)	(153,682)
Other income (expense), net	(305)	(188)
Net income	(54,638)	(149,220)
Earnings common share		
Primary	\$(0.08)	\$(0.23)
Fully Diluted	\$(0.08)	\$(0.23)
Common Shares:		
Full Diluted	666,397	639,934
Year-end	638,355	603,102

GILEAD SCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	21,518,000	21,185,000
Cost & expenses	13,480,000	21,974,000
Operating income	8,038,000	(790,000)
Other income (expense), net	449,000	41,000
Net before taxes	7,718,000	(1,477,000)
Income taxes	1,391,000	(174,000)
Net income	6,327,000	(1,303,000)
Earnings common share		
Primary	\$5.08	\$(1.04)
Fully Diluted	\$5.04	\$(1.04)
Common Shares:		
Full Diluted	1,256,000	1,247,000
Year-end	1,242,000	1,246,000

GLADSTONE INVESTMENT CORP**Earnings, 6 mos. to Sep 30(Consol. – \$):**

	2025	2024
Cost & expenses	35,456,000	25,038,000
Operating income	36,481,000	8,956,000
Other income (expense), net	53,052,000	(53,054,000)
Invest. income	(29,938,000)	42,305,000
Net income	36,481,000	8,956,000
Earnings common share		
Primary	\$0.97	\$0.24
Fully Diluted	\$0.97	\$0.24
Common Shares:		
Full Diluted	37,681,491	36,688,667
Year-end	39,591,037	36,688,667

GLADSTONE LAND CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Cost & expenses	13,732,000	15,716,000
Operating income	7,019,000	9,455,000
Other income (expense), net	16,366,000	7,245,000
Net income	9,317,000	12,750,000
Balance for common	(8,689,000)	(4,992,000)
Earnings common share		
Primary	\$(0.24)	\$(0.14)
Fully Diluted	\$(0.24)	\$(0.14)
Common Shares:		
Full Diluted	36,186,758	35,838,442
Year-end	36,307,401	35,838,442

GOGO INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	679,930	306,910
Cost & expenses	535,565	219,741
Operating income	99,891	75,426
Other income (expense), net	1,811	(1,286)
Gains or losses	(18,900)	
Net before taxes	35,403	54,534
Income taxes	12,484	12,575
Net income	22,919	41,959
Earnings common share		
Primary	\$0.17	\$0.33
Fully Diluted	\$0.17	\$0.32
Common Shares:		
Full Diluted	136,640	131,538
Year-end	133,854	126,141

GOLD RESOURCE CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	48,460,000	52,756,000
Cost & expenses	54,513,000	73,208,000
Operating income	(23,005,000)	(31,298,000)
Other income (expense), net	(15,025,000)	(8,188,000)
Invest. income	60,000	(520,000)
Net before taxes	(23,005,000)	(31,298,000)
Income taxes	1,455,000	10,952,000
Net income	(24,460,000)	(42,250,000)
Earnings common share		
Primary	\$(0.19)	\$(0.46)
Fully Diluted	\$(0.19)	\$(0.46)
Common Shares:		
Full Diluted	129,081,618	91,005,507
Year-end	161,765,685	93,523,028

GOLDEN ENTERTAINMENT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	479,281,000	502,614,000
Cost & expenses	387,602,000	334,847,000
Operating income	23,867,000	100,405,000
Other income (expense), net	(4,446,000)	
Net before taxes	700,000	68,704,000
Income taxes	(1,773,000)	20,951,000
Net income	2,473,000	47,753,000
Earnings common share		
Primary	\$0.09	\$1.67
Fully Diluted	\$0.09	\$1.58
Common Shares:		
Full Diluted	27,330,000	30,141,000
Year-end	26,174,000	27,563,000

GOPRO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	449,869	600,591
Cost & expenses	524,969	696,524
Operating income	(75,100)	(95,933)
Other income (expense), net	(603)	4,710
Net before taxes	(80,651)	(93,495)
Income taxes	3,732	301,625
Net income	(84,383)	(395,120)
Earnings common share		
Primary	\$(0.53)	\$(2.59)
Fully Diluted	\$(0.53)	\$(2.59)
Common Shares:		
Full Diluted	157,747	152,449
Year-end	155,455	154,761

GOSSAMER BIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	34,672	105,322
Cost & expenses	159,361	129,113
Operating income	(124,689)	(23,791)
Other income (expense), net	8,272	9,851
Net before taxes	(20,196)	
Income taxes		3,303
Net income	(123,132)	(23,499)
Earnings common share		
Primary	\$(0.54)	\$(0.10)
Fully Diluted	\$(0.54)	\$(0.10)
Common Shares:		
Full Diluted	227,363	226,102
Year-end	231,306	226,604

GRAND CANYON EDUCATION INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	797,951	740,429
Cost & expenses	633,805	558,742
Operating income	157,831	175,372
Net before taxes	168,075	187,363
Income taxes	38,637	43,008
Net income	129,438	144,355
Earnings common share		
Primary	\$4.62	\$4.94
Fully Diluted	\$4.60	\$4.91
Common Shares:		
Full Diluted	28,165	29,405
Year-end	28,004	29,274

GRAYSCALE ETHEREUM CLASSIC TRUST (ETC)**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	4,130,000	5,399,000
Operating income	(79,865,000)	(5,399,000)
Other income (expense), net	(78,289,000)	(29,389,000)
Invest. income	2,554,000	3,782,000
Net income	(79,865,000)	(31,006,000)
Earnings common share		
Primary	\$(5.71)	\$(2.22)
Fully Diluted	\$(5.71)	\$(2.22)
Common Shares:		
Full Diluted	13,993,800	13,993,800
Year-end	13,993,800	13,993,800

GRAYSCALE ZCASH TRUST (ZEC)**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	305,000	180,000
Operating income	(305,000)	(180,000)
Gains or losses	(595,000)	(717,000)
Invest. income	8,175,000	1,074,000
Net income	7,275,000	177,000
Earnings common share		
Primary	\$1.51	\$0.04
Fully Diluted	\$1.51	\$0.04
Common Shares:		
Full Diluted	4,811,500	4,568,000
Year-end	4,811,500	4,568,000

GREAT ELM CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	24,127	19,781
Operating income	13,287	10,403
Other income (expense), net	(29,608)	(10,742)
Invest. income	6,879	2,109
Net before taxes	(9,442)	1,770
Income taxes	374	80
Net income	(9,816)	1,690
Earnings common share		
Primary	\$(0.83)	\$0.18
Fully Diluted	\$(0.83)	\$0.18
Common Shares:		
Full Diluted	11,808	9,557
Year-end	13,998	10,450

GREEN PLAINS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,662,831,000	1,874,774,000
Cost & expenses	1,644,670,000	1,812,181,000
Operating income	(56,754,000)	(6,548,000)
Other income (expense), net	(4,227,000)	1,272,000
Equity earnings		2,384,000
Net before taxes	(128,830,000)	(24,908,000)
Income taxes	(23,238,000)	(769,000)
Net income	(105,592,000)	(26,523,000)
Earnings common share		
Primary	\$(1.99)	\$(0.43)
Fully Diluted	\$(1.99)	\$(0.43)
Common Shares:		
Full Diluted	66,826,000	63,741,000
Year-end	71,929,102	64,652,419

GROCERY OUTLET HOLDING CORP**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	3,473,492	3,273,647
Cost & expenses	3,460,404	3,206,693
Operating income	13,088	66,954
Other income (expense), net		(24)
Net before taxes	(6,681)	51,780
Income taxes	70	14,626
Net income	(6,751)	37,154
Earnings common share		
Primary	\$(0.07)	\$0.37
Fully Diluted	\$(0.07)	\$0.37
Common Shares:		
Full Diluted	97,921	100,146
Year-end	98,137	98,644

GROUPON INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	365,714	362,178
Cost & expenses	348,582	356,036
Operating income	17,132	6,142
Other income (expense), net	(99,925)	
Net before taxes	(55,559)	11,406
Income taxes	33,603	17,802
Income contin. oper.	(89,162)	
Net income	(89,633)	(6,396)
Earnings common share		
Primary	\$(2.26)	\$(0.22)
Fully Diluted	\$(2.26)	\$(0.22)
Common Shares:		
Full Diluted	40,165	38,966
Year-end	40,752	39,763

HACKETT GROUP INC**Earnings, 9 mos. to** (Consol. – \$):

	09/26/25	09/27/24
Total Revenues	229,875,000	234,620,000
Cost & expenses	215,418,000	197,779,000
Operating income	14,457,000	36,841,000
Net before taxes	13,451,000	35,489,000
Income taxes	6,100,000	9,423,000
Net income	7,351,000	26,066,000
Earnings common share		
Primary	\$0.27	\$0.95
Fully Diluted	\$0.26	\$0.93
Common Shares:		
Full Diluted	28,161,000	27,920,000
Year-end	27,130,815	27,592,440

HAIN CELESTIAL GROUP INC**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	367,883	394,596
Cost & expenses	373,536	389,363
Operating income	(6,865)	3,053
Other income (expense), net	656	(5,292)
Equity earnings	173	155
Net before taxes	(21,708)	(15,985)
Income taxes	(1,256)	3,523
Net income	(20,625)	(19,663)
Earnings common share		
Primary	\$(0.23)	\$(0.22)
Fully Diluted	\$(0.23)	\$(0.22)
Common Shares:		
Full Diluted	90,309	89,861
Year-end	90,344	89,907

Consolidated Balance Sheet Items, as of (\$000):

	2025
Assets:	
Cash & equivalents	47,886
Inventories	229,498
Current assets	523,019
Net property & equip.	255,992
Total assets	1,582,899
Liabilities:	
Current liabilities	276,837
Long-term debt	708,563
Stockholders' equity	444,989
Net current assets	246,182

HARROW INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	183,211,000	
Cost & expenses	168,287,000	136,860,000
Operating income	14,924,000	(4,077,000)
Other income (expense), net	(7,695,000)	76,000
Gains or losses		(3,171,000)
Net before taxes		(23,583,000)
Income taxes		675,000
Net income	(11,765,000)	(24,258,000)
Earnings common share		
Primary	\$(0.32)	\$(0.68)
Fully Diluted	\$(0.32)	\$(0.68)
Common Shares:		
Full Diluted	36,588,163	35,597,409
Year-end	37,034,582	35,611,365

HARVARD BIOSCIENCE INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	62,815	69,579
Cost & expenses	109,928	71,803
Operating income	(50,290)	(6,222)
Other income (expense), net	(1,333)	(2,084)
Gains or losses		(1,593)
Net before taxes	(54,182)	(12,255)
Income taxes	(329)	168
Net income	(53,853)	(12,423)
Earnings common share		
Primary	\$(1.22)	\$(0.29)
Fully Diluted	\$(1.22)	\$(0.29)
Common Shares:		
Full Diluted	44,320	43,499
Year-end	44,580	43,617

HASBRO, INC.**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	3,255,400	3,033,900
Cost & expenses	3,469,400	2,328,000
Operating income	(286,400)	630,200
Other income (expense), net	15,900	15,700
Net before taxes	(372,900)	554,200
Income taxes	148,400	133,300
Net income	(521,300)	420,900
Earnings common share		
Primary	\$(3.74)	\$3.01
Fully Diluted	\$(3.74)	\$3.00
Common Shares:		
Full Diluted	140,100	140,000
Year-end	140,323	139,488

HEALTH CATALYST INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	236,457	226,978
Cost & expenses	273,613	248,119
Operating income	(74,774)	(52,306)
Interest expense	9,789	
Other income (expense), net	274	(161)
Net before taxes	(86,612)	(49,121)
Income taxes	337	(292)
Net income	(86,949)	(48,829)
Earnings common share		
Primary	\$(1.25)	\$(0.82)
Fully Diluted	\$(1.25)	\$(0.82)
Common Shares:		
Full Diluted	69,525	59,449
Year-end	70,623	60,848

HEALTHSTREAM INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	224,355,000	217,411,000
Cost & expenses	174,082,000	170,034,000
Operating income	17,832,000	16,598,000
Other income (expense), net	(141,000)	2,722,000
Net before taxes	20,367,000	19,320,000
Income taxes	4,559,000	4,202,000
Net income	15,808,000	15,118,000
Earnings common share		
Primary	\$0.52	\$0.50
Fully Diluted	\$0.52	\$0.50
Common Shares:		
Full Diluted	30,283,000	30,512,000
Year-end	29,652,000	30,415,000

HIGHPEAK ENERGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	646,710,000	834,608,000
Cost & expenses	166,382,000	172,358,000
Operating income	35,490,000	144,889,000
Other income (expense), net	(28,148,000)	(3,405,000)
Gains or losses	25,432,000	(23,411,000)
Net before taxes	58,211,000	118,073,000
Income taxes	14,035,000	
Net income	44,176,000	86,088,000
Balance for common	40,047,000	77,808,000
Earnings common share		
Primary	\$0.32	\$0.62
Fully Diluted	\$0.32	\$0.60
Common Shares:		
Full Diluted	125,587,000	129,581,000
Year-end	125,587,093	126,625,221

HONEST CO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	283,280	278,503
Cost & expenses	277,572	283,805
Operating income	5,708	(5,302)
Net before taxes	8,078	(5,258)
Income taxes	195	56
Net income	7,883	(5,314)
Earnings common share		
Primary	\$0.07	\$(0.05)
Fully Diluted	\$0.07	\$(0.05)
Common Shares:		
Full Diluted	114,116	98,688
Year-end	112,124	101,204

HORIZON BANCORP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	237,086	243,215
Operating income	(233,848)	49,283
Net before taxes	(233,848)	49,283
Income taxes	(56,444)	2,972
Net income	(177,404)	46,311
Earnings common share		
Primary	\$(3.94)	\$1.06
Fully Diluted	\$(3.94)	\$1.05
Common Shares:		
Full Diluted	44,974	43,696
Year-end	51,217	43,712

ICU MEDICAL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,690,558	1,752,241
Cost & expenses	1,653,364	1,746,968
Operating income	37,194	5,273
Other income (expense), net	662	(1,981)
Gains or losses	44,792	(23)
Equity earnings	(1,296)	
Net before taxes	20,260	(74,229)
Income taxes	5,090	19,631
Net income	16,466	(93,860)
Earnings common share		
Primary	\$0.67	\$(3.85)
Fully Diluted	\$0.66	\$(3.85)
Common Shares:		
Full Diluted	24,783	24,353
Year-end	24,686	24,459

IHEARTMEDIA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,737,764	2,736,263
Cost & expenses	2,571,774	3,293,069
Operating income	(106,341)	(867,655)
Other income (expense), net	(531)	(2,225)
Invest. income	(32,698)	91,479
Net before taxes	(442,629)	(1,065,208)
Net income	(430,632)	(1,041,422)
Earnings common share		
Primary	\$(2.80)	\$(6.90)
Fully Diluted	\$(2.80)	\$(6.90)
Common Shares:		
Full Diluted	153,991	150,978
Year-end	150,151	147,063

IMMUNITYBIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	75,003	7,193
Cost & expenses	266,347	281,975
Operating income	(191,344)	(274,782)
Other income (expense), net	1,778	5,707
Gains or losses	(16,438)	29,786
Invest. income	(287)	(55)
Net income	(289,514)	(354,466)
Earnings common share		
Primary	\$(0.32)	\$(0.52)
Fully Diluted	\$(0.32)	\$(0.52)
Common Shares:		
Full Diluted	896,335	685,261
Year-end	984,965	696,831

IMMUNOVANT INC**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	258,986,000	210,024,000
Operating income	(245,608,000)	196,113,000
Other income (expense), net	1,437,000	657,000
Net before taxes	(245,608,000)	196,113,000
Income taxes	1,507,000	156,000
Net income	(247,115,000)	196,269,000
Earnings common share		
Primary	\$(1.43)	\$(1.34)
Fully Diluted	\$(1.43)	\$(1.34)
Common Shares:		
Full Diluted	172,295,320	146,313,696
Year-end	174,532,710	146,565,049

IN8BIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	14,828	24,443
Operating income	(14,498)	(24,277)
Net income	(14,498)	(24,277)
Earnings common share		
Primary	\$(4.18)	\$(15.90)
Fully Diluted	\$(4.18)	\$(15.90)
Common Shares:		
Full Diluted	3,465	1,523
Year-end	4,589	1,560

INNODATA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	179,287,000	111,281,000
Cost & expenses	149,221,000	98,144,000
Operating income	30,066,000	13,137,000
Net before taxes	30,066,000	13,137,000
Income taxes	6,718,000	(5,235,000)
Net income	23,348,000	18,372,000
Earnings common share		
Primary	\$0.74	\$0.64
Fully Diluted	\$0.67	\$0.55
Common Shares:		
Full Diluted	34,996,000	33,297,000
Year-end	31,859,000	29,000,000

INNOSPEC INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,322,400	1,378,600
Cost & expenses	1,239,700	1,241,800
Operating income	82,700	136,800
Other income (expense), net	(1,200)	3,300
Gains or losses	(3,600)	(1,100)
Net before taxes	87,800	143,800
Income taxes	18,600	37,800
Net income	69,200	106,000
Earnings common share		
Primary	\$2.78	\$4.25
Fully Diluted	\$2.76	\$4.22
Common Shares:		
Full Diluted	25,045	25,103
Year-end	24,778	24,942

INNOVAGE HOLDING CORP**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,322,400	1,378,600
Cost & expenses	1,239,700	1,241,800
Operating income	82,700	136,800
Other income (expense), net	(1,200)	3,300
Gains or losses	(3,600)	(1,100)
Net before taxes	87,800	143,800
Income taxes	18,600	37,800
Net income	69,200	106,000
Earnings common share		
Primary	\$2.78	\$4.25
Fully Diluted	\$2.76	\$4.22
Common Shares:		
Full Diluted	25,045	25,103
Year-end	24,778	24,942

	2025	2024
Total Revenues	236,105	205,142
Cost & expenses	222,731	204,628
Operating income	8,289	(4,896)
Other income (expense), net	878	833
Net before taxes	7,916	(5,306)
Income taxes	247	404
Net income	7,669	(5,710)
Earnings common share		
Primary	\$0.06	\$(0.04)
Fully Diluted	\$0.06	\$(0.04)
Common Shares:		
Full Diluted	136,761	135,770
Year-end	135,681	135,525
Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2025	2024
Cash & equivalents	67,146	
Current assets	161,698	
Net property & equip.	166,276	
Total assets	510,234	
Liabilities:		
Current liabilities	138,489	
Long-term debt	62,459	
Stockholders' equity	244,976	
Net current assets	23,209	

INNOVIVA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	296,715	266,905
Cost & expenses	171,958	123,786
Operating income	124,757	116,518
Other income (expense), net	(2,252)	(3,123)
Gains or losses	7,775	(103,824)
Net before taxes	131,826	12,694
Income taxes	24,814	9,634
Net income	107,012	3,060
Earnings common share		
Primary	\$1.65	\$0.05
Fully Diluted	\$1.35	\$0.05
Common Shares:		
Full Diluted	84,576	63,020
Year-end	74,769	62,601

INOGEN, INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	266,947	255,624
Cost & expenses	287,848	286,754
Operating income	(20,901)	(31,130)
Other income (expense), net	1,663	964
Net before taxes	(16,016)	(26,389)
Income taxes	(396)	(258)
Net income	(15,620)	(26,131)
Earnings common share		
Primary	\$(0.59)	\$(1.11)
Fully Diluted	\$(0.59)	\$(1.11)
Common Shares:		
Full Diluted	26,408	23,590
Year-end	27,148	23,818

INOVIO PHARMACEUTICALS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	65,343	100,762
Cost & expenses	69,410,846	92,130,123
Operating income	(69,345,503)	(92,029,361)
Other income (expense), net	(1,760,015)	(1,390,527)
Gains or losses	(19,576,086)	1,810,868
Net income	(88,710,781)	(87,872,447)
Earnings common share		
Primary	\$(2.12)	\$(3.35)
Fully Diluted	\$(2.12)	\$(3.35)
Common Shares:		
Full Diluted	41,837,956	26,216,983
Year-end	53,571,675	26,052,452

INSULET CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,924,300	1,474,100
Cost & expenses	1,596,800	1,274,500
Operating income	327,500	199,600
Other income (expense), net	(112,700)	(5,900)

Net before taxes	199,300	188,900
Income taxes	53,900	(128,700)
Net income	145,400	317,600
Earnings common share		
Primary	\$2.07	\$4.53
Fully Diluted	\$2.05	\$4.40
Common Shares:		
Full Diluted	72,292	73,830
Year-end	70,346	70,142

INTEL CORP**Earnings, 9 mos. to** (Consol. – \$Millions):

	09/27/25	09/28/24
Total Revenues	39,179	38,841
Cost & expenses	41,973	50,931
Operating income	(2,794)	(12,090)
Other income (expense), net	280	98
Gains or losses	3,859	
Net before taxes	1,219	(11,809)
Income taxes	860	7,271
Net income	359	(19,080)
Earnings common share		
Primary	\$0.07	\$(4.37)
Fully Diluted	\$0.07	\$(4.37)
Common Shares:		
Full Diluted	4,434	4,267
Year-end	4,766	4,309

INTELLIA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	44,654	45,003
Cost & expenses	386,934	442,819
Operating income	(342,280)	(397,816)
Gains or losses	2,653	(29,483)
Net income	(316,908)	(390,123)
Earnings common share		
Primary	\$(2.99)	\$(3.99)
Fully Diluted	\$(2.99)	\$(3.99)
Common Shares:		
Full Diluted	105,841	97,842
Year-end	115,787	101,796

INTERFACE INC.**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	1,037,461	980,648
Cost & expenses	908,827	875,876
Operating income	128,634	104,772
Other income (expense), net	(5,773)	(237)
Net before taxes	109,792	86,218
Income taxes	18,083	21,038
Net income	91,709	65,180
Balance for common		64,755
Earnings common share		
Primary	\$1.57	\$1.12
Fully Diluted	\$1.57	\$1.11
Common Shares:		
Full Diluted	59,155	58,754
Year-end	58,391	58,304

INTERPARFUMS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,102,334,000	1,090,821,000
Cost & expenses	859,525,000	852,025,000
Operating income	242,809,000	238,796,000
Other income (expense), net	1,302,000	35,000
Net before taxes	235,097,000	231,710,000
Income taxes	55,218,000	54,974,000
Net income	179,879,000	176,736,000
Earnings common share		
Primary	\$4.37	\$4.37
Fully Diluted	\$4.36	\$4.34
Common Shares:		
Full Diluted	32,158,000	32,266,000
Year-end	32,064,728	32,029,580

INVIVYD INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	36,219	11,564
Cost & expenses	79,224	169,211
Operating income	(43,005)	(157,647)

Other income (expense), net	1,586	6,165
Net income	(41,419)	(151,482)
Earnings common share		
Primary	\$(0.30)	\$(1.28)
Fully Diluted	\$(0.30)	\$(1.28)
Common Shares:		
Full Diluted	136,874	118,164
Year-end	214,409	119,604

IOVANCE BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	176,731,000	90,376,000
Cost & expenses	480,205,000	399,078,000
Operating income	(329,896,000)	(308,702,000)
Net before taxes	(321,329,000)	(298,004,000)
Income taxes	(2,255,000)	(4,386,000)
Net income	(319,074,000)	(293,618,000)
Earnings common share		
Primary	\$(0.94)	\$(1.03)
Fully Diluted	\$(0.94)	\$(1.03)
Common Shares:		
Full Diluted	340,623,000	284,836,000
Year-end	385,461,728	304,620,470

IROBOT CORP**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	374,959	
Cost & expenses	474,669	550,316
Operating income	(100,137)	(41,910)
Other income (expense), net	1,063	(426)
Gains or losses	(487)	(13,890)
Net before taxes	(128,528)	(66,493)
Income taxes	3,079	1,917
Net income	(131,607)	(68,410)
Earnings common share		
Primary	\$(3.97)	\$(2.34)
Fully Diluted	\$(3.97)	\$(2.34)
Common Shares:		
Full Diluted	33,128	29,276
Year-end	31,825	30,559

IRONWOOD PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	248,442	260,865
Cost & expenses	156,745	199,232
Operating income	91,697	61,633
Other income (expense), net	116	
Net before taxes	69,570	41,203
Income taxes	43,277	42,579
Net income	26,293	(1,376)
Earnings common share		
Primary	\$0.16	\$(0.01)
Fully Diluted	\$0.16	\$(0.01)
Common Shares:		
Full Diluted	177,057	158,810
Year-end	162,679	160,016

JACK HENRY & ASSOCIATES, INC.**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	644,738	600,982
Cost & expenses	460,673	449,706
Operating income	184,065	151,276
Net before taxes	190,318	156,798
Income taxes	46,332	37,607
Net income	143,986	119,191
Earnings common share		
Primary	\$1.98	\$1.63
Fully Diluted	\$1.97	\$1.63
Common Shares:		
Full Diluted	72,909	73,078
Year-end	72,544	72,959

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	2024
Cash & equivalents	36,239	
Current assets	651,655	
Net property & equip.	204,950	
Total assets	3,047,572	
Liabilities:		
Current liabilities	436,133	
Long-term debt	20,000	

Stockholders' equity	2,173,334
Net current assets	215,522

JAMF HOLDING CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	527,616	464,425
Cost & expenses	526,582	500,620
Operating income	(22,552)	(56,936)
Other income (expense), net	(850)	
Net before taxes	(23,266)	(48,308)
Income taxes	1,593	3,719
Net income	(24,859)	(52,027)
Earnings common share		
Primary	\$(0.19)	\$(0.41)
Fully Diluted	\$(0.19)	\$(0.41)
Common Shares:		
Full Diluted	131,672	127,736
Year-end	133,053	128,272

JANUX THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	10,000	10,588
Cost & expenses	125,266	80,413
Operating income	(115,266)	(69,825)
Net income	(81,679)	(48,778)
Earnings common share		
Primary	\$(1.32)	\$(0.93)
Fully Diluted	\$(1.32)	\$(0.93)
Common Shares:		
Full Diluted	61,907	52,717
Year-end	60,124	52,339

JOINT CORP (NEW)**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	39,728,545	37,449,148
Cost & expenses	40,173,370	39,129,966
Operating income	(1,655,786)	(2,698,741)
Other income (expense), net	485,640	200,558
Net before taxes	(1,170,146)	(2,498,183)
Income taxes	35,140	25,142
Income contin. oper.	(1,205,286)	(2,523,325)
Net income	1,916,168	(5,814,558)
Earnings common share		
Primary	\$0.12	\$(0.39)
Fully Diluted	\$0.12	\$(0.39)
Common Shares:		
Full Diluted	15,281,775	14,903,726
Year-end	15,172,257	14,958,447

KALTURA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	135,312	133,108
Cost & expenses	141,149	153,414
Operating income	(5,837)	(20,306)
Other income (expense), net	(415)	(297)
Net before taxes	(8,519)	(18,634)
Income taxes	2,978	6,076
Net income	(11,497)	(24,710)
Earnings common share		
Primary	\$(0.07)	\$(0.17)
Fully Diluted	\$(0.07)	\$(0.17)
Common Shares:		
Full Diluted	154,110	147,074
Year-end	155,464	149,646

KARAT PACKAGING INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	352,126	320,984
Cost & expenses	319,183	290,523
Operating income	32,943	30,461
Other income (expense), net	2,270	1,638
Net before taxes	33,354	32,378
Income taxes	7,884	7,413
Net income	25,470	24,965
Earnings common share		
Primary	\$1.23	\$1.22
Fully Diluted	\$1.22	\$1.21
Common Shares:		
Full Diluted	20,197	20,108
Year-end	20,098	20,021

KELLY SERVICES, INC.**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	3,201,700	3,140,700
Cost & expenses	3,270,800	3,099,100
Operating income	(69,100)	41,600
Other income (expense), net	100	(8,200)
Gains or losses		1,200
Net before taxes	(76,200)	33,700
Income taxes	49,100	2,500
Net income	(125,300)	31,200
Balance for common	(126,100)	30,400
Earnings common share		
Primary	\$(3.56)	\$0.86
Fully Diluted	\$(3.56)	\$0.85
Common Shares:		
Full Diluted	35,200	35,900
Year-end	35,300	35,600

KEROS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	243,676,000	508,000
Cost & expenses	146,837,000	158,087,000
Operating income	96,839,000	157,579,000
Other income (expense), net	20,033,000	16,252,000
Net before taxes	116,872,000	
Income taxes	6,397,000	
Net income	110,475,000	141,327,000
Earnings common share		
Primary	\$2.72	\$(3.88)
Fully Diluted	\$2.68	\$(3.88)
Common Shares:		
Full Diluted	41,202,371	36,463,906
Year-end	40,632,164	39,258,476

KFORCE INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	996,989	1,061,526
Cost & expenses	951,243	1,002,952
Operating income	41,521	54,143
Other income (expense), net	(2,352)	
Net before taxes	39,169	52,554
Income taxes	9,507	13,201
Net income	29,662	39,353
Earnings common share		
Primary	\$1.66	\$2.11
Fully Diluted	\$1.66	\$2.08
Common Shares:		
Full Diluted	17,884	18,878
Year-end	18,290	19,223

KIMBALL ELECTRONICS INC**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	365,603	374,256
Cost & expenses	351,149	365,141
Operating income	14,454	9,115
Other income (expense), net	(1,241)	(972)
Gains or losses		345
Net before taxes	10,999	2,884
Income taxes	913	(270)
Net income	10,086	3,154
Balance for common	10,074	3,151
Earnings common share		
Primary	\$0.41	\$0.13
Fully Diluted	\$0.40	\$0.12
Common Shares:		
Full Diluted	24,909	25,235
Year-end	24,338	24,679

Consolidated Balance Sheet Items, as of (\$000):

	2025
Assets:	
Cash & equivalents	75,696
Inventories	272,725
Current assets	690,552
Net property & equip.	273,937
Total assets	1,077,916
Liabilities:	
Current liabilities	312,020
Long-term debt	130,925
Stockholders' equity	577,139
Net current assets	378,532

KINETIK HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,333,970,000	1,097,213,000
Cost & expenses	935,603,000	705,400,000
Operating income	116,522,000	155,563,000
Other income (expense), net	173,837,000	169,143,000
Invest. income		89,837,000
Net before taxes	120,230,000	249,270,000
Income taxes	11,003,000	21,261,000
Net income	109,227,000	228,009,000
Balance for common	25,209,000	60,869,000
Earnings common share		
Primary	\$0.41	\$1.03
Fully Diluted	\$0.41	\$1.02
Common Shares:		
Full Diluted	62,120,000	59,852,000
Year-end	64,106,232	59,751,435

KINGSWAY FINANCIAL SERVICES INC (DE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	99,146	79,368
Operating income	(2,705)	374
Other income (expense), net	(5,970)	(5,898)
Gains or losses	289	173
Invest. income	1,273	2,396
Net before taxes	(11,113)	(6,435)
Income taxes	(2,445)	209
Income contin. oper.		(6,644)
Net income	(8,668)	(6,825)
Balance for common	(9,848)	(7,663)
Earnings common share		
Primary	\$(0.36)	\$(0.28)
Fully Diluted	\$(0.36)	\$(0.28)
Common Shares:		
Full Diluted	27,607	27,213
Year-end	28,613	27,124

KRATOS DEFENSE & SECURITY SOLUTIONS, INC.**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	1,001,700	853,200
Cost & expenses	984,300	827,200
Operating income	17,400	26,000
Other income (expense), net	2,000	(800)
Net before taxes	21,900	22,500
Income taxes	5,800	10,100
Net income	16,100	12,400
Earnings common share		
Primary	\$0.10	\$0.08
Fully Diluted	\$0.10	\$0.08
Common Shares:		
Full Diluted	162,300	147,800
Year-end	168,839	151,016

KRISPY KREME INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	1,130,249	1,261,374
Cost & expenses	1,489,120	1,159,049
Operating income	(462,000)	2,763
Other income (expense), net	2,161	(1,115)
Gains or losses	(11,501)	87,128
Net before taxes	(520,590)	44,308
Income taxes	(25,936)	18,330
Net income	(494,654)	25,978
Earnings common share		
Primary	\$(2.86)	\$0.15
Fully Diluted	\$(2.86)	\$0.15
Common Shares:		
Full Diluted	170,752	171,384
Year-end	171,244	169,799

KURA SUSHI USA INC**Annual Report****Consolidated Income Statement, Years Ended Aug. 31 (\$000):**

	2025	2024	2023						
Total restaurant operating costs	249,329	208,337	...	Cash and cash equivalents	47,498	50,986	Common Shares:		
Food and beverage costs	80,772	69,509	...	Lease receivables	6,410	4,573	Full Diluted	101,721	102,547
Labor and related costs	93,014	75,926	...	Beverages	2,141	2,219	Year-end	101,284	102,358
Depreciation and amortization expenses 1	13,598	11,362	...	Inventories - Food	1,897	2,013	LANTHEUS HOLDINGS INC		
Other costs	40,943	...	...	Beverages	244	206	Earnings, 9 mos. to Sep 30(Consol. - \$000):		
General and administrative expenses	37,747	39,050	...	Due from affiliate	126	166		2025	2024
Occupancy and related expenses	21,002	16,792	...	Prepaid expenses and other current assets -			Total Revenues	1,134,823	1,142,800
Sales	282,763	237,860	...	Balancing value	4,308	3,391	Cost & expenses	901,175	799,693
Sales	...	...	187,429	Prepaid expenses	3,380	3,013	Operating income	233,648	343,107
Food & beverage costs	...	...	56,631	Other current assets	928	378	Other income (expense), net	4,821	76,196
Labor & related costs	...	...	56,547	Short-term investments	14,964	...	Net before taxes	243,427	431,760
Occupancy & related expenses	...	...	13,141	Total current assets	75,447	61,335	Income taxes	63,956	107,528
Depreciation & amortization expenses	...	...	7,422	Leasehold improvements	129,909	100,345	Net income	179,471	324,232
Other costs	...	34,748	24,911	Lease assets	6,080	6,108	Earnings common share		
Total restaurant operating costs	...	...	158,652	Furniture, fixtures & equipment	223,817	177,458	Primary	\$2.63	\$4.69
General & administrative expenses	...	...	28,035	Computer equipment	4,632	3,714	Fully Diluted	\$2.60	\$4.55
Depreciation & amortization expenses	...	...	410	Vehicles	342	243	Common Shares:		
Impairment of long-lived assets, net	...	1,553	...	Software	1,017	1,017	Full Diluted	69,038	71,331
Total operating expenses	287,524	249,365	187,097	Construction in progress	11,203	15,080	Year-end	66,299	69,515
Operating income (loss)	(4,761)	(11,505)	332	Furniture & fixtures	70,634	50,951	LARIMAR THERAPEUTICS INC		
Interest Expense on Financial Lease Liabilities	70	47	...	Less: accumulated depreciation & amortization	52,627	38,869	Earnings, 9 mos. to Sep 30(Consol. - \$000):		
Interest expense	...	...	69	Property and equipment - net	171,190	138,589		2025	2024
Interest income	3,102	2,915	...	Operating lease right-of-use assets	146,416	123,682	Cost & expenses	108,479	59,597
Interest income	...	...	1,472	Deposits	2,394	...	Operating income	(108,479)	(59,597)
Income (loss) before income taxes	(1,729)	(8,637)	1,735	Liquor license	5,953	...	Other income (expense), net	5,304	7,817
Current state income taxes	175	167	233	Deposits & other assets	8,347	4,916	Net income	(103,175)	(51,780)
Current income taxes	175	167	233	Long-term investments	29,542	...	Earnings common share		
Income tax expense (benefit)	175	167	233	Total assets	430,942	328,522	Primary	\$(1.50)	\$(0.86)
Net income (loss)	(1,904)	(8,804)	1,502	Accounts payable	11,533	8,977	Fully Diluted	\$(1.50)	\$(0.86)
Weighted average shares outstanding - basic	11,916	11,204	10,305	Accrued expenses & other current liabilities	4,116	4,261	Common Shares:		
Weighted average shares outstanding - diluted	11,916	11,204	10,640	Salaries & wages payable	10,310	8,310	Full Diluted	68,825	60,400
Year end shares outstanding	12,111	11,253	11,147	Operating lease liabilities - current	14,083	10,674	Year-end	85,590	63,807
Net earnings (loss) per share - basic	\$(0.16)	\$(0.79)	\$0.15	Sales tax payable	2,213	1,904	LATHAM GROUP INC		
Net earnings (loss) per share - diluted	\$(0.16)	\$(0.79)	\$0.14	Due to affiliate	525	373	Earnings, 9 mos. to (Consol. - \$000):		
Full-Time Employees (Period End)	3,900	3,300	...	Total current liabilities	42,780	34,499		09/27/25	09/28/24
Total number of employees	3,900	3,300	3,219	Operating lease liabilities - non-current	155,932	130,677	Total Revenues	445,962	421,247
Total Revenue	282,763	237,860	...	Other liabilities	1,160	808	Cost & expenses	382,957	370,122
Common Shareholders - Number	3	5	4	Total liabilities	199,872	165,984	Operating income	41,301	31,303
Depreciation and amortization expenses	448	425	...	Class A common stock	1	1	Other income (expense), net	4,938	1,088
Consolidated Balance Sheet, Years Ended Aug. 31 (\$000):				Class B common stock	11	10	Net before taxes	26,652	12,241
	2025	2024		Additional paid-in capital	265,973	195,515	Income taxes	8,517	931
				Accumulated deficit	(34,892)	(32,988)	Net income	18,135	11,310
				Accumulated other comprehensive loss	(23)	...	Earnings common share		
				Total stockholders' equity (deficit)	231,070	162,538	Primary	\$0.16	\$0.10
				Total Equity	231,070	162,538	Fully Diluted	\$0.15	\$0.10
				Recent Dividends:			Common Shares:		
				1. Kura Sushi USA Inc class B common.			Full Diluted	119,721	117,131
				No dividends paid.			Year-end	116,656	115,593
				2. Kura Sushi USA Inc class A common.			LEGACY HOUSING CORP		
				No dividends paid.			Earnings, 9 mos. to Sep 30(Consol. - \$000):		
				Annual Dividends:				2025	2024
				1. Kura Sushi USA Inc class B common.			Total Revenues	126,310	130,004
				No dividends paid.			Cost & expenses	88,192	81,900
				2. Kura Sushi USA Inc class A common.			Operating income	38,118	48,104
				No dividends paid.			Other income (expense), net	1,414	7,945
				LAMAR ADVERTISING CO (NEW)			Net before taxes	40,761	57,633
				Earnings, 9 mos. to Sep 30(Consol. - \$000):			Income taxes	7,145	10,502
					2025	2024	Net income	33,616	47,131
				Total Revenues	1,670,282	1,627,536	Earnings common share		
				Cost & expenses	850,077	904,622	Primary	\$1.40	\$1.94
				Operating income	577,998	495,383	Fully Diluted	\$1.37	\$1.90
				Other income (expense), net	(1,806)	1,817	Common Shares:		
				Net before taxes	457,818	367,140	Full Diluted	24,576	24,871
				Income taxes	19,498	3,225	Year-end	23,869	24,158
				Net income	438,320	363,915	LEGALZOOM.COM INC		
				Balance for common	434,590	362,793	Earnings, 9 mos. to Sep 30(Consol. - \$000):		
				Earnings common share				2025	2024
				Primary	\$4.28	\$3.55	Total Revenues	565,777	520,175
				Fully Diluted	\$4.27	\$3.54	Cost & expenses	553,418	497,705
							Operating income	18,448	30,617
							Other income (expense), net	897	1,845
							Net before taxes	18,448	30,617
							Income taxes	9,078	13,508
							Net income	9,370	17,109
							Earnings common share		
							Primary	\$0.05	\$0.09
							Fully Diluted	\$0.05	\$0.09
							Common Shares:		
							Full Diluted	185,329	185,374
							Year-end	179,515	173,174

LEMAITRE VASCULAR INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	185,149	164,146
Cost & expenses	136,069	124,744
Operating income	49,080	39,402
Net before taxes	54,884	42,854
Income taxes	12,732	10,000
Net income	42,152	32,854
Earnings common share		
Primary	\$1.86	\$1.46
Fully Diluted	\$1.84	\$1.45
Common Shares:		
Full Diluted	22,915	22,723
Year-end	22,682	22,483

LEXICON PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	44,310,000	4,527,000
Cost & expenses	78,441,000	168,907,000
Operating income	(34,131,000)	164,380,000
Other income (expense), net	5,628,000	9,464,000
Net income	(34,811,000)	166,637,000
Earnings common share		
Primary	\$(0.10)	\$(0.54)
Fully Diluted	\$(0.10)	\$(0.54)
Common Shares:		
Full Diluted	362,927,000	306,109,000
Year-end	363,398,860	361,492,295

LIBERTY BROADBAND CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	753,000	753,000
Cost & expenses	31,000	517,000
Operating income	(31,000)	79,000
Other income (expense), net	955,000	938,000
Gains or losses	7,000	(125,000)
Net before taxes	743,000	743,000
Income taxes	165,000	165,000
Income contin. oper.	845,000	845,000
Net income	497,000	578,000
Earnings common share		
Primary	\$3.48	\$4.04
Fully Diluted	\$3.48	\$4.04
Common Shares:		
Full Diluted	143,000	143,000
Year-end	143,490	142,848

LIBERTY MEDIA CORP (DE) - FORMULA ONE GROUP**Earnings, 9 mos. to Sep 30**(Consol. – \$Millions):

	2025	2024
Total Revenues	2,873	2,486
Cost & expenses	2,247	1,959
Operating income	351	264
Interest expense	162	162
Other income (expense), net	298	50
Gains or losses	(224)	86
Net before taxes	227	238
Income taxes	5	20
Net income	222	218
Earnings common share		
Primary	\$0.92	\$0.92
Fully Diluted	\$0.90	\$0.90
Common Shares:		
Full Diluted	242	242
Year-end	249	249

LIFESTANCE HEALTH GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,042,090	925,490
Cost & expenses	994,707	901,883
Operating income	6,064	(32,672)
Other income (expense), net	(117)	(901)
Gains or losses	1,975	1,975
Net before taxes	(2,840)	(48,737)
Income taxes	(835)	1,594
Net income	(2,005)	(50,331)
Earnings common share		
Primary	\$(0.01)	\$(0.13)
Fully Diluted	\$(0.01)	\$(0.13)
Common Shares:		

Full Diluted	385,672	378,713
Year-end	389,000	382,640

LIFETIME BRANDS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	443,859	467,745
Cost & expenses	473,274	456,135
Operating income	(29,415)	11,610
Other income (expense), net	(14,152)	(14,152)
Gains or losses	(755)	(1,184)
Equity earnings	2,092	2,092
Net before taxes	(45,152)	(20,331)
Income taxes	(63)	1,660
Net income	(45,089)	(24,083)
Earnings common share		
Primary	\$(2.08)	\$(1.12)
Fully Diluted	\$(2.08)	\$(1.12)
Common Shares:		
Full Diluted	21,683	21,454
Year-end	22,657	22,157

LIGAND PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	208,421,000	124,321,000
Cost & expenses	156,650,000	112,589,000
Operating income	27,159,000	(12,969,000)
Other income (expense), net	(1,572,000)	(48,206,000)
Gains or losses	75,887,000	75,887,000
Invest. income	(3,630,000)	98,923,000
Net before taxes	102,180,000	41,718,000
Income taxes	22,511,000	14,662,000
Net income	79,669,000	27,056,000
Earnings common share		
Primary	\$4.11	\$1.50
Fully Diluted	\$3.95	\$1.46
Common Shares:		
Full Diluted	20,170,000	18,574,000
Year-end	19,656,000	18,760,000

LIGHT & WONDER INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,424,000	2,391,000
Cost & expenses	1,526,000	1,627,000
Operating income	600,000	500,000
Other income (expense), net	(4,000)	12,000
Net before taxes	367,000	289,000
Income taxes	76,000	61,000
Net income	291,000	228,000
Earnings common share		
Primary	\$3.45	\$2.55
Fully Diluted	\$3.39	\$2.49
Common Shares:		
Full Diluted	86,000	92,000
Year-end	83,000	89,000

LINCOLN EDUCATIONAL SERVICES CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	375,369	320,691
Cost & expenses	362,792	316,443
Operating income	12,577	4,248
Net before taxes	10,197	4,155
Income taxes	2,899	1,098
Net income	7,298	3,057
Earnings common share		
Primary	\$0.24	\$0.10
Fully Diluted	\$0.23	\$0.10
Common Shares:		
Full Diluted	31,221	30,806
Year-end	31,624	31,479

LUCID GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	831,060,000	573,359,000
Cost & expenses	3,268,059,000	2,861,229,000
Operating income	(2,436,999,000)	(2,287,870,000)
Other income (expense), net	112,068,000	(6,229,000)
Gains or losses	366,838,000	154,564,000
Net before taxes	(1,888,126,000)	(2,316,114,000)
Income taxes	(4,095,000)	610,000

Net income	(1,884,031,000)	(2,316,724,000)
Balance for common	(2,504,900,000)	(2,424,648,000)

Earnings common share		
Primary	\$(8.15)	\$(10.50)
Fully Diluted	\$(8.15)	\$(10.50)
Common Shares:		
Full Diluted	307,859,815	231,224,933
Year-end	324,164,267	233,751,854

LUMENTUM HOLDINGS INC**Earnings, 3 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	533,800	336,900
Cost & expenses	527,100	419,300
Operating income	6,700	(82,400)
Gains or losses	(5,900)	(5,900)
Net before taxes	5,200	(79,200)
Income taxes	1,000	3,200
Net income	4,200	(82,400)
Earnings common share		
Primary	\$0.06	\$(1.21)
Fully Diluted	\$0.05	\$(1.21)
Common Shares:		
Full Diluted	78,300	68,300
Year-end	70,900	68,600

Consolidated Balance Sheet Items, as of (\$000):

	2025
Assets:	
Cash & equivalents	772,900
Inventories	531,600
Current assets	2,085,600
Net property & equip.	794,800
Total assets	4,613,100
Liabilities:	
Current liabilities	1,526,200
Long-term debt	2,164,500
Stockholders' equity	780,800
Net current assets	559,400

LYFT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	4,723,550,000	4,235,739,000
Cost & expenses	4,726,916,000	4,382,603,000
Operating income	(3,366,000)	146,864,000
Other income (expense), net	113,710,000	12,876,000
Gains or losses	(96,000)	(96,000)
Net before taxes	94,420,000	(35,185,000)
Income taxes	5,465,000	3,762,000
Net income	88,955,000	(38,947,000)
Earnings common share		
Primary	\$0.21	\$(0.10)
Fully Diluted	\$0.21	\$(0.10)
Common Shares:		
Full Diluted	420,268,000	406,785,000
Year-end	401,465,000	414,811,159

MAGNITE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	508,597	508,597
Cost & expenses	462,961	463,333
Operating income	45,636	10,869
Other income (expense), net	(1,422)	(3,824)
Net before taxes	22,553	(15,774)
Income taxes	990	(2,153)
Net income	21,563	(13,621)
Earnings common share		
Primary	\$0.15	\$(0.10)
Fully Diluted	\$0.14	\$(0.10)
Common Shares:		
Full Diluted	150,516	140,376
Year-end	143,643	141,148

MANNKIND CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	237,011	208,728
Cost & expenses	190,523	162,636
Operating income	46,488	46,092
Other income (expense), net	(1,759)	(1,759)
Gains or losses	(6,409)	(1,550)
Net before taxes	22,338	22,073
Income taxes	527	1,907
Net income	21,811	20,166

Earnings common share		
Primary	\$0.07	\$0.07
Fully Diluted	\$0.07	\$0.07
Common Shares:		
Full Diluted	313,339	281,407
Year-end	307,027	275,775

MARAVAI LIFESCIENCES HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	135,877	202,627
Cost & expenses	292,348	400,542
Operating income	(156,471)	(197,915)
Other income (expense), net	(4,109)	(2,423)
Net before taxes	(171,965)	(215,408)
Income taxes	(4,218)	(1,853)
Net income	(167,747)	(213,555)

Earnings common share		
Primary	\$(0.66)	\$(0.87)
Fully Diluted	\$(0.66)	\$(0.87)
Common Shares:		
Full Diluted	144,119	136,595
Year-end	144,718	141,589

MARKETAXESS HOLDINGS INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Cost & expenses	313,941	298,515
Operating income	265,825	260,894
Other income (expense), net	2,958	(2,987)
Net before taxes	287,209	275,951
Income taxes	132,691	66,909
Net income	154,518	209,042

Earnings common share		
Primary	\$4.15	\$5.55
Fully Diluted	\$4.14	\$5.55
Common Shares:		
Full Diluted	37,288	37,696
Year-end	37,150	37,725

MARQETA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	452,771	371,205
Cost & expenses	471,904	346,305
Operating income	(38,136)	12,959
Other income (expense), net	26,544	41,845
Net before taxes	(11,592)	54,804
Income taxes	939	399
Net income	(12,531)	54,405

Earnings common share		
Primary	\$(0.03)	\$0.11
Fully Diluted	\$(0.03)	\$0.10
Common Shares:		
Full Diluted	470,294	522,394
Year-end	449,345	504,150

MASIMO CORP.**Earnings, 9 mos. to (Consol. – \$000):**

	09/27/25	09/28/24
Total Revenues	1,114,400	1,493,700
Cost & expenses	888,300	1,401,300
Operating income	226,100	92,400
Net before taxes	198,600	56,400
Income taxes	52,800	11,700
Income contin. oper.	145,800	
Net income	(219,800)	44,700

Earnings common share		
Primary	\$(4.06)	\$0.84
Fully Diluted	\$(4.06)	\$0.82
Common Shares:		
Full Diluted	54,100	54,300
Year-end	53,100	53,500

MASTERCRAFT BOAT HOLDINGS INC**Earnings, 3 mos. to (Consol. – \$000):**

	09/28/25	09/29/24
Total Revenues	69,002	65,359
Cost & expenses	64,774	63,905
Operating income	3,778	1,004
Net before taxes	4,547	1,209
Income taxes	891	193
Income contin. oper.	3,656	1,016
Net income	3,636	(5,145)

Earnings common share		
Primary	\$0.22	\$(0.31)
Fully Diluted	\$0.22	\$(0.31)
Common Shares:		
Full Diluted	16,255	16,545
Year-end	16,290	16,816

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	
Cash & equivalents	31,760	
Inventories	33,437	
Current assets	120,670	
Net property & equip.	55,088	
Total assets	259,307	
Liabilities:		
Current liabilities	62,740	
Stockholders' equity	185,528	
Net current assets	57,930	

MATCH GROUP INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,609,191	2,619,197
Cost & expenses	1,936,811	1,888,949
Operating income	587,848	599,924
Other income (expense), net	2,213	27,099
Net before taxes	491,296	506,512
Income taxes	87,491	113,477
Net income	403,805	393,035

Earnings common share		
Primary	\$1.65	\$1.49
Fully Diluted	\$1.55	\$1.43
Common Shares:		
Full Diluted	265,303	281,255
Year-end	239,011	253,956

MATRIX SERVICE CO.**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	211,884	165,579
Cost & expenses	217,384	176,346
Operating income	(5,500)	(10,767)
Other income (expense), net	231	61
Net before taxes	(3,594)	
Income taxes	69	
Net income	(3,663)	(9,223)

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	
Cash & equivalents	192,307	
Inventories	5,579	
Current assets	410,412	
Net property & equip.	41,347	
Total assets	598,186	
Liabilities:		
Current liabilities	443,455	
Stockholders' equity	136,266	
Net current assets	(33,043)	

MESA LABORATORIES, INC.**Earnings, 6 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	120,280,000	116,003,000
Cost & expenses	112,492,000	106,915,000
Operating income	7,788,000	9,088,000
Other income (expense), net	6,283,000	4,489,000
Net before taxes	9,011,000	7,717,000
Income taxes	1,793,000	901,000
Net income	7,218,000	6,816,000

Earnings common share		
Primary	\$1.32	\$1.26
Fully Diluted	\$1.30	\$1.25
Common Shares:		
Full Diluted	5,543,000	5,448,000
Year-end	5,510,741	5,419,855

MGE ENERGY INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	554,101	505,529
Cost & expenses	331,090	306,273
Operating income	138,163	118,620
Other income (expense), net	16,199	12,576
Net before taxes	129,647	106,471
Income taxes	17,060	7,924
Net income	112,587	98,547

Earnings common share		
Primary	\$3.08	\$2.72
Fully Diluted	\$3.08	\$2.72
Common Shares:		
Full Diluted	36,565	36,202
Year-end	36,542	36,205

MICROCHIP TECHNOLOGY INC**Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,215,900	2,405,100
Cost & expenses	1,879,200	1,793,700
Operating income	121,000	365,700
Other income (expense), net	200	3,700
Net before taxes	16,000	253,300
Income taxes	(7,100)	45,600
Net income	23,100	207,700

Balance for common	(32,500)	
Earnings common share		
Primary	\$(0.06)	\$0.39
Fully Diluted	\$(0.06)	\$0.38

Common Shares:		
Full Diluted	539,600	542,400
Year-end	540,446	537,010

MIDDLEBY CORP**Earnings, 9 mos. to (Consol. – \$000):**

	09/27/25	09/28/24
Total Revenues	2,866,617	2,861,281
Cost & expenses	3,124,876	2,375,001
Operating income	(258,259)	486,280
Other income (expense), net	(2,887)	10,249
Net before taxes	(324,501)	424,290
Income taxes	(9,831)	108,161
Net income	(314,670)	316,129

Earnings common share		
Primary	\$(6.02)	\$5.88
Fully Diluted	\$(6.02)	\$5.84
Common Shares:		
Full Diluted	52,244	54,168
Year-end	50,370	53,771

MKS INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	2,898,000,000	2,652,000,000
Cost & expenses	2,329,000,000	2,106,000,000
Operating income	385,000,000	362,000,000
Other income (expense), net	(19,000,000)	(49,000,000)
Net before taxes	215,000,000	100,000,000
Income taxes	27,000,000	1,000,000
Net income	188,000,000	99,000,000

Earnings common share		
Primary	\$2.79	\$1.48
Fully Diluted	\$2.78	\$1.47
Common Shares:		
Full Diluted	67,600,000	67,500,000
Year-end	67,200,000	67,298,941

MODERNA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,266,000	2,270,000
Cost & expenses	3,483,000	4,969,000
Operating income	(2,217,000)	(2,699,000)
Other income (expense), net	9,000	7,000
Invest. income	(3,000)	(47,000)
Net before taxes	(1,969,000)	(2,423,000)
Income taxes	27,000	18,000
Net income	(1,996,000)	(2,441,000)

Earnings common share		
Primary	\$(5.15)	\$(6.37)
Fully Diluted	\$(5.15)	\$(6.37)
Common Shares:		
Full Diluted	388,000	383,000
Year-end	391,000	385,000

MONOLITHIC POWER SYSTEMS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	2,039,304,000	1,585,435,000
Cost & expenses	1,510,604,000	1,209,384,000
Operating income	528,700,000	376,051,000
Other income (expense), net	7,665,000	6,981,000
Net before taxes	556,443,000	403,381,000
Income taxes	110,652,000	66,044,000
Net income	445,791,000	337,337,000
Earnings common share		
Primary	\$9.31	\$6.93
Fully Diluted	\$9.28	\$6.89
Common Shares:		
Full Diluted	48,022,000	48,945,000
Year-end	47,905,000	48,779,000

MONROE CAPITAL CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Cost & expenses	20,522	27,994
Operating income	9,197	18,510
Other income (expense), net		20
Invest. income	(11,671)	(7,111)
Net income	(2,474)	11,419
Earnings common share		
Primary	\$(0.11)	\$0.53
Fully Diluted	\$(0.11)	\$0.53
Common Shares:		
Full Diluted	21,666	21,666
Year-end	21,666	21,666

MONSTER BEVERAGE CORP (NEW)**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	6,163,290,000	5,680,668,000
Cost & expenses	4,286,570,000	4,131,598,000
Operating income	1,876,720,000	1,549,070,000
Net before taxes	1,914,242,000	1,603,381,000
Income taxes	458,000,000	365,044,000
Net income	1,456,242,000	1,238,337,000
Earnings common share		
Primary	\$1.49	\$1.22
Fully Diluted	\$1.48	\$1.21
Common Shares:		
Full Diluted	983,532,000	1,023,912,000
Year-end	976,997,000	972,450,000

MONTE ROSA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	120,891	14,975
Cost & expenses	125,384	109,091
Operating income	(4,493)	(94,116)
Gains or losses	59	
Net before taxes		(85,731)
Income taxes		406
Net income	6,353	(86,137)
Earnings common share		
Primary	\$0.09	\$(1.21)
Fully Diluted	\$0.09	\$(1.21)
Common Shares:		
Full Diluted	82,943	71,174
Year-end	61,790	61,377

NATERA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,640,615	1,220,850
Cost & expenses	1,927,741	1,378,404
Operating income	(287,126)	(157,554)
Net before taxes	(254,763)	(134,605)
Income taxes	655	2,050
Net income	(255,418)	(136,655)
Earnings common share		
Primary	\$(1.88)	\$(1.12)
Fully Diluted	\$(1.88)	\$(1.12)
Common Shares:		
Full Diluted	136,181	122,486
Year-end	137,533	124,137

NATHAN'S FAMOUS, INC.**Earnings, 6 mos. to (Consol. – \$000):**

	09/28/25	09/29/24
Total Revenues	92,685	85,876
Cost & expenses	71,928	62,003
Operating income	20,293	23,377
Other income (expense), net	43	(290)
Net before taxes	19,278	20,883
Income taxes	5,151	5,576
Net income	14,127	15,307
Earnings common share		
Primary	\$3.45	\$3.75
Fully Diluted	\$3.42	\$3.75
Common Shares:		
Full Diluted	4,127	4,092
Year-end	4,090	4,085

NATIONAL RESEARCH CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	102,196,000	106,154,000
Cost & expenses	78,796,000	76,042,000
Operating income	17,921,000	25,606,000
Other income (expense), net	(34,000)	(28,000)
Net before taxes	14,576,000	23,815,000
Income taxes	4,774,000	5,592,000
Net income	9,802,000	18,223,000
Balance for common		18,221,000
Earnings common share		
Primary	\$0.43	\$0.76
Fully Diluted	\$0.43	\$0.76
Common Shares:		
Full Diluted	22,590,000	23,868,000
Year-end	22,657,421	23,476,040

NATIONAL VISION HOLDINGS INC**Earnings, 9 mos. to (Consol. – \$000):**

	09/27/25	09/28/24
Total Revenues	1,484,077	1,386,042
Cost & expenses	1,364,199	1,302,227
Operating income	52,194	15,212
Other income (expense), net		859
Net before taxes	39,293	4,511
Income taxes	13,010	2,239
Income contin. oper.		2,272
Net income	26,283	92
Earnings common share		
Primary	\$0.33	\$
Fully Diluted	\$0.33	\$
Common Shares:		
Full Diluted	80,170	78,747
Year-end	79,260	78,691

NEKTAR THERAPEUTICS**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	33,425	69,252
Cost & expenses	145,862	188,798
Operating income	(112,437)	(119,546)
Other income (expense), net	405	(255)
Net before taxes	(120,785)	(126,202)
Income taxes	(169)	20
Net income	(120,616)	(126,222)
Earnings common share		
Primary	\$(8.14)	\$(0.62)
Fully Diluted	\$(8.14)	\$(0.62)
Common Shares:		
Full Diluted	15,716	204,292
Year-end	19,653	184,458

NERDWALLET INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues		503,800
Cost & expenses	565,400	503,100
Operating income	45,800	700
Gains or losses	500	(100)
Net before taxes	48,300	4,300
Income taxes	13,600	12,500
Net income	34,700	(8,200)
Earnings common share		
Primary	\$0.46	\$(0.11)
Fully Diluted	\$0.45	\$(0.11)
Common Shares:		
Full Diluted	76,500	77,500
Year-end	72,713	73,439

NETSCOUT SYSTEMS INC**Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	405,764	365,673
Cost & expenses	357,561	791,618
Operating income	25,922	(449,201)
Other income (expense), net	(3,273)	5,933
Net before taxes	28,554	(441,370)
Income taxes	6,405	(7,021)
Net income	22,149	(434,349)
Earnings common share		
Primary	\$0.31	\$(6.08)
Fully Diluted	\$0.30	\$(6.08)
Common Shares:		
Full Diluted	73,130	71,457
Year-end	72,186	71,715

NEUMORA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Cost & expenses	182,676	200,542
Operating income	(182,676)	(200,542)
Other income (expense), net	(498)	(93)
Net before taxes	(177,348)	(184,790)
Income taxes	130	178
Net income	(177,478)	(184,968)
Earnings common share		
Primary	\$(1.10)	\$(1.16)
Fully Diluted	\$(1.10)	\$(1.16)
Common Shares:		
Full Diluted	161,663	158,837
Year-end	161,947	160,480

NEURONETICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	107,380	52,397
Cost & expenses	133,773	75,488
Operating income	(26,393)	(23,091)
Other income (expense), net	561	(2,426)
Net income	(31,929)	(31,046)
Earnings common share		
Primary	\$(0.49)	\$(1.04)
Fully Diluted	\$(0.49)	\$(1.04)
Common Shares:		
Full Diluted	65,006	29,931
Year-end	68,445	30,317

NEUROPACE INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues		58,440,000
Cost & expenses	87,969,000	76,458,000
Operating income	(14,571,000)	(18,018,000)
Other income (expense), net	(486,000)	390,000
Net income	(18,736,000)	(21,891,000)
Earnings common share		
Primary	\$(0.58)	\$(0.76)
Fully Diluted	\$(0.58)	\$(0.76)
Common Shares:		
Full Diluted	32,498,907	28,863,120
Year-end	33,280,887	29,777,966

NEWS CORP (NEW)**Earnings, 3 mos. to Sep 30(Consol. – \$Millions):**

	2025	2024
Total Revenues	2,144	2,096
Cost & expenses	1,815	1,774
Operating income	212	210
Net before taxes	212	210
Income taxes	62	61
Income contin. oper.		149
Net income	150	144
Earnings common share		
Primary	\$0.20	\$0.21
Fully Diluted	\$0.20	\$0.21
Common Shares:		
Full Diluted	567	571
Year-end	564	569

Consolidated Balance Sheet Items, as of (\$Millions):

	2025
Assets:	
Cash & equivalents	2,198
Inventories	327
Current assets	4,473

Net property & equip.	1,321	
Total assets	15,343	
Liabilities:		
Current liabilities	2,537	
Long-term debt	1,931	
Stockholders' equity	8,704	
Net current assets	1,936	

NEXSTAR MEDIA GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,660,000	3,920,000
Cost & expenses	2,461,000	2,481,000
Operating income	607,000	851,000
Other income (expense), net	45,000	111,000
Net before taxes	364,000	622,000
Income taxes	111,000	169,000
Net income	253,000	453,000
Balance for common	263,000	464,000
Earnings common share		
Primary	\$8.66	\$14.17
Fully Diluted	\$8.57	\$13.96
Common Shares:		
Full Diluted	30,696	33,248
Year-end	30,324	31,476

NEXTCURE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	47,859	47,293
Operating income	(47,859)	(47,293)
Other income (expense), net	1,451	3,242
Net income	(46,408)	(44,051)
Earnings common share		
Primary	\$(18.84)	\$(18.96)
Fully Diluted	\$(18.84)	\$(18.96)
Common Shares:		
Full Diluted	2,463	2,329
Year-end	2,676	2,331

NEXTNAV INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	3,628,000	3,758,000
Cost & expenses	51,389,000	45,165,000
Operating income	(54,109,000)	(45,333,000)
Other income (expense), net	(23,698,000)	2,091,000
Gains or losses	(34,401,000)	(19,523,000)
Net before taxes	(121,145,000)	(69,471,000)
Income taxes	146,000	138,000
Net income	(121,291,000)	(69,609,000)
Earnings common share		
Primary	\$(0.92)	\$(0.59)
Fully Diluted	\$(0.92)	\$(0.59)
Common Shares:		
Full Diluted	132,535,000	118,978,000
Year-end	134,727,753	127,545,321

NKARTA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	91,036,000	97,271,000
Operating income	(91,036,000)	(97,271,000)
Other income (expense), net	2,163,000	(7,000)
Net income	(76,675,000)	(82,855,000)
Earnings common share		
Primary	\$(1.04)	\$(1.26)
Fully Diluted	\$(1.04)	\$(1.26)
Common Shares:		
Full Diluted	73,973,278	65,941,355
Year-end	71,024,512	70,568,754

NLIGHT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	180,145	151,167
Cost & expenses	201,290	190,374
Operating income	(21,145)	(39,207)
Other income (expense), net	(108)	2,594
Net before taxes	(18,131)	(35,305)
Income taxes	427	525
Net income	(18,558)	(35,830)
Earnings common share		
Primary	\$(0.37)	\$(0.75)

Fully Diluted	\$(0.37)	\$(0.75)
Common Shares:		
Full Diluted	49,658	47,679
Year-end	50,784	48,343

NOODLES & CO**Earnings, 9 mos. to** (Consol. – \$000):

	09/30/25	10/01/24
Total Revenues	372,313	371,497
Cost & expenses	378,964	369,926
Operating income	(27,484)	(20,414)
Net before taxes	(35,711)	(26,472)
Income taxes	49	48
Net income	(35,760)	(26,520)
Earnings common share		
Primary	\$(0.78)	\$(0.58)
Fully Diluted	\$(0.78)	\$(0.58)
Common Shares:		
Full Diluted	46,135	45,390
Year-end	46,775	45,679

NORTHFIELD BANCORP INC (DE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	156,775	159,831
Operating income	39,449	26,576
Net before taxes	39,449	26,576
Income taxes	11,251	7,882
Net income	28,198	18,694
Earnings common share		
Primary	\$0.70	\$0.45
Fully Diluted	\$0.70	\$0.45
Common Shares:		
Full Diluted	40,293	41,829
Year-end	41,811	42,904

NOVAVAX, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	976,340,000	593,851,000
Cost & expenses	537,775,000	711,702,000
Operating income	438,565,000	(117,851,000)
Other income (expense), net	2,422,000	27,307,000
Net before taxes	424,264,000	103,034,000
Income taxes	1,489,000	3,435,000
Net income	422,775,000	(106,469,000)
Earnings common share		
Primary	\$2.61	\$(0.71)
Fully Diluted	\$2.53	\$(0.71)
Common Shares:		
Full Diluted	168,195,000	149,486,000
Year-end	162,470,138	160,148,088

O'REILLY AUTOMOTIVE, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	13,367,678	12,612,878
Cost & expenses	10,735,675	10,100,371
Operating income	2,632,003	2,512,507
Other income (expense), net	6,591	9,266
Net before taxes	2,469,456	2,359,867
Income taxes	536,480	524,317
Net income	1,932,976	1,835,550
Earnings common share		
Primary	\$2.26	\$2.09
Fully Diluted	\$2.25	\$2.08
Common Shares:		
Full Diluted	858,452	884,130
Year-end	846,832	867,584

ODP CORP (THE)**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	4,911,000	5,367,000
Cost & expenses	4,900,000	5,224,000
Operating income	11,000	143,000
Other income (expense), net	(6,000)	(4,000)
Net before taxes		130,000
Income taxes		35,000
Income contin. oper.		95,000
Net income	(6,000)	95,000
Earnings common share		
Primary	\$(0.21)	\$.....
Fully Diluted	\$(0.21)	\$.....

Common Shares:		
Full Diluted	30,000	36,000
Year-end	30,118	31,205

OFS CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	21,634	23,680
Operating income	9,688	12,636
Other income (expense), net	(20,508)	4,943
Invest. income	(11,425)	(14,612)
Net income	(22,245)	2,967
Earnings common share		
Primary	\$(1.66)	\$0.22
Fully Diluted	\$(1.66)	\$0.22
Common Shares:		
Full Diluted	13,398	13,398
Year-end	13,398	13,398

OLAPLEX HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	317,841	321,929
Cost & expenses	273,658	225,231
Operating income	11,455	63,891
Other income (expense), net	10,683	(541)
Net before taxes	516	37,709
Income taxes	(3,334)	9,387
Net income	3,850	28,322
Earnings common share		
Primary	\$0.01	\$0.04
Fully Diluted	\$0.01	\$0.04
Common Shares:		
Full Diluted	667,550	664,723
Year-end	667,432	662,479

OLEMA PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	128,614,000	105,490,000
Operating income	(128,614,000)	105,490,000
Other income (expense), net	10,000	195,000
Net income	(116,390,000)	(95,907,000)
Earnings common share		
Primary	\$(1.36)	\$(1.80)
Fully Diluted	\$(1.36)	\$(1.80)
Common Shares:		
Full Diluted	85,553,078	53,194,081
Year-end	68,652,730	57,288,319

OMNICELL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	870,861	805,359
Cost & expenses	866,116	817,418
Operating income	4,745	(12,059)
Net before taxes	10,626	1,993
Income taxes	6,548	5,304
Net income	4,078	(3,311)
Earnings common share		
Primary	\$0.09	\$(0.07)
Fully Diluted	\$0.09	\$(0.07)
Common Shares:		
Full Diluted	46,657	45,947
Year-end	44,876	46,313

ONKURE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	48,825	20,591
Operating income	(48,825)	(20,591)
Other income (expense), net		3,112
Net income	(46,014)	(17,479)
Earnings common share		
Primary	\$(3.41)	\$(5.23)
Fully Diluted	\$(3.41)	\$(5.23)
Common Shares:		
Full Diluted	13,488	3,343
Year-end	13,548	3,344

OPENDOOR TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	3,635,000,000	
Cost & expenses	3,772,000,000	4,295,000,000
Operating income	(137,000,000)	226,000,000
Other income (expense), net	37,000,000	49,000,000
Net before taxes	(203,000,000)	278,000,000
Income taxes	1,000,000	1,000,000
Net income	(204,000,000)	279,000,000
Earnings common share		
Primary	\$(0.28)	\$(0.40)
Fully Diluted	\$(0.28)	\$(0.40)
Common Shares:		
Full Diluted	731,722,000	693,796,000
Year-end	771,534,057	711,660,871

ORASURE TECHNOLOGIES INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	88,258,000	148,382,000
Cost & expenses	140,124,000	164,214,000
Operating income	(51,866,000)	(15,832,000)
Other income (expense), net	5,712,000	9,338,000
Equity earnings	1,700,000	1,171,000
Net before taxes	(46,154,000)	(6,494,000)
Income taxes		1,041,000
Net income	(49,445,000)	(8,706,000)
Earnings common share		
Primary	\$(0.67)	\$(0.12)
Fully Diluted	\$(0.67)	\$(0.12)
Common Shares:		
Full Diluted	74,131,000	74,330,000
Year-end	72,265,000	74,593,000

PACIFIC BIOSCIENCES OF CALIFORNIA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	115,360	114,790
Cost & expenses	264,316	422,698
Operating income	(512,664)	(321,285)
Other income (expense), net	11,989	19,718
Net before taxes	(505,889)	
Income taxes	116	
Net income	(506,005)	(312,222)
Earnings common share		
Primary	\$(1.69)	\$(1.15)
Fully Diluted	\$(1.69)	\$(1.15)
Common Shares:		
Full Diluted	299,303	271,631
Year-end	301,853	273,812

PACIRA BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	529,538	513,713
Cost & expenses	469,721	568,822
Operating income	16,851	(98,075)
Other income (expense), net	(7,431)	7,198
Net before taxes	16,303	(88,632)
Income taxes	10,906	26,969
Net income	5,397	(115,601)
Earnings common share		
Primary	\$0.12	\$(2.50)
Fully Diluted	\$0.12	\$(2.50)
Common Shares:		
Full Diluted	45,729	46,269
Year-end	42,966	46,148

PALOMAR HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	287,058,000	181,748,000
Operating income	180,732,000	106,233,000
Net before taxes	180,732,000	106,233,000
Income taxes	39,827,000	23,625,000
Net income	140,905,000	82,608,000
Earnings common share		
Primary	\$5.28	\$3.28
Fully Diluted	\$5.12	\$3.19
Common Shares:		
Full Diluted	27,533,533	25,877,257
Year-end	26,494,524	26,452,242

PAPA JOHN'S INTERNATIONAL, INC.**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues	1,555,629	1,528,617
Cost & expenses	1,428,927	1,348,916
Operating income	64,626	127,173
Net before taxes	34,018	94,585
Income taxes	10,531	25,347
Net income	23,487	69,238
Balance for common	22,742	
Earnings common share		
Primary	\$0.69	\$2.10
Fully Diluted	\$0.69	\$2.09
Common Shares:		
Full Diluted	32,962	32,850
Year-end	32,786	32,637

PARK-OHIO HOLDINGS CORP.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,204,100	1,267,800
Cost & expenses	1,147,800	1,195,600
Operating income	56,300	72,200
Other income (expense), net	3,300	3,800
Net before taxes	24,900	40,000
Income taxes	3,300	5,300
Income contin. oper.	21,600	34,700
Net income	21,100	29,400
Earnings common share		
Primary	\$1.65	\$2.46
Fully Diluted	\$1.63	\$2.40
Common Shares:		
Full Diluted	14,000	13,000
Year-end	14,502	14,042

PATRICK INDUSTRIES INC**Earnings, 9 mos. to** (Consol. – \$):

	09/28/25	09/29/24
Total Revenues	3,026,605,000	2,869,560,000
Cost & expenses	2,734,683,000	2,579,567,000
Operating income	218,584,000	218,448,000
Other income (expense), net	(24,420,000)	
Net before taxes	137,732,000	157,965,000
Income taxes	31,755,000	34,122,000
Net income	105,977,000	123,843,000
Earnings common share		
Primary	\$3.26	\$3.81
Fully Diluted	\$3.08	\$3.70
Common Shares:		
Full Diluted	34,440,000	33,445,500
Year-end	33,276,895	33,630,840

PAYLOCITY HOLDING CORP**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	408,172	362,956
Cost & expenses	333,961	298,812
Operating income	74,211	64,144
Other income (expense), net	702	4,742
Net before taxes	74,913	68,886
Income taxes	26,922	19,313
Net income	47,991	49,573
Earnings common share		
Primary	\$0.87	\$0.89
Fully Diluted	\$0.86	\$0.88
Common Shares:		
Full Diluted	55,859	56,266
Year-end	54,376	55,738

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	2024
Cash & equivalents	165,192	
Current assets	3,162,958	
Net property & equip.	51,723	
Total assets	4,236,132	
Liabilities:		
Current liabilities	2,945,328	
Long-term debt	81,250	
Stockholders' equity	1,103,479	
Net current assets	217,630	

PAYONEER GLOBAL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	636,255,000	563,889,000
Operating income	95,743,000	119,847,000
Other income (expense), net	(7,613,000)	5,397,000

Gains or losses		(11,979,000)
Net before taxes	88,130,000	113,265,000
Income taxes	33,950,000	10,292,000
Net income	54,180,000	102,973,000
Earnings common share		
Primary	\$0.15	\$0.29
Fully Diluted	\$0.14	\$0.27
Common Shares:		
Full Diluted	388,619,245	379,125,363
Year-end	358,836,004	356,575,542

PDF SOLUTIONS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	156,621	129,380
Cost & expenses	151,717	128,243
Operating income	2,389	5,105
Net before taxes	562	5,105
Income taxes	1,154	1,587
Net income	(592)	3,518
Earnings common share		
Primary	\$(0.02)	\$0.09
Fully Diluted	\$(0.02)	\$0.09
Common Shares:		
Full Diluted	39,247	39,028
Year-end	39,507	38,763

PELTON INTERACTIVE INC**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	550,800,000	586,000,000
Cost & expenses	509,500,000	573,400,000
Operating income	41,300,000	12,500,000
Other income (expense), net	(300,000)	(100,000)
Net before taxes	14,600,000	
Income taxes	700,000	800,000
Net income	13,900,000	(800,000)
Earnings common share		
Primary	\$0.03	\$
Fully Diluted	\$0.03	\$
Common Shares:		
Full Diluted	430,004,926	378,776,423
Year-end	417,593,321	381,277,874

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025
Cash & equivalents	1,103,600,000
Inventories	237,700,000
Current assets	1,512,100,000
Net property & equip.	219,300,000
Total assets	2,170,200,000
Liabilities:	
Current liabilities	795,000,000
Long-term debt	1,290,000,000
Stockholders' equity	(347,000,000)
Net current assets	717,100,000

PENN ENTERTAINMENT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	5,154,800	4,909,100
Cost & expenses	5,478,200	4,462,000
Operating income	(656,100)	120,600
Interest expense		356,900
Other income (expense), net	239,900	24,600
Net before taxes	(712,500)	(192,500)
Income taxes	59,400	(13,000)
Net income	(771,900)	(179,500)
Earnings common share		
Primary	\$(5.20)	\$(1.17)
Fully Diluted	\$(5.20)	\$(1.17)
Common Shares:		
Full Diluted	148,200	152,100
Year-end	137,719	152,157

PENNANT GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	658,382	506,348
Cost & expenses	617,787	473,176
Operating income	34,416	28,880
Other income (expense), net	368	192
Net before taxes	31,359	22,766
Income taxes	7,970	4,957
Net income	23,389	17,809

Earnings common share		
Primary	\$0.61	\$0.56
Fully Diluted	\$0.59	\$0.54
Common Shares:		
Full Diluted	35,274	30,869
Year-end	34,570	30,308

PHIBRO ANIMAL HEALTH CORP.**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	363,893	
Cost & expenses	312,633	242,733
Operating income	51,260	17,699
Net before taxes	36,267	9,620
Income taxes	9,740	2,645
Net income	26,527	6,975
Earnings common share		
Primary	\$0.65	\$0.17
Fully Diluted	\$0.65	\$0.17
Common Shares:		
Full Diluted	40,877	40,582
Year-end	40,484	40,504

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	
Cash & equivalents	72,769	
Inventories	471,775	
Current assets	835,799	
Net property & equip.	354,780	
Total assets	1,385,524	
Liabilities:		
Current liabilities	270,139	
Long-term debt	724,518	
Stockholders' equity	311,681	
Net current assets	565,660	

PLAINS ALL AMERICAN PIPELINE LP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	33,698,000	36,854,000
Cost & expenses	31,922,000	35,296,000
Operating income	1,080,000	883,000
Other income (expense), net	328,000	312,000
Net before taxes	1,078,000	908,000
Income contin. oper.	1,061,000	837,000
Net income	1,342,000	993,000
Balance for common	880,000	540,000
Earnings common share		
Primary	\$1.25	\$0.77
Fully Diluted	\$1.25	\$0.77
Common Shares:		
Full Diluted	704,000	702,000
Year-end	705,498	703,669

PLAINS GP HOLDINGS LP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	33,698,000	36,854,000
Cost & expenses	31,926,000	35,301,000
Operating income	1,076,000	878,000
Other income (expense), net	297,000	312,000
Gains or losses	31,000	
Net before taxes	1,074,000	903,000
Income contin. oper.	998,000	797,000
Net income	1,279,000	953,000
Earnings common share		
Primary	\$1.00	\$0.58
Fully Diluted	\$0.99	\$0.58
Common Shares:		
Full Diluted	233,000	197,000
Year-end	197,888	197,466

PLAYSTUDIOS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	179,695,000	221,647,000
Cost & expenses	165,046,000	197,278,000
Operating income	(14,094,000)	(10,444,000)
Other income (expense), net	(2,807,000)	(626,000)
Gains or losses	37,000	929,000
Net before taxes	(14,095,000)	(6,220,000)
Income taxes	851,000	55,000
Net income	(14,946,000)	(6,275,000)
Earnings common share		
Primary	\$(0.12)	\$(0.05)

Fully Diluted	\$(0.12)	\$(0.05)
Common Shares:		
Full Diluted	125,467,000	130,997,000
Year-end	126,084,000	125,185,000

PLAYTIKA HOLDING CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,076,600	1,899,000
Cost & expenses	1,800,700	1,562,700
Operating income	275,900	336,300
Other income (expense), net	(300)	(500)
Net before taxes	144,300	258,900
Income taxes	41,400	80,000
Net income	102,900	178,900
Earnings common share		
Primary	\$0.28	\$0.48
Fully Diluted	\$0.28	\$0.48
Common Shares:		
Full Diluted	373,100	371,700
Year-end	376,500	372,600

PLIANT THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Cost & expenses	132,796	175,045
Operating income	(132,796)	(175,045)
Net income	(125,767)	(160,572)
Earnings common share		
Primary	\$(2.05)	\$(2.66)
Fully Diluted	\$(2.05)	\$(2.66)
Common Shares:		
Full Diluted	61,339	60,433
Year-end	61,449	60,850

POTLATCHDELTIC CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	857,424	803,929
Cost & expenses	781,010	784,071
Operating income	76,414	19,858
Other income (expense), net	704	1,950
Net before taxes	53,753	3,759
Income taxes	(5,299)	(12,923)
Net income	59,052	16,682
Earnings common share		
Primary	\$0.75	\$0.21
Fully Diluted	\$0.75	\$0.21
Common Shares:		
Full Diluted	78,477	79,563
Year-end	77,291	78,862

POWER INTEGRATIONS INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	340,300	313,723
Cost & expenses	338,880	299,713
Operating income	1,420	14,010
Other income (expense), net	8,412	9,441
Net before taxes	9,832	23,451
Income taxes	1,029	357
Net income	8,803	23,094
Earnings common share		
Primary	\$0.16	\$0.41
Fully Diluted	\$0.16	\$0.40
Common Shares:		
Full Diluted	56,586	57,106
Year-end	55,312	56,840

POWERFLEET INC**Earnings, 6 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	215,800,000	152,448,000
Cost & expenses	213,595,000	170,110,000
Operating income	2,205,000	(17,662,000)
Other income (expense), net	(1,789,000)	1,050,000
Net before taxes	(12,889,000)	(22,873,000)
Income taxes	1,633,000	1,309,000
Net income	(14,522,000)	(24,182,000)
Balance for common	(14,522,000)	(24,225,000)
Earnings common share		
Primary	\$(0.11)	\$(0.23)
Fully Diluted	\$(0.11)	\$(0.23)
Common Shares:		

Full Diluted	133,510,000	107,335,000
Year-end	133,806,000	107,821,000

PRAXIS PRECISION MEDICINES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues		1,090
Cost & expenses	229,154	137,299
Operating income	(229,154)	(136,209)
Net income	(214,357)	(124,140)
Earnings common share		
Primary	\$(9.97)	\$(7.21)
Fully Diluted	\$(9.97)	\$(7.21)
Common Shares:		
Full Diluted	21,506	17,211
Year-end	21,166	17,786

PRIME MEDICINE INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,794	800
Cost & expenses	163,536	159,045
Operating income	(159,742)	(158,245)
Other income (expense), net	99	(2)
Gains or losses	(107)	(544)
Invest. income	1,621	3,201
Net income	(155,063)	(153,606)
Earnings common share		
Primary	\$(1.11)	\$(1.34)
Fully Diluted	\$(1.11)	\$(1.34)
Common Shares:		
Full Diluted	139,245	114,492
Year-end	180,309	131,161

PRIVIA HEALTH GROUP INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,581,669	1,275,490
Cost & expenses	1,551,462	1,258,320
Operating income	22,957	11,734
Net before taxes	30,567	19,848
Income taxes	11,426	8,171
Net income	19,141	11,677
Earnings common share		
Primary	\$0.11	\$0.08
Fully Diluted	\$0.11	\$0.08
Common Shares:		
Full Diluted	128,392	125,458
Year-end	122,868	119,953

PROCEPT BIROBOTICS CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	231,671	156,262
Cost & expenses	304,489	233,166
Operating income	(72,818)	(76,904)
Net income	(65,727)	(72,557)
Earnings common share		
Primary	\$(1.19)	\$(1.41)
Fully Diluted	\$(1.19)	\$(1.41)
Common Shares:		
Full Diluted	55,366	51,550
Year-end	55,870	52,146

PROGYNY INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	970,258	868,790
Cost & expenses	900,203	817,122
Operating income	70,055	51,668
Net before taxes	77,578	65,544
Income taxes	31,543	21,740
Net income	46,035	43,804
Earnings common share		
Primary	\$0.54	\$0.48
Fully Diluted	\$0.51	\$0.46
Common Shares:		
Full Diluted	89,884	95,759
Year-end	86,147	88,343

PROTAGONIST THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024								
Total Revenues	38,579	263,795	Operating income (loss)	12,355,000	10,071,000	7,788,000	operations - basic	\$0.00	\$0.03	\$(0.10)
Cost & expenses	146,351	137,732	Interest expense	664,000	697,000	694,000	Net earnings (loss) per share - basic	\$5.05	\$9.09	\$6.47
Operating income	(107,772)	126,063	Interest & dividend income	...	675,000	313,000	Earnings (loss) per share - continuing operations - diluted	\$5.01	\$8.94	\$6.52
Other income (expense), net	151	219	Net gains (losses) on marketable securities	...	14,000	75,000	Earns per share-disp of discount opers - diluted	\$0.00	\$0.03	...
Net before taxes	(85,593)	145,744	Net gains (losses) on other investments	...	175,000	21,000	Earnings (loss) per share - discontinued operations - diluted	\$0.00	\$0.03	\$(0.10)
Income taxes	172	2,230	Net gains (losses) on deferred compensation plan assets	...	...	86,000	Net earnings (loss) per share - diluted	\$5.01	\$8.97	\$6.42
Net income	(85,765)	143,514	Impairment losses on other investments	...	79,000	132,000	Dividends per share announced	...	...	\$3.10
Earnings common share			Other investment & other income (expense), net	...	...	(14,000)	Full-Time Employees (Period End)	52,000	49,000	...
Primary	\$(1.35)	\$2.34	Investment & other income (expense), net	...	(21,000)	349,000	Total number of employees	52,000	49,000	50,000
Fully Diluted	\$(1.35)	\$2.22	Net gain on sale of investments	972,000	962,000	...	Number of common stockholders	5,564	5,848	6,124
Common Shares:			Income (loss) before income taxes - United States	...	...	6,400,000	Cost of revenues	19,738,000	17,060,000	...
Full Diluted	63,419	64,612	Income (loss) before income taxes - foreign	...	...	1,043,000	Inc from cont operations after income tax	5,541,000	10,110,000	...
Year-end	62,447	59,522	Income (loss) before income taxes	12,663,000	10,336,000	7,443,000	Common DPS - by Period End Date - Gross	\$3.48	\$3.30	...
PROTARA THERAPEUTICS INC			Income (loss) before income taxes	1,682,000	1,306,000	1,229,000	Sale of Discontinued Operations - Net - Gain/Loss	...	32,000	...
Earnings, 9 mos. to Sep 30(Consol. - \$000):			Current federal income tax provision (benefit)	7,000	3,000	10,000	Foreign currency translation adjustments	...	121,000	140,000
Cost & expenses	45,470	34,842	Current state income tax provision (benefit)	981,000	805,000	491,000	Net gains on deferred compensation plan assets	...	198,000	...
Operating income	(45,470)	(34,842)	Total current income tax provision (benefit)	2,670,000	2,114,000	...	Restructuring Charges & Provisions	39,000	...	...
Other income (expense), net	510	...	Deferred federal income tax provision (benefit)	4,373,000	(1,553,000)	(1,475,000)	Consolidated Balance Sheet, Years Ended (\$000):			
Net income	(40,132)	(31,827)	Deferred state income tax provision (benefit)	(5,000)	(4,000)	(8,000)	09/28/25	09/29/24		
Earnings common share			Deferred foreign income tax provision (benefit)	84,000	(331,000)	(143,000)	Cash and cash equivalents	5,520,000	7,849,000	
Primary	\$(0.96)	\$(1.74)	Total deferred income tax provision (benefit)	4,452,000	(1,888,000)	...	Marketable Securities	4,635,000	5,451,000	
Fully Diluted	\$(0.96)	\$(1.74)	Income tax expense (benefit)	7,122,000	226,000	104,000	Other accounts receivable	4,315,000	3,929,000	
Common Shares:			Income (loss) from continuing operations	5,541,000	10,110,000	7,339,000	Accounts receivable, net	2,855,000	2,347,000	
Full Diluted	41,756	18,343	Discontinued operations, net of income taxes	...	...	(107,000)	Raw materials	336,000	340,000	
Year-end	38,587	20,630	Net income (loss)	5,541,000	10,142,000	7,232,000	Work-in-process	3,985,000	3,497,000	
PUBMATIC INC			Weighted average shares outstanding - basic	1,096,000	1,116,000	1,117,000	Finished goods	2,205,000	2,586,000	
Earnings, 9 mos. to Sep 30(Consol. - \$000):			Weighted average shares outstanding - diluted	1,105,000	1,130,000	1,126,000	Inventories	6,526,000	6,423,000	
Cost & expenses	228,663	216,629	Year end shares outstanding	1,074,000	1,113,000	1,114,000	Other current assets	2,435,000	1,579,000	
Operating income	(25,783)	(10,875)	Earnings (loss) per share - continuing operations - basic	\$5.05	\$9.06	\$6.57	Unbilled	1,443,000	1,546,000	
Other income (expense), net	(3,939)	3,356	Earnings per share-disp of discontinued opers	\$0.00	\$0.03	...	Other	17,000	36,000	
Net before taxes	(25,552)	(646)	Earnings (loss) per share - discontinued				Restricted cash	2,323,000	...	
Income taxes	(4,406)	749					Total current assets	25,754,000	25,231,000	
Net income	(21,146)	(1,395)					Deferred tax assets	743,000	5,162,000	
Earnings common share							Land	168,000	169,000	
Primary	\$(0.45)	\$(0.03)					Buildings & improvements	1,915,000	1,888,000	
Fully Diluted	\$(0.45)	\$(0.03)					Computer equipment	2,165,000	2,022,000	
Common Shares:							Computer equipment & software	14,504,000	13,541,000	
Full Diluted	47,146	49,623					Machinery & equipment	9,360,000	8,647,000	
Year-end	46,168	48,293					Furniture & office equipment	148,000	139,000	
PUMA BIOTECHNOLOGY INC							Leasehold improvements	594,000	550,000	
Earnings, 9 mos. to Sep 30(Consol. - \$):							Construction in progress	154,000	126,000	
Total Revenues	152,918,000	171,391,000					accumulated depreciation and amortization	9,814,000	8,876,000	
Cost & expenses	132,725,000	153,790,000					Property, plant and equipment, net	4,690,000	4,665,000	
Operating income	20,193,000	17,601,000					Goodwill	11,358,000	10,799,000	
Other income (expense), net	884,000	594,000					Other intangible assets, net	1,148,000	1,244,000	
Net before taxes	18,675,000	11,862,000					Other assets	6,450,000	8,053,000	
Income taxes	1,002,000	889,000					Total assets	50,143,000	55,154,000	
Net income	17,673,000	10,973,000								
Earnings common share										
Primary	\$0.35	\$0.23								
Fully Diluted	\$0.35	\$0.22								
Common Shares:										
Full Diluted	50,334,553	49,025,103								
Year-end	50,384,274	49,067,348								
QUALCOMM INC										
Annual Report										
Consolidated Income Statement, Years Ended (\$000):										
09/28/25	09/29/24	09/24/23								
Communications systems	6,415,000	6,171,000	...							
Equipment & services revenues	37,869,000	32,791,000	30,028,000							
Licensing revenues	...	...	5,792,000							
Total revenues	44,284,000	38,962,000	35,820,000							
Cost of revenues	...	...	15,869,000							
Research & development expenses	9,042,000	8,893,000	8,818,000							
Selling, general & administrative expenses	3,110,000	2,759,000	2,483,000							
Other expenses	39,000	179,000	862,000							
Total costs & expenses	31,929,000	28,891,000	28,032,000							

Payroll and other benefits related liabilities	1,839,000	1,834,000
Unearned revenues	358,000	297,000
Short-term debt	...	1,364,000
Held for sale liabilities	1,201,000	865,000
Income taxes payable	1,007,000	1,080,000
Accounts payable & accrued liabilities	2,791,000	2,584,000
Customer incentives and other customer-related liabilities	1,948,000	2,480,000
Total current liabilities	9,144,000	10,504,000
Unearned revenues	71,000	88,000
Notes	14,811,000	13,270,000
Other liabilities	4,911,000	5,018,000
Total liabilities	28,937,000	28,880,000
Common stock	...	111
Retained earnings	20,646,000	25,687,000
Accumulated other comprehensive income	560,000	587,000
Balancing Item - Shareholders Equity	...	(111)
Total Qualcomm, Inc. stockholders' equity	21,206,000	26,274,000
Total stockholders' equity	21,206,000	26,274,000

Recent Dividends:**1. Qualcomm Inc common.**

ExDate	Amt	Declared	Record	Payable
03/02/2022	0.68	01/18/2022	03/03/2022	03/24/2022
06/01/2022	0.75	04/13/2022	06/02/2022	06/23/2022
08/31/2022	0.75	07/15/2022	09/01/2022	09/22/2022
11/30/2022	0.75	10/14/2022	12/01/2022	12/15/2022
03/01/2023	0.75	01/18/2023	03/02/2023	03/23/2023
05/31/2023	0.80	04/12/2023	06/01/2023	06/22/2023
08/30/2023	0.80	07/14/2023	08/31/2023	09/21/2023
11/29/2023	0.80	10/13/2023	11/30/2023	12/14/2023
02/28/2024	0.80	01/19/2024	02/29/2024	03/21/2024
05/30/2024	0.85	04/17/2024	05/30/2024	06/20/2024
09/05/2024	0.85	07/17/2024	09/05/2024	09/26/2024
12/05/2024	0.85	10/16/2024	12/05/2024	12/19/2024
03/06/2025	0.85	01/17/2025	03/06/2025	03/27/2025
06/05/2025	0.89	04/17/2025	06/05/2025	06/26/2025
09/04/2025	0.89	07/07/2025	09/04/2025	09/25/2025

Annual Dividends:**1. Qualcomm Inc common.**

2022	2.93	2023	3.15	2024	3.35
2025	2.63				

QUANTUM-SI INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2025	2024
Total Revenues	1,985,000	1,866,000
Cost & expenses	96,990,000	79,765,000
Operating income	(95,005,000)	(77,899,000)
Other income (expense), net	7,404,000	9,139,000
Gains or losses	3,923,000	917,000
Net before taxes	(83,678,000)	(67,843,000)
Income taxes	50,000	43,000
Net income	(83,728,000)	(67,886,000)
Earnings common share		
Primary	\$(0.44)	\$(0.48)
Fully Diluted	\$(0.44)	\$(0.48)
Common Shares:		
Full Diluted	191,754,000	142,039,000
Year-end	215,458,247	142,712,852

QUIDELORTHO CORP**Earnings, 9 mos. to (Consol. - \$000):**

	09/28/25	09/29/24
Total Revenues	2,006,600	2,075,100
Cost & expenses	2,715,900	3,780,100
Operating income	(852,900)	(1,860,500)
Other income (expense), net	(15,800)	(7,200)
Gains or losses	7,500	21,300
Net before taxes	(995,300)	(1,990,600)
Income taxes	5,800	(117,000)
Net income	(1,001,100)	(1,873,600)
Earnings common share		

Primary	\$(14.79)	\$(27.92)
Fully Diluted	\$(14.79)	\$(27.92)
Common Shares:		
Full Diluted	67,700	67,100
Year-end	67,900	67,200

QUINSTREET, INC.**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Total Revenues	285,853	279,219
Cost & expenses	281,064	280,426
Operating income	4,789	(1,207)
Other income (expense), net	(5)	(98)
Net before taxes	4,719	(1,415)
Income taxes	184	(49)
Net income	4,535	(1,366)
Earnings common share		
Primary	\$0.08	\$(0.02)
Fully Diluted	\$0.08	\$(0.02)
Common Shares:		
Full Diluted	58,769	55,823
Year-end	57,368	56,128

Consolidated Balance Sheet Items, as of (\$000):

	2025	2024
Assets:		
Cash & equivalents	101,298	
Current assets	259,647	
Net property & equip.	16,968	
Total assets	442,644	
Liabilities:		
Current liabilities	172,165	
Stockholders' equity	246,699	
Net current assets	87,482	

RACKSPACE TECHNOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Total Revenues	2,002,900	2,051,500
Cost & expenses	2,100,300	2,931,800
Operating income	(97,400)	(880,300)
Other income (expense), net	(13,200)	135,400
Invest. income	300	200
Net before taxes	(172,200)	(824,800)
Income taxes	20,900	(22,600)
Net income	(193,100)	(802,200)
Earnings common share		
Primary	\$(0.82)	\$(3.59)
Fully Diluted	\$(0.82)	\$(3.59)
Common Shares:		
Full Diluted	236,800	223,600
Year-end	243,600	227,600

RADNET INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2025	2024
Total Revenues	1,492,498,000	1,352,563,000
Cost & expenses	1,347,056,000	1,170,645,000
Operating income	34,167,000	80,096,000
Other income (expense), net	35,042,000	18,647,000
Gains or losses	(6,433,000)	(7,429,000)
Net before taxes	10,993,000	29,538,000
Income taxes	3,807,000	4,927,000
Net income	7,186,000	24,611,000
Earnings common share		
Primary	\$(0.24)	\$(0.04)
Fully Diluted	\$(0.24)	\$(0.04)
Common Shares:		
Full Diluted	74,703,658	72,587,321
Year-end	77,032,154	73,976,284

RALLYBIO CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Total Revenues	636	598
Cost & expenses	27,288	49,486
Operating income	(26,652)	(48,888)
Other income (expense), net	22,771	561
Gains or losses	(874)	(1,809)
Net income	(3,126)	(46,731)
Earnings common share		
Primary	\$(0.07)	\$(1.08)
Fully Diluted	\$(0.07)	\$(1.08)
Common Shares:		
Full Diluted	44,892	43,170
Year-end	41,936	41,488

RANI THERAPEUTICS HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Total Revenues	172	
Cost & expenses	29,947	38,356
Operating income	(29,775)	(38,356)
Net income	(31,876)	(40,862)
Earnings common share		
Primary	\$(0.50)	\$(0.78)
Fully Diluted	\$(0.50)	\$(0.78)
Common Shares:		
Full Diluted	38,856	27,071
Year-end	47,941	29,807

RAPID7 INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Total Revenues	642,406	627,746
Cost & expenses	633,110	599,990
Operating income	9,296	27,756
Net before taxes	24,455	35,769
Income taxes	4,203	12,415
Net income	20,252	23,354
Earnings common share		
Primary	\$0.31	\$0.37
Fully Diluted	\$0.31	\$0.31
Common Shares:		
Full Diluted	64,691	74,225
Year-end	65,338	63,178

RAPPORT THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Cost & expenses	86,590	59,534
Operating income	(86,590)	(59,534)
Gains or losses		(7,390)
Net income	(77,720)	(58,327)
Earnings common share		
Primary	\$(2.15)	\$(3.66)
Fully Diluted	\$(2.15)	\$(3.66)
Common Shares:		
Full Diluted	36,224	15,926
Year-end	47,650	36,576

RAPT THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2025	2024
Cost & expenses	58,171	81,636
Operating income	(58,171)	(81,636)
Other income (expense), net	5,783	5,020
Net income	(52,388)	(76,616)
Earnings common share		
Primary	\$(1.94)	\$(15.76)
Fully Diluted	\$(1.94)	\$(15.76)
Common Shares:		
Full Diluted	26,946	4,850
Year-end	16,855	4,363

RECURSION PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2025	2024
Total Revenues	39,143,000	54,293,000
Cost & expenses	578,941,000	349,529,000
Operating income	(539,798,000)	295,236,000
Other income (expense), net	3,005,000	9,347,000
Net before taxes	(536,793,000)	285,889,000
Income taxes	(156,000)	(1,134,000)
Net income	(536,637,000)	284,755,000
Earnings common share		
Primary	\$(1.27)	\$(1.12)
Fully Diluted	\$(1.27)	\$(1.12)
Common Shares:		
Full Diluted	422,642,653	253,447,099
Year-end	491,180,881	285,926,876

RED ROBIN GOURMET BURGERS INC**Earnings, 9 mos. to (Consol. - \$):**

	10/05/25	10/06/24
Total Revenues	941,182,000	963,333,000
Cost & expenses	895,386,000	937,998,000
Operating income	6,765,000	(19,551,000)
Net before taxes	(13,003,000)	(37,782,000)
Income taxes	174,000	43,000
Net income	(13,177,000)	(37,825,000)

Earnings common share		
Primary	\$(0.74)	\$(2.42)
Fully Diluted	\$(0.74)	\$(2.42)
Common Shares:		
Full Diluted	17,732,000	15,652,000
Year-end	17,966,000	15,779,000

RED ROCK RESORTS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,499,706	1,443,316
Cost & expenses	900,546	877,967
Operating income	453,865	426,401
Other income (expense), net	10,453	(12,409)
Gains or losses	(5,653)	(11,671)
Net before taxes	306,437	229,688
Income taxes	35,354	26,118
Net income	271,083	203,570
Earnings common share		
Primary	\$2.43	\$1.82
Fully Diluted	\$2.37	\$1.77
Common Shares:		
Full Diluted	102,925	103,709
Year-end	59,970	59,633

REGENXBIO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	140,104	62,114
Cost & expenses	243,666	244,092
Operating income	(103,562)	(181,978)
Other income (expense), net	9,500	9,213
Net income	(126,729)	(175,916)
Earnings common share		
Primary	\$(2.46)	\$(3.59)
Fully Diluted	\$(2.46)	\$(3.59)
Common Shares:		
Full Diluted	51,513	49,051
Year-end	50,619	49,534

RELAY THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	8,355	10,007
Cost & expenses	250,463	297,496
Operating income	(242,108)	(287,489)
Other income (expense), net	(806)	13
Net income	(221,589)	(261,704)
Earnings common share		
Primary	\$(1.30)	\$(1.94)
Fully Diluted	\$(1.30)	\$(1.94)
Common Shares:		
Full Diluted	170,974	134,652
Year-end	172,631	166,887

REMITLY GLOBAL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,192,970	912,068
Cost & expenses	1,136,161	935,175
Operating income	38,653	(35,347)
Other income (expense), net	(4,023)	6,272
Net before taxes	35,479	(25,116)
Income taxes	8,762	6,138
Net income	26,717	(31,254)
Earnings common share		
Primary	\$0.13	\$(0.16)
Fully Diluted	\$0.12	\$(0.16)
Common Shares:		
Full Diluted	218,228	193,168
Year-end	209,331	198,034

REPLIMUNE GROUP INC**Earnings, 6 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	174,715	116,283
Operating income	(174,715)	(116,283)
Other income (expense), net	8,924	13,385
Net income	(169,793)	(106,827)
Earnings common share		
Primary	\$(1.85)	\$(1.45)
Fully Diluted	\$(1.85)	\$(1.45)
Common Shares:		
Full Diluted	91,717	73,904
Year-end	78,403	68,395

RESERVOIR MEDIA INC**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	82,599,344	74,984,236
Cost & expenses	51,595,509	47,085,901
Operating income	16,133,235	15,083,559
Other income (expense), net	(254,483)	(98,489)
Gains or losses	(1,313,163)	(5,617,202)
Net before taxes	2,236,378	(747,749)
Income taxes	676,247	(446,561)
Net income	1,560,131	(301,188)
Earnings common share		
Primary	\$0.03	\$(0.00)
Fully Diluted	\$0.03	\$(0.00)
Common Shares:		
Full Diluted	66,166,846	65,079,114
Year-end	65,588,223	65,222,555

REVOLUTION MEDICINES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	820,743	473,214
Operating income	(820,743)	(473,214)
Other income (expense), net	(42)	(2,511)
Gains or losses	(2,731)	4,543
Net income	(766,409)	(405,524)
Earnings common share		
Primary	\$(4.06)	\$(2.45)
Fully Diluted	\$(4.06)	\$(2.45)
Common Shares:		
Full Diluted	188,658	165,576
Year-end	189,711	167,748

ROBINHOOD MARKETS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,190,000	1,937,000
Cost & expenses	1,746,000	1,439,000
Operating income	1,447,000	506,000
Other income (expense), net	3,000	8,000
Net before taxes	1,447,000	506,000
Income taxes	169,000	11,000
Net income	1,278,000	495,000
Earnings common share		
Primary	\$1.44	\$0.56
Fully Diluted	\$1.39	\$0.55
Common Shares:		
Full Diluted	918,606	903,556
Year-end	898,668	883,609

ROCKET PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	187,784	210,511
Operating income	(187,784)	(210,511)
Other income (expense), net	6,089	6,855
Net income	(180,585)	(198,419)
Earnings common share		
Primary	\$(1.63)	\$(2.11)
Fully Diluted	\$(1.63)	\$(2.11)
Common Shares:		
Full Diluted	110,900	93,894
Year-end	108,209	91,117

ROCKY BRANDS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	342,260,000	325,718,000
Cost & expenses	309,758,000	303,157,000
Operating income	27,597,000	22,561,000
Other income (expense), net	92,000	
Net before taxes	20,230,000	8,597,000
Income taxes	4,468,000	2,011,000
Net income	15,762,000	6,586,000
Earnings common share		
Primary	\$2.11	\$0.89
Fully Diluted	\$2.10	\$0.88
Common Shares:		
Full Diluted	7,511,000	7,479,000
Year-end	7,488,341	7,449,020

ROOT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	1,068,800	806,200
Operating income	51,300	43,600
Net before taxes	35,400	
Income taxes	400	
Net income	35,000	8,800
Balance for common		
	33,200	
Earnings common share		
Primary	\$2.17	\$0.56
Fully Diluted	\$2.05	\$0.52
Common Shares:		
Full Diluted	17,100	16,800
Year-end	15,500	15,000

ROYAL GOLD INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	655,148,000	516,835,000
Cost & expenses	130,801,000	109,691,000
Operating income	427,296,000	296,455,000
Gains or losses	(35,000)	(42,000)
Net before taxes	427,488,000	292,493,000
Income taxes	49,631,000	67,535,000
Net income	377,857,000	224,958,000
Earnings common share		
Primary	\$5.66	\$3.41
Fully Diluted	\$5.65	\$3.41
Common Shares:		
Full Diluted	65,814,682	65,767,668
Year-end	65,763,800	65,689,357

RUMBLE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	73,553,866	65,259,903
Cost & expenses	153,943,100	162,776,877
Operating income	(91,164,595)	(106,635,577)
Other income (expense), net	(476)	(73,881)
Gains or losses	34,079,616	(1,480,395)
Net before taxes	(49,105,575)	(101,543,838)
Income taxes	31,310	66,315
Net income	(49,136,885)	(101,610,153)
Earnings common share		
Primary	\$(0.19)	\$(0.50)
Fully Diluted	\$(0.19)	\$(0.50)
Common Shares:		
Full Diluted	252,722,453	203,660,885
Year-end	339,071,363	283,656,336

RUSH ENTERPRISES INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	5,662,302	5,795,160
Cost & expenses	5,307,175	5,387,939
Operating income	302,105	355,845
Other income (expense), net	(1,250)	370
Net before taxes	263,548	301,114
Income taxes	62,204	71,422
Net income	201,344	229,692
Earnings common share		
Primary	\$2.53	\$2.91
Fully Diluted	\$2.46	\$2.81
Common Shares:		
Full Diluted	81,167	81,607
Year-end	77,840	79,003

RXSIGHT INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	101,871	99,713
Cost & expenses	138,725	127,943
Operating income	(36,854)	(28,230)
Net before taxes	(29,731)	(21,479)
Income taxes	61	38
Net income	(29,792)	(21,517)
Earnings common share		
Primary	\$(0.73)	\$(0.56)
Fully Diluted	\$(0.73)	\$(0.56)
Common Shares:		
Full Diluted	40,741	38,368
Year-end	41,082	40,254

SABRE CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,104,458	2,099,983
Cost & expenses	1,830,304	1,904,225
Operating income	274,154	195,758
Other income (expense), net	(76,970)	(36,998)
Net before taxes	(135,162)	(182,675)
Income taxes	21,068	16,564
Income contin. oper.	(156,230)	(199,239)
Net income	627,495	(203,723)
Earnings common share		
Primary	\$1.61	\$(0.53)
Fully Diluted	\$1.61	\$(0.53)
Common Shares:		
Full Diluted	390,616	383,013
Year-end	394,879	385,831

SAFETY INSURANCE GROUP, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	841,926	753,503
Operating income	101,267	79,747
Net before taxes	101,267	79,747
Income taxes	22,124	17,144
Net income	79,143	62,603
Balance for common	78,779	62,328
Earnings common share		
Primary	\$5.35	\$4.24
Fully Diluted	\$5.33	\$4.24
Common Shares:		
Full Diluted	14,769	14,715
Year-end	14,894	14,838

SANA BIOTECHNOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	189,120	221,857
Operating income	(189,120)	(221,857)
Other income (expense), net	1,207	(4,648)
Net income	(185,341)	(217,690)
Earnings common share		
Primary	\$(0.75)	\$(0.95)
Fully Diluted	\$(0.75)	\$(0.95)
Common Shares:		
Full Diluted	245,580	229,076
Year-end	262,264	223,108

SANGAMO THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	25,324,000	50,249,000
Cost & expenses	108,360,000	128,228,000
Operating income	(83,036,000)	(77,979,000)
Other income (expense), net	(3,542,000)	
Net before taxes	(85,528,000)	(74,285,000)
Income taxes	(15,000)	260,000
Net income	(85,513,000)	(74,545,000)
Balance for common	(85,513,000)	(74,545,000)
Earnings common share		
Primary	\$(0.33)	\$(0.37)
Fully Diluted	\$(0.33)	\$(0.37)
Common Shares:		
Full Diluted	260,803,000	198,849,000
Year-end	322,009,039	208,619,712

SAREPTA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	1,755,303,000	1,243,567,000
Cost & expenses	2,041,556,000	1,185,363,000
Operating income	(288,198,000)	56,400,000
Other income (expense), net	(134,960,000)	32,359,000
Gains or losses	11,100,000	(8,565,000)
Invest. income	(17,268,000)	
Net before taxes	(423,929,000)	89,031,000
Income taxes	6,634,000	12,841,000
Net income	(430,563,000)	76,190,000
Earnings common share		
Primary	\$(4.37)	\$0.80
Fully Diluted	\$(4.37)	\$0.78
Common Shares:		
Full Diluted	98,545,000	99,572,000
Year-end	104,768,111	95,493,005

SCANSOURCE, INC.**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	739,650,000	775,580,000
Cost & expenses	707,766,000	750,735,000
Operating income	25,903,000	17,630,000
Other income (expense), net	(173,000)	4,782,000
Net before taxes	26,996,000	22,962,000
Income taxes	7,118,000	5,988,000
Net income	19,878,000	16,974,000
Earnings common share		
Primary	\$0.90	\$0.70
Fully Diluted	\$0.89	\$0.69
Common Shares:		
Full Diluted	22,405,000	24,646,000
Year-end	22,067,128	24,005,107

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025	
Cash & equivalents	124,924,000	
Inventories	505,339,000	
Current assets	1,307,335,000	
Net property & equip.	32,221,000	
Total assets	1,716,976,000	
Liabilities:		
Current liabilities	606,158,000	
Long-term debt	126,047,000	
Stockholders' equity	914,032,000	
Net current assets	701,177,000	

SCHRODINGER INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	168,634	119,222
Cost & expenses	318,373	307,806
Operating income	(149,739)	(188,584)
Gains or losses	1,175	27,763
Net before taxes	(135,299)	(146,458)
Income taxes	477	449
Net income	(135,776)	(146,907)
Earnings common share		
Primary	\$(1.85)	\$(2.02)
Fully Diluted	\$(1.85)	\$(2.02)
Common Shares:		
Full Diluted	73,368	72,606
Year-end	73,634	72,846

SCRIPPS (EW) COMPANY (THE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,590,327	1,781,393
Cost & expenses	1,335,759	1,444,502
Operating income	141,702	220,874
Other income (expense), net	(58,836)	17,355
Net before taxes	(78,756)	76,747
Income taxes	(6,380)	25,916
Net income	(72,376)	50,831
Balance for common	(119,548)	7,279
Earnings common share		
Primary	\$(1.36)	\$0.08
Fully Diluted	\$(1.36)	\$0.08
Common Shares:		
Full Diluted	87,773	85,546
Year-end	88,802	86,363

SCYNEXIS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,955	2,769
Cost & expenses	28,550	31,833
Operating income	(26,595)	(29,064)
Gains or losses	4,454	10,794
Net before taxes	(16,727)	
Income taxes	128	
Net income	(20,867)	(16,855)
Earnings common share		
Primary	\$(0.42)	\$(0.35)
Fully Diluted	\$(0.42)	\$(0.35)
Common Shares:		
Full Diluted	49,697	48,460
Year-end	41,957	37,943

SENECA FOODS CORP.**Earnings, 6 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	757,480	730,192
Cost & expenses	692,793	680,070

Operating income	64,687	50,122
Other income (expense), net	3,812	2,805
Net before taxes	58,405	33,569
Income taxes	13,781	7,605
Net income	44,624	25,964
Balance for common	44,565	25,921
Earnings common share		
Primary	\$6.49	\$3.74
Fully Diluted	\$6.43	\$3.70
Common Shares:		
Full Diluted	6,937	7,005
Year-end	6,855	6,890

SERES THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	351	
Cost & expenses	74,945	92,480
Operating income	(74,594)	(92,480)
Other income (expense), net	14,255	(21,184)
Gains or losses	79,588	
Income contin. oper.		(110,134)
Net income	21,031	15,773
Earnings common share		
Primary	\$2.41	\$2.20
Fully Diluted	\$2.40	\$2.20
Common Shares:		
Full Diluted	8,745	7,505
Year-end	8,765	8,510

SERVICE PROPERTIES TRUST**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	1,096,172	1,059,029
Operating income	(197,113)	(192,589)
Other income (expense), net	25,317	(15,071)
Equity earnings	2,873	5,091
Net before taxes	(197,113)	(192,589)
Income taxes		1,454
Net income	(201,539)	(199,134)
Earnings common share		
Primary	\$(1.22)	\$(1.21)
Fully Diluted	\$(1.22)	\$(1.21)
Common Shares:		
Full Diluted	165,816	165,252
Year-end	168,090	166,648

SHATTUCK LABS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,000	5,721
Cost & expenses	39,137	66,647
Operating income	(38,137)	(60,926)
Other income (expense), net	1,921	4,195
Net income	(36,216)	(56,731)
Earnings common share		
Primary	\$(0.62)	\$(1.12)
Fully Diluted	\$(0.62)	\$(1.12)
Common Shares:		
Full Diluted	58,103	50,731
Year-end	63,152	47,740

SIGA TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	90,780,818	57,250,527
Cost & expenses	57,578,927	44,353,199
Operating income	33,201,891	12,897,328
Other income (expense), net	5,143,981	4,590,935
Net before taxes	38,345,872	17,488,263
Income taxes	9,636,811	4,034,362
Net income	28,709,061	13,453,901
Earnings common share		
Primary	\$0.40	\$0.19
Fully Diluted	\$0.40	\$0.19
Common Shares:		
Full Diluted	71,801,188	71,853,341
Year-end	71,611,302	71,369,274

SIGHT SCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024	Income (loss)				Total property, plant, & equipment, gross				4,306,600	4,210,100	
Total Revenues	56,978	60,792	before income taxes				Accumulated depreciation				3,112,000	2,929,800	
Cost & expenses	90,408	99,395	- foreign										
Operating income	(33,430)	(38,603)	Income (loss)				Property, plant and equipment, net				1,194,600	1,280,300	
Other income (expense), net	(118)	(1,987)	before income taxes				526,700	636,400	1,078,800				
Invest. income	3,139	4,628	Current tax expense				Operating lease, right-of-use assets				192,400	191,600	
Net before taxes	(34,262)	(39,463)	(benefit) - federal				45,300	79,000	164,400				
Income taxes	2	198	Current tax expense (benefit) - state				100	200	100				
Net income	(34,264)	(39,661)	Current tax expense (benefit) - foreign				59,500	60,800	74,400				
Earnings common share			Total current tax expense (benefit)				104,900	140,000	238,900				
Primary	\$(0.66)	\$(0.79)	Deferred tax expense (benefit) - federal				(80,800)	(120,500)	(102,400)				
Fully Diluted	\$(0.66)	\$(0.79)	Deferred tax expense (benefit) - state				...	(500)	(100)				
Common Shares:			Deferred tax expense (benefit) - foreign				25,500	21,400	(40,400)				
Full Diluted	51,834	49,912	Total deferred tax expense (benefit)				(55,300)	(99,600)	(142,900)				
Year-end	52,474	50,398	Net Income After Taxes				477,100	596,000	...				
SILGAN HOLDINGS INC			Taxes				477,100	596,000	...				
Earnings, 9 mos. to Sep 30 (Consol. – \$000):			Provision (benefit) for income taxes				49,600	40,400	96,000				
	2025	2024	Net income (loss)				477,100	596,000	982,800				
Total Revenues	5,014,561	4,443,527	Weighted average shares outstanding				154,400	160,100	159,400				
Cost & expenses	4,517,828	4,022,668	- basic				154,400	160,100	159,400				
Operating income	496,733	420,859	Weighted average shares outstanding				155,100	161,500	160,300				
Equity earnings	(2,492)		Year end shares outstanding				148,700	159,900	159,500				
Net before taxes	355,117	298,998	Earnings (loss) per share - cont opers				...	...	...				
Income taxes	87,410	67,684	- basic				\$3.09	\$3.72	\$6.17				
Net income	270,199	231,314	Net earnings (loss) per share - basic				\$3.09	\$3.72	\$6.17				
Earnings common share			Earnings (loss) per share - cont opers				...	...	...				
Primary	\$2.53	\$2.17	- diluted				\$3.08	\$3.69	\$6.13				
Fully Diluted	\$2.52	\$2.16	Net earnings (loss) per share - diluted				\$3.08	\$3.69	\$6.13				
Common Shares:			Common DPS - by Period End Date - Gross				\$2.81	\$2.74	...				
Full Diluted	107,129	107,068	Cash dividends declared & paid per share				...	...	\$2.54				
Year-end	105,668	106,795	Number of full time employees				10,000	10,100	9,750				
SITIME CORP			Total number of employees				10,000	10,100	9,750				
Earnings, 9 mos. to Sep 30 (Consol. – \$000):			Number of common stockholders				7,211	7,658	8,175				
	2025	2024	Cost of goods sold				2,404,800	2,457,200	...				
Total Revenues	213,375	134,586	Consolidated Balance Sheet, Years Ended (\$000):										
Cost & expenses	282,117	226,807	Cash and cash equivalents				1,161,300	1,368,600	...				
Operating income	(68,742)	(92,221)	Short-term investments				212,900	194,100	...				
Other income (expense), net	53	(248)	Receivables, gross				599,000	509,700	...				
Net before taxes	(51,857)	(74,674)	Allowance for doubtful accounts				900	900	...				
Income taxes	213	114	Accounts receivable, net				598,100	508,800	...				
Net income	(52,070)	(74,788)	Raw materials				44,800	30,300	...				
Earnings common share			Work-in-process				540,600	520,500	...				
Primary	\$(2.12)	\$(3.25)	Finished goods				169,300	234,000	...				
Fully Diluted	\$(2.12)	\$(3.25)	Inventory				754,700	784,800	...				
Common Shares:			Other current assets				350,000	484,700	...				
Full Diluted	24,551	23,001	Prepayments & other current assets				149,000	249,900	...				
Year-end	26,101	23,362	Prepaid Expenses				201,000	234,800	...				
SKYWORKS SOLUTIONS INC			Total current assets				3,077,000	3,341,000	...				
Annual Report			Land & improvements				11,900	11,900	...				
Consolidated Income Statement, Years Ended (\$000):			Buildings & improvements				649,000	610,200	...				
	10/03/25	09/27/24	09/29/23	Furniture & fixtures				95,600	81,300	...			
Net revenue	4,086,900	4,178,000	4,772,400	Machinery & equipment				3,463,400	3,418,000	...			
Net revenue	4,086,900	4,178,000	4,772,400	Construction in progress				86,700	88,700	...			
Cost of goods sold	2,404,800	2,457,200	...	Cash dividends declared & paid per share				...	...	...			
Cost of goods sold	...	...	2,665,100	Number of full time employees				10,000	10,100	9,750			
Gross profit	1,682,100	1,720,800	2,107,300	Total number of employees				10,000	10,100	9,750			
Research & development				Number of common stockholders				7,211	7,658	8,175			
expenses	785,500	631,700	606,800	Cost of goods sold				2,404,800	2,457,200	...			
Selling, general, & administrative				Consolidated Balance Sheet, Years Ended (\$000):									
expenses	371,500	300,800	314,000	Cash and cash equivalents				1,161,300	1,368,600	...			
Amortization of intangibles	900	900	33,200	Short-term investments				212,900	194,100	...			
Restructuring Costs and Asset				Receivables, gross				599,000	509,700	...			
Impairment Charges	24,200	150,000	...	Allowance for doubtful accounts				900	900	...			
Repositioning expense	...	...	28,300	Accounts receivable, net				598,100	508,800	...			
Total operating expenses	1,182,100	1,083,400	982,300	Raw materials				44,800	30,300	...			
Operating income (loss)	500,000	637,400	1,125,000	Work-in-process				540,600	520,500	...			
Interest expense	27,100	30,700	...	Finished goods				169,300	234,000	...			
Interest expense	...	...	64,400	Inventory				754,700	784,800	...			
Other income (expense), net	53,800	29,700	18,200	Other current assets				350,000	484,700	...			
Income (loss) before income taxes				Prepayments & other current assets				149,000	249,900	...			
- United States	...	...	484,900	Prepaid Expenses				201,000	234,800	...			
				Total current assets				3,077,000	3,341,000	...			
				Land & improvements				11,900	11,900	...			
				Buildings & improvements				649,000	610,200	...			
				Furniture & fixtures				95,600	81,300	...			
				Machinery & equipment				3,463,400	3,418,000	...			
				Construction in progress				86,700	88,700	...			
				Cash dividends declared & paid per share				...	...	...			
				Number of full time employees				10,000	10,100	9,750			
				Total number of employees				10,000	10,100	9,750			
				Number of common stockholders				7,211	7,658	8,175			
				Cost of goods sold				2,404,800	2,457,200	...			
				Consolidated Balance Sheet, Years Ended (\$000):									
				Cash and cash equivalents				1,161,300	1,368,600	...			
				Short-term investments				212,900	194,100	...			
				Receivables, gross				599,000	509,700	...			
				Allowance for doubtful accounts				900	900	...			
				Accounts receivable, net				598,100	508,800	...			
				Raw materials				44,800	30,300	...			
				Work-in-process				540,600	520,500	...			
				Finished goods				169,300	234,000	...			
				Inventory				754,700	784,800	...			
				Other current assets				350,000	484,700	...			
				Prepayments & other current assets				149,000	249,900	...			
				Prepaid Expenses				201,000	234,800	...			
				Total current assets				3,077,000	3,341,000	...			
				Land & improvements				11,900	11,900	...			
				Buildings & improvements				649,000	610,200	...			
				Furniture & fixtures				95,600	81,300	...			
				Machinery & equipment				3,463,400	3,418,000	...			
				Construction in progress				86,700	88,700	...			
				Cash dividends declared & paid per share				...	...	...			
				Number of full time employees				10,000	10,100	9,750			
				Total number of employees				10,000	10,100	9,750			
				Number of common stockholders				7,211	7,658	8,175			
				Cost of goods sold				2,404,800	2,457,200	...			
				Consolidated Balance Sheet, Years Ended (\$000):									
				Cash and cash equivalents				1,161,300	1,368,600	...			
				Short-term investments				212,900	194,100	...			
				Receivables, gross				599,000	509,700	...			
				Allowance for doubtful accounts				900	900	...			
				Accounts receivable, net				598,100	508,800	...			
				Raw materials				44,800	30,300	...			
				Work-in-process				540,600	520,500	...			
				Finished goods				169,300	234,000	...			
				Inventory				754,700	784,800	...			
				Other current assets				350,000	484,700	...			
				Prepayments & other current assets				149,000	249,900	...			
				Prepaid Expenses				201,000	234,800	...			
				Total current assets				3,077,000	3,341,000	...			
				Land & improvements				11,900	11,900	...			
				Buildings & improvements				649,000	610,200	...			
				Furniture & fixtures				95,600	81,300	...			
				Machinery & equipment				3,463,400	3,418,000	...			
				Construction in progress				86,700	88,700	...			
				Cash dividends declared & paid per share				...	...	...			
				Number of full time employees				10,000	10,100	9,750			
				Total number of employees				10,000	10,100	9,750			
				Number of common stockholders				7,211	7,658	8,175			
				Cost of goods sold				2,404,800	2,457,200	...			
				Consolidated Balance Sheet, Years Ended (\$000):									
				Cash and cash equivalents				1,161,300	1,368,600	...			
				Short-term investments				212,900	194,100	...			
				Receivables, gross				599,000	509,700	...			
				Allowance for doubtful accounts				900	900	...			
				Accounts receivable, net				598,100	508,800	...			
				Raw materials				44,800	30,300	...			
				Work-in-process				540,600	520,500	...			
				Finished goods				169,300	234,000	...			
				Inventory				754,700	784,800	...			
				Other current assets				350,000	484,700	...			
				Prepayments & other current assets				149,000	249,900	...			
				Prepaid Expenses				201,000	234,800	...			
				Total current assets				3,077,000	3,341,000	...			
				Land & improvements				11,900	11,900	...			
				Buildings & improvements				649,000	610,200	...			
				Furniture & fixtures				95,600	81,300	...			
				Machinery & equipment				3,463,400	3,418,000	...			
				Construction in progress				86,700	88,700	...			
				Cash dividends declared & paid per share				...	...	...			
				Number of full time employees				10,000	10,100	9,750			
				Total number of employees				10,000	10,100	9,750			
				Number of common stockholders				7,211	7,658	8,175			
				Cost of goods sold				2,404,800	2,457,200	...			
				Consolidated Balance Sheet, Years Ended (\$000):									
				Cash and cash equivalents				1,161,300	1,368,600	...			
				Short-term investments				212,900	194,100	...			
				Receivables, gross				599,000	509,700	...			
				Allowance for doubtful accounts				900	900	...			
				Accounts receivable, net				598,100	508,800	...			
				Raw materials				44,800	30,300	...			
				Work-in-process				540,600	520,500	...			
				Finished goods				169,300	234,000	...			
				Inventory				754,700	784,800	...			
				Other current assets				350,000	484,700	...			
				Prepayments & other current assets				149,000	249,900	...			
				Prepaid Expenses				201,000	234,800	...			
				Total current assets				3,077,000	3,341,000	...			

SOLAREEDGE TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	849,086	705,239
Cost & expenses	1,102,455	2,149,860
Operating income	(253,369)	(1,444,621)
Other income (expense), net	(10,846)	14,623
Equity earnings	951	1,440
Net before taxes	(258,430)	(1,432,369)
Income taxes	13,946	85,109
Net income	(273,327)	(1,518,918)
Earnings common share		
Primary	\$(4.66)	\$(26.67)
Fully Diluted	\$(4.66)	\$(26.67)
Common Shares:		
Full Diluted	58,660	56,953
Year-end	59,560	57,182

SOLID POWER INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	18,116,000	15,679,000
Cost & expenses	92,437,000	95,988,000
Operating income	(74,321,000)	(80,309,000)
Other income (expense), net	(732,000)	(167,000)
Gains or losses	(802,000)	1,793,000
Equity earnings	1,000	
Net before taxes	(65,989,000)	(65,013,000)
Income taxes	365,000	887,000
Net income	(66,355,000)	(65,900,000)
Earnings common share		
Primary	\$(0.37)	\$(0.37)
Fully Diluted	\$(0.37)	\$(0.37)
Common Shares:		
Full Diluted	181,369,650	179,177,452
Year-end	190,209,602	179,633,575

SOTERA HEALTH CO**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	860,176	810,238
Cost & expenses	575,810	553,101
Operating income	77,009	68,910
Other income (expense), net	(59,580)	(20,076)
Net before taxes	77,009	68,910
Income taxes	33,907	36,835
Net income	43,102	32,075
Balance for common	43,099	32,022
Earnings common share		
Primary	\$0.15	\$0.11
Fully Diluted	\$0.15	\$0.11
Common Shares:		
Full Diluted	286,019	284,660
Year-end	284,090	283,239

SOUNDHOUND AI INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	113,861,000	50,150,000
Cost & expenses	168,781,000	130,828,000
Operating income	(65,845,000)	(84,281,000)
Other income (expense), net	14,871,000	(6,500,000)
Net before taxes	(51,531,000)	(101,640,000)
Income taxes	2,532,000	(9,558,000)
Net income	(54,063,000)	(92,082,000)
Balance for common	(56,772,000)	(92,498,000)
Earnings common share		
Primary	\$(0.13)	\$(0.28)
Fully Diluted	\$(0.13)	\$(0.28)
Common Shares:		
Full Diluted	401,325,300	326,166,633
Year-end	418,835,699	369,216,809

SPRUCE BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	25,413	36,291
Operating income	(25,413)	(32,077)
Other income (expense), net	1,177	2,851
Net income	(24,320)	(29,477)
Earnings common share		
Primary	\$(41.25)	\$(54.00)
Fully Diluted	\$(41.25)	\$(54.00)
Common Shares:		

Full Diluted	590	549
Year-end	563	551

STAAR SURGICAL CO.**Earnings, 9 mos. to (Consol. – \$000):**

	09/26/25	09/27/24
Total Revenues	181,641	264,951
Cost & expenses	250,516	249,652
Operating income	(68,875)	15,299
Other income (expense), net	604	1,040
Net before taxes	(61,611)	21,282
Income taxes	528	7,262
Net income	(62,139)	14,020
Earnings common share		
Primary	\$(1.26)	\$0.29
Fully Diluted	\$(1.26)	\$0.28
Common Shares:		
Full Diluted	49,499	49,614
Year-end	49,354	49,271

STEPSTONE GROUP INC**Earnings, 6 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	1,600,291	359,946
Operating income	(696,176)	112,730
Other income (expense), net	85,386	12,991
Invest. income	3,456	3,036
Net before taxes	(696,176)	112,730
Income taxes	(108,675)	11,547
Net income	(587,501)	101,183
Earnings common share		
Primary	\$(5.17)	\$0.46
Fully Diluted	\$(5.17)	\$0.46
Common Shares:		
Full Diluted	78,206	69,148
Year-end	79,124	72,681

STERLING INFRASTRUCTURE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,734,436	1,616,923
Cost & expenses	1,433,413	1,401,715
Operating income	285,949	202,351
Net before taxes	290,987	202,686
Net income	218,028	153,726
Earnings common share		
Primary	\$6.64	\$4.67
Fully Diluted	\$6.56	\$4.63
Common Shares:		
Full Diluted	30,875	31,184
Year-end	30,708	30,693

STRATEGIC EDUCATION INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	945,010	908,474
Cost & expenses	822,414	788,868
Operating income	122,596	119,606
Other income (expense), net	1,623	3,935
Net before taxes	124,219	123,541
Income taxes	35,514	36,193
Net income	88,705	87,348
Earnings common share		
Primary	\$3.87	\$3.73
Fully Diluted	\$3.76	\$3.62
Common Shares:		
Full Diluted	23,597	24,137
Year-end	23,505	24,569

SUNRUN INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,798,164	1,519,227
Cost & expenses	2,021,650	1,958,175
Operating income	(223,486)	(438,948)
Other income (expense), net	(77,807)	71,710
Net before taxes	(1,041,652)	(982,219)
Income taxes	(207,652)	(26,953)
Net income	(834,000)	(955,266)
Earnings common share		
Primary	\$1.51	\$(0.15)
Fully Diluted	\$1.33	\$(0.15)
Common Shares:		
Full Diluted	262,196	222,078
Year-end	231,605	224,087

SUPERNUS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	507,380	487,658
Cost & expenses	500,796	367,664
Operating income	(58,346)	60,261
Net before taxes	(47,116)	71,488
Income taxes	(12,671)	12,951
Net income	(34,445)	58,537
Earnings common share		
Primary	\$(0.61)	\$1.06
Fully Diluted	\$(0.61)	\$1.05
Common Shares:		
Full Diluted	56,134	55,791
Year-end	57,119	55,219

SURGERY PARTNERS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,423,700	2,249,900
Cost & expenses	2,028,300	1,909,500
Operating income	279,300	221,700
Net before taxes	74,300	72,900
Income taxes	4,400	13,800
Net income	69,900	59,100
Earnings common share		
Primary	\$(0.50)	\$(0.47)
Fully Diluted	\$(0.50)	\$(0.47)
Common Shares:		
Full Diluted	126,932	126,093
Year-end	129,018	127,128

SUTRO BIOPHARMA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	90,837	47,234
Cost & expenses	211,155	220,429
Operating income	(120,318)	(173,195)
Other income (expense), net	(28,661)	(22,380)
Net before taxes	(144,335)	(155,010)
Income taxes	(11)	8
Net income	(144,324)	(155,018)
Earnings common share		
Primary	\$(1.71)	\$(2.07)
Fully Diluted	\$(1.71)	\$(2.07)
Common Shares:		
Full Diluted	84,192	74,935
Year-end	85,102	82,395

SYNAPTICS INC**Earnings, 3 mos. to (Consol. – \$000):**

	09/27/25	09/28/24
Total Revenues	292,500	257,700
Cost & expenses	311,000	282,300
Operating income	(23,200)	(28,400)
Net before taxes	(22,700)	(34,300)
Income taxes	(2,100)	(11,200)
Net income	(20,600)	(23,100)
Earnings common share		
Primary	\$(0.53)	\$(0.58)
Fully Diluted	\$(0.53)	\$(0.58)
Common Shares:		
Full Diluted	38,800	39,800
Year-end	39,095	40,049

Consolidated Balance Sheet Items, as of (\$000):

	2025
Assets:	
Cash & equivalents	459,900
Inventories	143,100
Current assets	749,000
Net property & equip.	77,400
Total assets	2,577,100
Liabilities:	
Current liabilities	262,000
Long-term debt	835,400
Stockholders' equity	1,400,600
Net current assets	487,000

SYNCHRONOSS TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	292,500	257,700
Cost & expenses	311,000	282,300
Operating income	(23,200)	(28,400)
Net before taxes	(22,700)	(34,300)
Income taxes	(2,100)	(11,200)
Net income	(20,600)	(23,100)
Earnings common share		
Primary	\$(0.53)	\$(0.58)
Fully Diluted	\$(0.53)	\$(0.58)
Common Shares:		
Full Diluted	38,800	39,800
Year-end	39,095	40,049

	2025	2024
Total Revenues	126,702	129,387
Cost & expenses	92,806	102,226
Operating income	20,958	14,388
Other income (expense), net	(6,824)	25
Gains or losses		205
Net before taxes	(16,863)	2,205
Income taxes	745	3,939
Net income	(17,608)	(1,734)
Balance for common	(17,608)	(3,282)
Earnings common share		
Primary	\$(1.70)	\$(0.33)
Fully Diluted	\$(1.70)	\$(0.33)
Common Shares:		
Full Diluted	10,357	9,994
Year-end	11,507	10,839

TAKE-TWO INTERACTIVE SOFTWARE, INC.**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	3,277,600,000	2,691,300,000
Cost & expenses	3,254,800,000	3,081,300,000
Operating income	(76,400,000)	482,100,000
Gains or losses		(4,300,000)
Net before taxes	(129,300,000)	536,500,000
Income taxes	16,500,000	91,000,000
Net income	(145,800,000)	627,500,000
Earnings common share		
Primary	\$(0.80)	\$(3.61)
Fully Diluted	\$(0.80)	\$(3.61)
Common Shares:		
Full Diluted	182,700,000	173,800,000
Year-end	184,700,000	175,500,000

TALKSPACE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	165,873,000	138,873,000
Cost & expenses	164,496,000	143,939,000
Operating income	(677,000)	(5,066,000)
Net before taxes	3,252,000	57,000
Income taxes	224,000	123,000
Net income	3,028,000	(66,000)
Earnings common share		
Primary	\$0.02	\$
Fully Diluted	\$0.02	\$
Common Shares:		
Full Diluted	174,009,390	168,805,882
Year-end	165,105,058	168,824,458

TANDEM DIABETES CARE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	724,353,000	657,555,000
Cost & expenses	919,904,000	756,100,000
Operating income	(195,551,000)	(98,545,000)
Other income (expense), net	(9,641,000)	(1,268,000)
Net before taxes	(204,954,000)	(91,886,000)
Income taxes	(833,000)	4,894,000
Net income	(204,121,000)	(96,780,000)
Earnings common share		
Primary	\$(3.04)	\$(1.48)
Fully Diluted	\$(3.04)	\$(1.48)
Common Shares:		
Full Diluted	67,040,000	65,287,000
Year-end	67,773,000	65,646,000

TASKUS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	870,591	720,743
Cost & expenses	722,649	604,789
Operating income	102,541	70,474
Other income (expense), net	9,907	2,007
Net before taxes	98,523	55,949
Income taxes	25,953	18,938
Net income	72,570	37,011
Earnings common share		
Primary	\$0.81	\$0.42
Fully Diluted	\$0.78	\$0.40
Common Shares:		
Full Diluted	93,097	92,020
Year-end	90,397	89,448

TEADS HOLDING CO**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	948,225	655,289
Cost & expenses	1,001,200	670,462
Operating income	(52,975)	(15,173)
Interest expense		2,950
Other income (expense), net	1,225	8,782
Net before taxes	(112,466)	(1,654)
Income taxes	(23,620)	(1,110)
Net income	(88,846)	(544)
Balance for common		(544)
Earnings common share		
Primary	\$(1.00)	\$(0.01)
Fully Diluted	\$(1.00)	\$(0.01)
Common Shares:		
Full Diluted	89,250	49,171
Year-end	95,469	49,654

TELOS CORP. (MD)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	118,028	81,900
Cost & expenses	139,401	127,846
Operating income	(21,373)	(45,946)
Other income (expense), net	1,625	3,299
Net before taxes	(20,172)	(43,139)
Income taxes	63	51
Net income	(20,235)	(43,190)
Earnings common share		
Primary	\$(0.28)	\$(0.60)
Fully Diluted	\$(0.28)	\$(0.60)
Common Shares:		
Full Diluted	72,819	71,654
Year-end	72,220	72,381

TENAYA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	72,556	91,296
Operating income	(72,556)	(91,296)
Other income (expense), net	27	78
Net income	(70,422)	(87,293)
Earnings common share		
Primary	\$(0.48)	\$(1.04)
Fully Diluted	\$(0.48)	\$(1.04)
Common Shares:		
Full Diluted	145,531	84,291
Year-end	163,745	79,221

TERNS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	82,526	75,922
Operating income	(82,526)	(75,922)
Other income (expense), net	(46)	(58)
Net before taxes	(72,438)	(66,834)
Income taxes	198	220
Net income	(72,636)	(67,054)
Earnings common share		
Primary	\$(0.79)	\$(0.89)
Fully Diluted	\$(0.79)	\$(0.89)
Common Shares:		
Full Diluted	91,584	75,568
Year-end	87,511	84,917

TEXAS ROADHOUSE INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/30/25	09/24/24
Total Revenues	4,396,044	3,935,418
Cost & expenses	3,865,849	3,428,533
Operating income	378,023	377,967
Other income (expense), net	1,771	778
Net before taxes	382,782	383,752
Income taxes	55,130	57,913
Net income	327,652	325,839
Earnings common share		
Primary	\$4.84	\$4.76
Fully Diluted	\$4.82	\$4.74
Common Shares:		
Full Diluted	66,564	67,023
Year-end	66,228	66,714

THE REALREAL INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	498,794	436,489
Cost & expenses	529,000	487,830
Operating income	(30,206)	(51,341)
Other income (expense), net	41,427	4,177
Gains or losses	3,112	(9,209)
Net before taxes	(2,809)	(65,569)
Income taxes	208	178
Net income	(3,017)	(65,747)
Earnings common share		
Primary	\$(0.03)	\$(0.61)
Fully Diluted	\$(0.03)	\$(0.61)
Common Shares:		
Full Diluted	113,793	107,044
Year-end	116,675	109,690

THE TRADE DESK INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,049,493	1,703,819
Cost & expenses	1,717,045	1,471,961
Operating income	332,448	231,858
Net before taxes	388,489	285,703
Income taxes	132,135	74,856
Net income	256,354	210,847
Earnings common share		
Primary	\$0.52	\$0.43
Fully Diluted	\$0.52	\$0.42
Common Shares:		
Full Diluted	497,198	500,273
Year-end	484,729	493,447

THREDUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Total Revenues	231,109,000	192,764,000
Cost & expenses	246,176,000	225,228,000
Operating income	(15,067,000)	(32,464,000)
Other income (expense), net	1,969,000	2,503,000
Net before taxes	(14,585,000)	(31,919,000)
Income taxes	54,000	21,000
Income contin. oper.		(31,940,000)
Net income	(14,639,000)	(55,279,000)
Earnings common share		
Primary	\$(0.12)	\$(0.50)
Fully Diluted	\$(0.12)	\$(0.50)
Common Shares:		
Full Diluted	120,318,000	111,054,000
Year-end	125,086,000	113,758,000

TPI COMPOSITES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	712,136	663,357
Cost & expenses	856,284	766,192
Operating income	(144,148)	(102,835)
Other income (expense), net	(10,788)	3,323
Net before taxes	(224,659)	(164,668)
Income taxes	4,928	7,774
Income contin. oper.	(229,587)	(172,442)
Net income	(244,701)	(192,625)
Balance for common	(244,701)	(192,625)
Earnings common share		
Primary	\$(5.05)	\$(4.06)
Fully Diluted	\$(5.05)	\$(4.06)
Common Shares:		
Full Diluted	48,473	47,422
Year-end	48,730	47,563

TRACTOR SUPPLY CO.**Earnings, 9 mos. to** (Consol. – \$000):

	09/27/25	09/28/24
Total Revenues	11,625,726	11,109,700
Cost & expenses	10,089,820	9,633,410
Operating income	1,169,658	1,149,183
Net before taxes	1,117,367	1,111,794
Income taxes	248,687	246,960
Net income	868,680	864,834
Earnings common share		
Primary	\$1.64	\$1.61
Fully Diluted	\$1.63	\$1.60
Common Shares:		
Full Diluted	532,816	540,735
Year-end	529,042	534,605

TRANSCAT INC**Earnings, 6 mos. to (Consol. – \$):**

	09/27/25	09/28/24
Total Revenues	158,696,000	134,533,000
Cost & expenses	149,853,000	125,699,000
Operating income	8,843,000	8,834,000
Other income (expense), net	(545,000)	(363,000)
Net before taxes	6,594,000	8,941,000
Income taxes	2,064,000	1,247,000
Net income	4,530,000	7,694,000
Earnings common share		
Primary	\$0.49	\$0.84
Fully Diluted	\$0.48	\$0.83
Common Shares:		
Full Diluted	9,392,000	9,222,000
Year-end	9,327,667	9,199,277

TRAVELZOO**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	69,245,000	63,224,000
Cost & expenses	62,893,000	49,577,000
Operating income	6,352,000	13,647,000
Other income (expense), net	727,000	674,000
Net before taxes	7,079,000	14,321,000
Income taxes	2,158,000	3,920,000
Net income	4,921,000	10,401,000
Earnings common share		
Primary	\$0.41	\$0.81
Fully Diluted	\$0.39	\$0.79
Common Shares:		
Full Diluted	11,974,000	12,851,000
Year-end	10,932,000	11,880,000

TREACE MEDICAL CONCEPTS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	150,171	140,649
Cost & expenses	198,403	196,133
Operating income	(48,232)	(55,484)
Other income (expense), net	344	206
Net income	(49,608)	(55,242)
Earnings common share		
Primary	\$(0.79)	\$(0.89)
Fully Diluted	\$(0.79)	\$(0.89)
Common Shares:		
Full Diluted	63,070	62,035
Year-end	63,705	62,275

TRIMBLE INC**Earnings, 9 mos. to (Consol. – \$000):**

	10/03/25	09/27/24
Total Revenues	2,617,500	2,699,900
Cost & expenses	2,162,100	2,333,000
Operating income	375,800	287,200
Other income (expense), net	500	3,300
Gains or losses	4,200	1,695,000
Net before taxes	324,800	1,908,100
Income taxes	57,400	493,900
Net income	267,400	1,414,200
Earnings common share		
Primary	\$1.11	\$5.76
Fully Diluted	\$1.10	\$5.73
Common Shares:		
Full Diluted	242,000	246,900
Year-end	237,900	245,800

TRIPADVISOR INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,480,000	1,424,000
Cost & expenses	1,298,300	1,269,000
Operating income	114,000	92,000
Other income (expense), net	(8,000)	(7,000)
Net before taxes	90,000	88,000
Income taxes	12,000	84,000
Net income	78,000	4,000
Earnings common share		
Primary	\$0.61	\$0.03
Fully Diluted	\$0.59	\$0.03
Common Shares:		
Full Diluted	133,681	144,971
Year-end	116,803	139,215

TRUBRIDGE INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	259,043,000	254,416,000
Cost & expenses	223,441,000	232,103,000
Operating income	15,855,000	76,000
Other income (expense), net	566,000	1,139,000
Net before taxes	6,971,000	(11,133,000)
Income taxes	(1,670,000)	4,257,000
Net income	8,641,000	(15,390,000)
Balance for common	8,347,000	(14,824,000)
Earnings common share		
Primary	\$0.58	\$(1.04)
Fully Diluted	\$0.58	\$(1.04)
Common Shares:		
Full Diluted	14,474,000	14,474,000
Year-end	15,001,000	14,927,000

TRUECAR INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	135,015	129,391
Cost & expenses	152,257	145,776
Operating income	(27,125)	(30,062)
Other income (expense), net	11,397	
Net before taxes	(12,755)	(25,186)
Income taxes	11	13
Net income	(12,766)	(25,199)
Earnings common share		
Primary	\$(0.15)	\$(0.28)
Fully Diluted	\$(0.15)	\$(0.28)
Common Shares:		
Full Diluted	87,903	91,133
Year-end	88,849	88,507

TRUPANION INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,062,452	948,377
Cost & expenses	1,043,643	945,513
Operating income	15,701	(11,332)
Other income (expense), net	18,379	9,417
Net before taxes	15,701	(11,332)
Income taxes	1,898	(43)
Net income	13,803	(11,289)
Earnings common share		
Primary	\$0.32	\$(0.27)
Fully Diluted	\$0.32	\$(0.27)
Common Shares:		
Full Diluted	43,550	42,077
Year-end	43,192	42,341

TTEC HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,566,942	1,640,150
Cost & expenses	1,443,936	1,754,705
Operating income	55,394	(188,813)
Other income (expense), net	7,141	953
Net before taxes	16,176	(249,386)
Income taxes	30,720	65,850
Net income	(14,544)	(315,236)
Earnings common share		
Primary	\$(0.42)	\$(6.79)
Fully Diluted	\$(0.42)	\$(6.79)
Common Shares:		
Full Diluted	48,098	47,573
Year-end	48,463	47,724

TURTLE BEACH CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	201,135,000	226,689,000
Cost & expenses	194,561,000	230,090,000
Operating income	6,574,000	(3,401,000)
Other income (expense), net	(780,000)	(974,000)
Net before taxes	(1,979,000)	(9,457,000)
Income taxes	(101,000)	(5,501,000)
Net income	(1,878,000)	(3,956,000)
Earnings common share		
Primary	\$(0.09)	\$(0.20)
Fully Diluted	\$(0.09)	\$(0.20)
Common Shares:		
Full Diluted	20,413,000	20,050,000
Year-end	19,307,514	20,079,323

TWIN DISC INCORPORATED**Earnings, 3 mos. to (Consol. – \$000):**

	09/26/25	09/27/24
Total Revenues	79,996	72,897
Cost & expenses	77,761	73,062
Operating income	2,235	(165)
Other income (expense), net	(864)	(1,344)
Net before taxes	571	(2,145)
Income taxes	983	627
Net income	(412)	(2,772)
Earnings common share		
Primary	\$(0.04)	\$(0.20)
Fully Diluted	\$(0.04)	\$(0.20)
Common Shares:		
Full Diluted	13,961	13,778
Year-end	14,388	14,104

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025
Cash & equivalents	14,241
Inventories	158,272
Current assets	254,547
Net property & equip.	64,615
Total assets	363,536
Liabilities:	
Current liabilities	122,201
Long-term debt	40,719
Stockholders' equity	160,317
Net current assets	132,346

TYRA BIOSCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Cost & expenses	96,246	74,433
Operating income	(96,246)	(74,433)
Net income	(86,113)	(60,910)
Earnings common share		
Primary	\$(1.45)	\$(1.08)
Fully Diluted	\$(1.45)	\$(1.08)
Common Shares:		
Full Diluted	59,524	56,599
Year-end	53,318	52,872

UFP INDUSTRIES INC**Earnings, 9 mos. to (Consol. – \$):**

	09/27/25	09/28/24
Total Revenues	4,990,520,000	5,190,308,000
Cost & expenses	4,685,706,000	4,777,525,000
Operating income	304,814,000	412,783,000
Other income (expense), net	1,072,000	(1,313,000)
Net before taxes	331,760,000	449,136,000
Income taxes	75,924,000	100,186,000
Net income	255,836,000	348,950,000
Balance for common	245,312,000	333,032,000
Earnings common share		
Primary	\$4.29	\$5.66
Fully Diluted	\$4.28	\$5.65
Common Shares:		
Full Diluted	57,327,000	58,980,000
Year-end	58,257,224	60,724,664

UNIVERSAL DISPLAY CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2025	2024
Total Revenues	477,684,000	485,391,000
Cost & expenses	282,696,000	285,429,000
Operating income	181,342,000	186,314,000
Other income (expense), net	6,905,000	416,000
Net before taxes	218,130,000	216,803,000
Income taxes	42,397,000	40,743,000
Net income	175,733,000	176,060,000
Balance for common	175,610,000	175,608,000
Earnings common share		
Primary	\$3.69	\$3.69
Fully Diluted	\$3.68	\$3.69
Common Shares:		
Full Diluted	47,681,477	47,644,026
Year-end	47,542,245	47,461,274

UPLAND SOFTWARE INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2025	2024
Total Revenues	167,564	206,767
Cost & expenses	149,087	272,824
Operating income	(2,739)	(100,323)
Other income (expense), net	(3,888)	(109)
Gains or losses	(24,364)	
Net before taxes	(41,774)	(108,109)
Income taxes	(1,775)	1,193
Net income	(39,999)	(109,302)
Balance for common	(44,361)	(113,473)
Earnings common share		
Primary	\$(1.56)	\$(4.07)
Fully Diluted	\$(1.56)	\$(4.07)
Common Shares:		
Full Diluted	28,510	27,851
Year-end	28,891	27,441

UPSTART HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	747,767	417,564
Cost & expenses	724,055	585,670
Operating income	23,712	(168,106)
Other income (expense), net	11,455	42,354
Net before taxes	35,167	(125,752)
Income taxes	202	74
Net income	34,965	(125,826)
Earnings common share		
Primary	\$0.37	\$(1.42)
Fully Diluted	\$0.28	\$(1.42)
Common Shares:		
Full Diluted	105,922	83,158
Year-end	97,276	90,998

VEECO INSTRUMENTS INC (DE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	499,277	535,170
Cost & expenses	459,792	466,665
Operating income	37,072	63,102
Other income (expense), net	(653)	
Net before taxes	39,481	64,479
Income taxes	5,205	5,730
Net income	34,276	58,749
Earnings common share		
Primary	\$0.58	\$1.04
Fully Diluted	\$0.57	\$0.97
Common Shares:		
Full Diluted	60,436	62,103
Year-end	60,159	56,778

VENTYX BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	84,304	116,032
Operating income	(84,304)	(116,032)
Other income (expense), net	(40)	(99)
Net income	(77,256)	(105,771)
Earnings common share		
Primary	\$(1.08)	\$(1.56)
Fully Diluted	\$(1.08)	\$(1.56)
Common Shares:		
Full Diluted	71,212	67,695
Year-end	71,337	70,669

VERA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2025	2024
Cost & expenses	221,267,000	118,256,000
Operating income	(221,267,000)	118,256,000
Other income (expense), net	(586,000)	1,237,000
Net income	(208,518,000)	108,723,000
Earnings common share		
Primary	\$(3.27)	\$(2.03)
Fully Diluted	\$(3.27)	\$(2.03)
Common Shares:		
Full Diluted	63,769,948	53,537,910
Year-end	63,894,845	55,026,111

VERACYTE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	376,509	327,132
Cost & expenses	354,062	312,666

Operating income	20,582	11,967
Other income (expense), net	(6,257)	1,287
Net before taxes	27,567	22,301
Income taxes	2,363	3,276
Net income	25,204	19,025
Earnings common share		
Primary	\$0.32	\$0.25
Fully Diluted	\$0.32	\$0.25
Common Shares:		
Full Diluted	79,946	77,340
Year-end	79,034	77,491

VIA RENEWABLES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	335,615	294,526
Cost & expenses	285,572	236,426
Operating income	34,148	51,348
Other income (expense), net		(4)
Net before taxes	28,779	46,068
Income taxes	6,761	9,654
Net income	22,018	36,414
Balance for common	5,262	10,199
Earnings common share		
Primary	\$1.42	\$3.12
Fully Diluted	\$1.42	\$3.12
Common Shares:		
Full Diluted	3,707	3,272
Year-end	3,792	3,323

VIATRIS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	10,596,300	11,211,200
Cost & expenses	13,066,700	11,021,300
Operating income	(2,470,400)	189,900
Other income (expense), net	(499,900)	143,200
Net before taxes	(3,322,000)	(96,700)
Income taxes	(147,200)	21,000
Net income	(3,174,800)	(117,700)
Earnings common share		
Primary	\$(2.70)	\$(0.10)
Fully Diluted	\$(2.70)	\$(0.10)
Common Shares:		
Full Diluted	1,176,700	1,193,300
Year-end	1,159,162	1,193,581

VICTORY CAPITAL HOLDINGS INC (DE)**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	555,503	322,675
Operating income	325,248	315,769
Other income (expense), net	11,853	12,055
Net before taxes	296,661	275,163
Income taxes	79,411	63,238
Net income	217,250	211,925
Balance for common	181,968	
Earnings common share		
Primary	\$2.77	\$3.28
Fully Diluted	\$2.73	\$3.21
Common Shares:		
Full Diluted	66,620	66,044
Year-end	65,082	64,924

VIR BIOTECHNOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	4,486	61,831
Cost & expenses	435,893	531,846
Operating income	(431,407)	(470,015)
Other income (expense), net	(74)	(1,715)
Gains or losses	4,335	(4,356)
Net before taxes	(394,710)	(418,430)
Income taxes	354	(1,059)
Net income	(395,064)	(417,371)
Earnings common share		
Primary	\$(2.86)	\$(3.07)
Fully Diluted	\$(2.86)	\$(3.07)
Common Shares:		
Full Diluted	138,288	136,058
Year-end	139,023	136,706

VIRTUS INVESTMENT PARTNERS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Cost & expenses	470,871	491,642
Operating income	128,865	131,769
Other income (expense), net	2,671	1,695
Gains or losses	5,237	6,415
Invest. income	(27,766)	(16,529)
Net before taxes	139,997	149,369
Income taxes	37,861	36,376
Net income	102,136	112,993
Earnings common share		
Primary	\$15.02	\$12.45
Fully Diluted	\$14.81	\$12.23
Common Shares:		
Full Diluted	6,953	7,234
Year-end	6,753	7,016

VTV THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues		1,000
Cost & expenses	24,923	20,288
Operating income	(24,923)	(19,288)
Other income (expense), net	(39)	157
Gains or losses	20	(173)
Net before taxes		(18,168)
Income taxes		100
Net income	(23,942)	(18,268)
Earnings common share		
Primary	\$(2.80)	\$(2.70)
Fully Diluted	\$(2.80)	\$(2.70)
Common Shares:		
Full Diluted	7,081	5,498
Year-end	3,938	2,612

VYNE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	440	417
Cost & expenses	24,970	31,284
Operating income	(24,530)	(30,867)
Other income (expense), net	2,754	3,074
Income contin. oper.	(21,776)	(27,793)
Net income	(21,646)	(27,812)
Earnings common share		
Primary	\$(0.51)	\$(0.65)
Fully Diluted	\$(0.51)	\$(0.65)
Common Shares:		
Full Diluted	42,745	42,592
Year-end	31,773	14,751

WARNER BROS DISCOVERY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	27,836,000	29,294,000
Cost & expenses	23,078,000	34,094,000
Operating income	389,000	(10,194,000)
Other income (expense), net	3,159,000	689,000
Net before taxes	2,047,000	(11,032,000)
Income taxes	1,051,000	(190,000)
Net income	996,000	(10,842,000)
Earnings common share		
Primary	\$0.40	\$(4.42)
Fully Diluted	\$0.39	\$(4.42)
Common Shares:		
Full Diluted	2,510,000	2,449,000
Year-end	2,477,000	2,453,000

WENDY'S CO (THE)**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/25	09/29/24
Total Revenues		1,672,219
Cost & expenses	1,229,101	1,276,238
Operating income	279,435	275,338
Other income (expense), net	8,583	19,393
Net before taxes	194,053	201,931
Income taxes	55,459	55,071
Net income	138,594	146,860
Earnings common share		
Primary	\$0.71	\$0.72
Fully Diluted	\$0.71	\$0.71
Common Shares:		
Full Diluted	195,195	205,803
Year-end	190,311	203,089

WERNER ENTERPRISES, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,236,761	2,275,579
Cost & expenses	1,976,303	2,004,259
Operating income	47,468	52,794
Other income (expense), net	813	(25)
Net before taxes	23,797	29,990
Income taxes	11,479	8,002
Net income	12,318	21,988
Earnings common share		
Primary	\$0.22	\$0.36
Fully Diluted	\$0.22	\$0.36
Common Shares:		
Full Diluted	61,015	62,862
Year-end	59,830	61,808

WEYCO GROUP, INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2025	2024
Total Revenues	199,372,000	209,819,000
Cost & expenses	180,393,000	184,744,000
Operating income	18,979,000	25,075,000
Other income (expense), net	(129,000)	(423,000)
Net before taxes	21,095,000	27,400,000
Income taxes	6,710,000	7,080,000
Net income	14,385,000	20,320,000
Earnings common share		
Primary	\$1.52	\$2.15
Fully Diluted	\$1.50	\$2.12
Common Shares:		
Full Diluted	9,585,000	9,576,000
Year-end	9,548,388	9,490,681

WILLDAN GROUP INC

Earnings, 9 mos. to (Consol. – \$):

	10/03/25	09/27/24
Total Revenues	507,865,000	421,737,000
Cost & expenses	460,294,000	390,317,000
Operating income	33,714,000	20,483,000
Other income (expense), net	840,000	2,293,000
Net before taxes	29,664,000	16,745,000
Income taxes	(4,180,000)	1,863,000
Net income	33,844,000	14,882,000
Earnings common share		
Primary	\$2.35	\$1.08
Fully Diluted	\$2.26	\$1.05
Common Shares:		
Full Diluted	14,987,000	14,130,000
Year-end	14,754,000	14,117,000

WW INTERNATIONAL INC

Earnings, 9 mos. to (Consol. – \$000):

	09/30/25	09/28/24
Total Revenues	547,826	601,508
Cost & expenses	516,002	873,952
Operating income	31,824	(272,444)
Other income (expense), net	1,135,959	(4,187)
Net before taxes	1,116,144	(358,554)
Income taxes	54,303	12,270
Net income	1,061,841	(370,824)
Earnings common share		
Primary	\$106.32	\$(4.67)
Fully Diluted	\$106.32	\$(4.67)
Common Shares:		
Full Diluted	9,987	79,474
Year-end	9,987	79,734

WYNN RESORTS LTD

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	5,271,941	5,289,164
Cost & expenses	3,967,107	4,015,717
Operating income	843,678	765,836
Other income (expense), net	(12,371)	23,653
Gains or losses	(43,827)	(7,920)
Net before taxes	369,539	362,432
Income taxes	82,746	45,076
Net income	286,793	317,356
Earnings common share		
Primary	\$2.19	\$2.03
Fully Diluted	\$2.18	\$2.02
Common Shares:		
Full Diluted	104,373	110,810
Year-end	103,977	109,922

XENCOR, INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	97,339	57,700
Cost & expenses	221,213	222,930
Operating income	(123,874)	(165,230)
Other income (expense), net	41,756	(20,892)
Net before taxes	(85,367)	
Income taxes	117	
Net income	(85,484)	(190,340)
Earnings common share		
Primary	\$(1.15)	\$(3.00)
Fully Diluted	\$(1.15)	\$(3.00)
Common Shares:		
Full Diluted	74,122	62,310
Year-end	71,343	69,963

XERIS BIOPHARMA HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues	206,038	142,971
Cost & expenses	189,783	170,164
Operating income	8,123	(35,325)
Other income (expense), net		(2,690)
Gains or losses		4,395
Net before taxes		(51,991)
Income taxes		(2,268)
Net income	(10,527)	(49,723)
Earnings common share		
Primary	\$(0.07)	\$(0.34)
Fully Diluted	\$(0.07)	\$(0.34)
Common Shares:		
Full Diluted	158,559	145,962
Year-end	165,528	149,004

ZENTALIS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2025	2024
Total Revenues		40,560
Cost & expenses	115,415	181,905
Operating income	(115,415)	(141,345)
Other income (expense), net	13,571	23,332
Net before taxes		(118,013)
Income taxes		382
Net income	(101,844)	(118,395)
Earnings common share		
Primary	\$(1.42)	\$(1.67)
Fully Diluted	\$(1.42)	\$(1.67)
Common Shares:		
Full Diluted	71,938	71,017
Year-end	72,246	71,150

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2025 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.